













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Functional Characterisation of 
Superantigens in 















Doctor of Philosophy 
 










I declare that I have composed this thesis and the work described here is my own. It is 
clearly indicated where the work described was performed by collaborating researchers. This 








































Firstly, I am very grateful to Professor Ross Fitzgerald for his guidance, advice and support 
throughout my PhD. I would also like to thanks Professor Ivan Morrison for all the help and 
ideas he has provided to this project.  
I am indebted to all the people who have trained me and shared their expertise during my 
PhD and helped me develop my skills as a scientist. These people include Andy Gill, Tim 
Connelly, Edith Paxton and Irene McGuiness. 
I am very grateful for the invitation from Professor Jos Van Strijp to work in his lab in 
Utrecht for two months. His lab provided me with the opportunity to develop new skills and 
techniques which contributed significantly to the success of this project. Special thanks go to 
Jovanka Bestebroer for looking after me during this trip and teaching me a vast amount.  
I was lucky enough to have a great group of collaborators to work with including Professor 
Victor Torres and Dr. David James who assisted us with the pull down analysis, Dr. Keun 
Seok Seo who helped with T-cell proliferation assays and finally Dr. Hisaya Ono and 
Professor Akio Nakane who performed the emesis experiments.  
I have been lucky to work in a lab with talented and knowledgeable people who have 
provided invaluable advice throughout my project. I am particularly grateful to Amy 
Richards, Chriselle Mendonca, Emily Richardson, Robyn Cartwright, Paul McAdam and 
Gillian Johnston for all the contributions they have made. I am especially grateful to Mariya 
Goncheva who has been both a supportive colleague and a great friend.  





CONTENTS   
  Page 







 List of Figures 12 
 List of Tables 15 





Chapter 1 Introduction 24 
1.1 Staphylococcus aureus 25 
1.1.1 Microbiology 25 
1.1.2 S. aureus infections; clinical presentation and 
epidemiology 
25 
1.1.3 Community-associated methicillin resistant S. 
aureus (CA-MRSA) 
28 
1.2 Antibiotic resistance in S. aureus 29 
1.3 S. aureus Evolution and Genetics 30 
1.3.1 Genome organisation of S. aureus 30 
1.3.2 Mechanisms of S. aureus evolution 31 
1.3.3 Restriction Modification Systems and other 
defences against foreign DNA 
34 
1.4 Human Immune System 35 
6 
 
  Page 
1.4.1 Neutrophil  granulocyte 36 
1.4.2 Complement 37 
1.4.3 T-lymphocytes 43 
1.5 S. aureus pathogenesis 48 
1.5.1 Enzymes 48 
1.5.2 α-Haemolysin 49 
1.5.3 Leukocidins 51 
1.5.4 Phenol soluble modulins 54 
1.5.5 Other secreted immune modulatory proteins 55 
1.5.6 Staphylococcal superantigen-like proteins 56 
1.5.7 Cell Wall anchored Proteins 60 
1.5.8 S. aureus host cell invasion  65 
1.6 Superantigens 66 
           1.6.1 SAg structure and binding 70 
           1.6.2 Role of SAgs in S. aureus pathogenesis 74 
           1.6.3 Distribution of S. aureus SAg Genes 77 
1.7 Regulation of virulence determinants in S. aureus 80 
1.8 Staphylococcal enterotoxin-like toxin X (SElX) 85 
1.9 Staphylococcal enterotoxin like toxins Y and Z 
(SElY and SElZ) 
86 
1.10 Hypothesis 86 
1.11 Project Aims 87 
Chapter 2 General materials and methods 88 





2.2 Bacterial culture conditions 89 
2.3 Genomic DNA extraction  89 
2.4 Plasmid and DNA isolation 90 
2.5 DNA quantification 90 
2.6 Restriction digestion 90 
2.7 Polymerase chain reaction 91 
2.8 Agarose gel electrophoresis 91 
2.9 DNA sequencing 92 
2.10 Gene cloning 92 
2.11 Preparation of electro-competent cells and 
electroporation 
93 
2.12 Sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE) 
93 
2.13 Recombinant protein purification 94 
2.13.1 Protein induction 94 
2.13.2 Affinity chromatography 94 
2.13.3 Protein quantification 95 
2.15 Western Immunoblot analysis 97 
2.16 Isolation of human PMN and PBMC 97 






Structural and Expression Analysis of SElX, 
SElY and SElZ 
100 
3.1 Introduction 101 
8 
 
  Page 
3.2 Materials and methods 103 
3.2.1 Bacterial strains and culture conditions 103 
3.2.2 Cloning and purification of recombinant protein 103 
3.2.3 Phylogenetic and amino acid sequence analysis 104 
3.2.4 Circular Dichroism analysis 108 
3.2.5 Thermal shift analysis 108 
3.2.6 Western blot analysis 108 
3.2.7 qRT-PCR analysis 111 
3.2.7.1 RNA extraction from S. aureus 111 
3.2.7.2 Quantitative reverse transcriptase-PCR 111 
3.2.8 House musk shrew model of emesis 112 
3.3 Results 113 
3.3.1 Distribution and genetic relation of SElY and SElZ. 113 
3.3.2 SElX, SElY and SElZ exhibit features associated 
with other SAgs. 
116 
3.3.3 SElX contains a conserved sialic acid binding 
motif. 
117 
3.3.4 SElX, SElY and SElZ circular dichroism analysis 
suggest novel features. 
122 
3.3.5 SElX, SElY and SElZ exhibit a high level of 
stability. 
126 







  Page 
3.3.7 SElX and SElZ do not exhibit emetic activity. 132 








Superantigen binding to Leukocytes 141 
4.1 Introduction 142 
4.2 Materials and methods 144 
4.2.1 Neutrophil Isolation form different mammalian 
species 
144 
4.2.2 Protein expression and purification 146 
4.2.3 Cell binding experiments 147 
4.2.4 Site-directed mutagenesis 147 
4.2.5 Circular dichroism analysis 150 
4.2.6 Thermal shift analysis 150 
4.2.7 Affinity precipitation and mass spectrometry 
analysis 
150 
4.2.8 Enzyme-linked immunesorbent assay (ELISA) 
validation of protein-protein interaction 
152 
4.3 Results 153 
4.3.1 Characterisation of binding of SAgs to human cells. 153 
4.3.2 SElX interacts with PMNs from a number of 





  Page 
4.3.3 SElX binding to PMNs is dependent on the 
predicted sialic acid binding motif. 
158 
4.3.4 SElX interacts with a number of neutrophil 
glycoprotein receptors. 
161 








Impact of SElX on Neutrophil Function 173 
5.1 Introduction 174 
5.2 Materials and methods 176 
5.2.1 Preparation of human serum and antibodies 176 
5.2.2 Bacterial survival assays 176 
5.2.3 Phagocytosis assays 177 
5.2.4 Cell line binding experiments 180 
5.2.5 Cytotoxicity determined by lactate dehydrogenase 
(LDH) release 
180 
5.2.6 Determination of apoptosis 181 
5.3 Results 182 
5.3.1 The mechanism of neutrophil binding of SElX is 
distinct from its superantigenicity. 
182 
5.3.2 SElX contributes to enhanced survival of S. aureus 





  Page 
5.3.3 SElX inhibits IgG-mediated phagocytosis. 185 
5.3.4 
 
SElX inhibition of phagocytosis is not associated 







General Discussion 195 
6.1 Sequence diversity amongst staphylococcal SAg. 197 
6.2 Staphylococcal virulence determinants can exhibit a 
broad functional complement. 
198 
6.3 Mitogenic activity of SElX, SElY and SElZ. 199 
6.4 Emetic functions of SElX, SElY and SElZ. 200 
6.5 SElX exhibits two distinct immunomodulatory 
roles. 
202 
6.6 Potential mechanisms of SElX inhibition of 
neutrophil inhibition. 
203 













LIST OF FIGURES  
  Page 
Chapter 1   
Figure 1.1 The role of neutrophils and complement in S. aureus 
clearance. 
39 
Figure 1.2 Model of T-cell differentiation after stimulation with 
antigen. 
46 
Figure 1.3 Superantigens induce T-cell proliferation by by-passing 
normal antigen presentation. 
68 
Figure 1.4 The two domain structure of SAgs. 73 
Figure 1.5 Different SAgs can bind to the MHC class II molecule 
through a variety of mechanisms. 
79 
Figure 1.6 S. aureus virulence regulators coordinate to ensure correct 





Figure 3.1 Phylogenetic analysis of selx, sely, and selz. 115 
Figure 3.2 SElX and SElY share a number of common features with 
other characterised SAgs. 
118 
Figure 3.3 SElZ shares a number of common features with other 
characterised SAgs. 
119 
Figure 3.4 SElX and novel SAgs all encode the outside-in signalling 
sequence. 
120 





  Page 
Figure 3.6 Recombinant staphylococcal superantigen proteins tested 
induce T-cell proliferation. 
124 
Figure 3.7 Staphylococcal SAgs exhibit distinct CD spectra. 125 
Figure 3.8 Staphylococcal SAgs exhibit a high level of tolerance to pH 
variation. 
128 
Figure 3.9 SAgs demonstrate limited variation in stability at different 
pH. 
129 




Expression of selx is regulated by the two component sensor 
system saeRS. 
134 
Chapter 4   
Figure 4.1 SElX and SElY bind to human monocytes and neutrophils. 155 
Figure 4.2  SElX binding to different lymphocyte subpopulations. 156 
Figure 4.3 SElX interacts with neutrophils from a range of mammalian 
species. 
157 
Figure 4.4 Mutations in the predicted sialic acid binding site of SElX 
have limited impact on protein structure and stability.   
159 
Figure 4.5 SElX interaction with Neutrophils is mediated via the sialic 
acid binding motif. 
160 
Figure 4.6 SElX binding mutants exhibit differences in protein 
enrichment for neutrophil lysates. 
165 
Figure 4.7 SElX interacts with CD50 in a sialic acid-dependent manner. 167 
   
14 
 
  Page 
Chapter 5   






Figure 5.2 SElX enhances S. aureus survival in the presence of human 
neutrophils. 
184 
Figure 5.3 SElX inhibits IgG-mediated neutrophil phagocytosis. 187 
Figure 5.4 SElX inhibition of IgG mediated phagocytosis is 
independent of Fcγ receptors. 
188 
Figure 5.5 SElX does not induce necrosis of human PMNs. 190 
















LIST OF TABLES 
  Page 
Chapter 1   
Table 1.1 T-lymphocyte types and functions. 45 
Table 1.2 Staphylococcal superantigen-like (SSl) proteins, ligands and 
proposed functions. 
59 
Table 1.3 Major characterised CWA proteins from S. aureus and their 
ligands. 
63 
Table 1.4 Properties of Characterised staphylococcal SAgs 67 
Table 1.5 
 
Characterised two-component regulators of S. aureus. 81 
Chapter 2   
Table 2.1  
 
Protein purification buffers 96 
Chapter 3   
Table 3.1 Bacterial strains used in this study. 105 
Table 3.2 Oligonucleotide primers used in this study. 106 
Table 3.3 Plasmids used in this study. 107 
Table 3.4 
 
S. aureus whole genome sequences, plasmids and gene 







   
16 
 
   
  Page 
Chapter 4   
Table  4.1 Oligonucleotide Primers used for site directed mutagenesis of 
pet15b::selx2 
149 
Table  4.2 
 
  
Mass spectrometry results from proteins enriched by SElX 
and neutrophil lysate from affinity precipitation experiment. 
163 
Chapter 5   














LIST OF COMMONLY USED ABBREVIATIONS 
Abbreviation Full description 
α alpha 
agr accessory gene regulator 
AIP auto inducing peptide 
APC antigen presenting cell 
APS ammonium persulphate 
β beta 
BLAST basic local alignment search tool 
bp base pair 
BHI brain heart infusion 
°C degrees Celsius 
CA-MRSA Community associated methicillin-resistant Staphylococcus 
aureus 
CC clonal complex 
CFU colony forming units 
CD circular dichroism 
CD- cluster of differentiation 
CO2 carbon dioxide 
cpm counts per minute 
CT cycle threshold 
CWA cell wall associated 
d days 
ddH2O double distilled water 
DMSO dimethyl sulpoxide 
18 
 
Abbreviation Full description 
DNA deoxyribonucleic acid 
ECL enhanced chemiluminescence 
EDTA ethylene-diamine-tetra acetic acid 
egc enterotoxin gene cluster 
FACS fluorescence-activated cell sorting 
FCS foetal calf serum 
FITC fluorescein isothiocyanate 
x g force of gravity 
γ gamma 
g grams 
gDNA genomic DNA 
h hours 
HA-MRSA Hospital-associated methicillin-resistant Staphylococcus aureus 
HBSS hanks balanced salt solution 
HCl hydrochloric acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGT horizontal gene transfer 
3
H hydrogen radioactive isotope 3 (tritium) 









Abbreviation Full description 
kV kilo-volts 
LA-MRSA Livestock-associated methicillin-resistant Staphylococcus 
aureus 
L litres 
LB Luria broth 
LC-MS/MS liquid chromatography tandem mass spectrometry 
kb kilo-base 
MEGA Molecular Evolutionary Genetics Analysis 
mM milli-molar 
MGE mobile genetic element 
MHC major histocompatibility complex 






MRSA methicillin-resistant Staphylococcus aureus 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
MWCO molecular weight cut off 






Abbreviation Full description 
NK not known 
NTC no template control 
OD optical density 
PBMC peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PCR polymerase chain reaction 
PDB protein data bank 
PE phycoerythrin 
PMN polymorphonuclear leukocytes 
PSG penicillin, streptomycin, L-glutamine 
PSGL-1 P-selectin glycoprotein ligand-1 
PVL Panton-Valentin leukocidin 
qRT-PCR quantitative reverse transcriptase-polymerase chain reaction 
RBC red blood cells 
RNA ribonucleic acid 
Rot repressor of toxins 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute medium 
RT reverse transcriptase 
s second 
SAB sialic acid binding motif 
SAg superantigen 
sae Staphylococcus aureus exoprotein regulator 
SaPI staphylococcal pathogenicity islands 
SDS sodium dodecyl sulphate 
21 
 
Abbreviation Full description 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SE staphylococcal enterotoxin 
SEl staphylococcal enterotoxin-like 
Src sarcoma 
ST sequence type 
TAE tris-acetate ethylene diamine-tetra-acetic acid 
TCR T-cell receptor 
TCS two component system 
TE Tris-ethylene-diamine-tetra-acetic acid 
TEMED tetramethylethylenediamine 
Th1 T helper 1 
Th2 T helper 2 
Th17 T helper 17 
TNF Tumour necrosis factor 
Tregs Regulatory T-cells 
TSA tryptone soya agar 
TSB tryptone soya broth 
TSS toxic shock syndrome 




v/v volume for volume 
WT wild type 




Bacterial superantigens (SAgs) are virulence factors that induce nonspecific T-cell 
proliferation contributing to host immune avoidance, and occasionally severe life-threatening 
toxinoses such as toxic shock syndrome. In the current study, the multiple functions of 3 
superantigens named staphylococcal enterotoxin-like toxins X, Y and Z are investigated.  
SElX and SElZ were non-emetic in a musk shrew model of emesis. SElX is structurally and 
phylogenetically related to staphylococcal superantigen-like proteins (SSls) which are non-
mitogenic but exhibit a variety of immune modulatory properties. We carried out protein and 
gene expression analysis of mutants of different S. aureus gene regulators and demonstrated 
that selx expression is controlled by saeRS, a two-component regulator linked to the bacterial 
response to phagocytic signals. Considering the co-regulation of SElX with known mediators 
of innate immune evasion we investigated a potential role for SElX in both humoral and 
cellular innate immune modulation and discovered that SElX strongly binds to human, 
bovine, murine, and laprine neutrophils and interferes with IgG-mediated phagocytosis, 
independently of Fcγ receptor signalling. Bacterial survival assays with neutrophils 
demonstrated that the deletion of selx significantly reduced the ability of S. aureus to resist 
neutrophil killing. Site-directed mutagenesis in the conserved sialic acid-binding motif of 
SElX abolished its neutrophil binding capacity, which is consistent with a critical role for 
glycosylated receptors in this interaction. Importantly, the sialic-acid binding mutants of 
SElX retained the ability to induce T-cell proliferation demonstrating that the distinct 
functions of SElX are mechanistically independent. Affinity precipitation experiments 
identified potential glycoprotein receptors for SElX and the interaction with protein ICAM-
3, an important ligand for MAC-1 integrins, was validated suggesting SElX may interfere 
with cell signalling. Taken together, we present the first example of a bi-functional SAg that 
can manipulate two distinct arms of the human immune system and contribute to S. aureus 




The bacterium Staphylococcus aureus is responsible for an array of diseases in both humans 
and animals. S. aureus infection can cause serious life threatening illness in humans in both 
the hospital and community setting. S. aureus produces a range of virulence factors that 
allow the bacteria to establish and maintain an infection by mediating transmission, entry 
into the host and avoidance of the immune system. In the current study the S. aureus proteins 
SElX, SElY and SElZ were examined to determine how these factors are deployed by S. 
aureus to contribute to infection. The three proteins examined have already been shown to be 
superantigens, which are proteins that induce non-specific T-cell activation. T-cells are 
important signalling cells in the immune system and by activating T-cells non-specifically 
can cause dysregulation of the immune system. SElY and SElZ have been recently identified 
and so far been poorly characterised, in the current study the mechanisms of 
superantigenicity of these proteins has been better defined. The superantigens are a diverse 
group of proteins and may exhibit a range of different functions. In this study we 
demonstrated that SElY is highly resistant to variations in temperature and pH which may 
contribute to its role as a food poisoning toxin. We also demonstrated that the protein SElX 
can inhibit the function of a group of immune cells called neutrophils. These cells are 
important in clearing S. aureus infections as they take up the bacteria and kill them. If these 
cells are being inhibited by SElX it can contribute further to immune avoidance by S. aureus. 
This is the first example of a superantigen exhibiting more than one immune evasion 
function. Within the field of S. aureus disease the observation of S. aureus virulence factors 
exhibiting more than one function is increasing. Understanding the full functional 
complement of virulence factors secreted by S.aureus is important as it will allow the 
development of targeted therapies that can block all functions of S. aureus virulence factors 






















1.1 Staphylococcus aureus 
1.1.1 Microbiology  
Staphylococcus aureus is a facultatively anaerobic Gram-positive coccal bacterium that is 
responsible for an array of diseases in both the hospital and the community setting. S. aureus 
is a commensal commonly found in the anterior nares of humans with colonisation rates of 
25% to 30% of healthy individuals and can also be isolated from the axillae, vagina, pharynx 
or damaged skin (Thomas et al., 2007, Dinges et al., 2000, Wilson et al., 2011).  Under 
certain circumstances S. aureus can deploy a wide variety of virulence determinants which 
can lead to local and systemic diseases in humans including sepsis, necrotizing pneumonia, 
and toxic shock syndrome (TSS) (Choi et al., 1989). S. aureus has also been implicated in an 
array of veterinary diseases including blood stream infections, mastitis and pneumonia in a 
number of hosts including horses, cattle and poultry (Dellabona et al., 1990, Drake and 
Kotzin, 1992).  
 
1.1.2 S. aureus infections; clinical presentation and epidemiology  
S. aureus is a common cause of infection in the hospital environment associated with a 
number of clinical complications including skin and soft tissue infections (SSTIs), 
bloodstream infections (BSIs) and ventilator-associated pneumonia (VAP)  (Fraser and Proft, 
2008a, Kawabe and Ochi, 1990, Ferens and Bohach, 2000). Methicillin resistant 
Staphylococcus aureus (MRSA) is widespread in hospitals across the world (Sol et al., 
2000), and is estimated to cause 171 200 healthcare-associated infections in Europe each 
year (Thomas et al., 2009). MRSA represents a serious clinical problem owing to the varied 
level of antibiotic resistance found in different strains of this organism (Seo et al., 2010b, 
Ono et al., 2008b).  
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SSTI with S. aureus can range in severity and can present in many forms including 
abscesses, impetigo, cellulitis and necrotising fasciitis (Deringer et al., 1997). S. aureus was 
already the leading cause of SSTIs worldwide but the incidence has increased dramatically 
since the emergence of community associated MRSA (CA-MRSA) (Deringer et al., 1996). 
The most common S. aureus SSTIs presented in the clinic are cutaneous abscesses which 
normally can be resolved by drainage and antibiotic treatment (Fitzgerald et al., 2001a). Skin 
infections can also result from 2 % to 4 % of surgical procedures, with S. aureus found to be 
the most common cause of infections, accounting for 30 % of cases (Connelley et al., 2009, 
Elsik et al., 2009). Other manifestations of SSTIs include impetigo, which is the most 
common form of skin infection in children, and S. aureus is the most common pathogen 
isolated from these infections (70 % of cases) (Wilson et al., 2011).  Necrotizing fasciitis is 
another condition in which S. aureus can play a role; it is associated with patients that have 
S. aureus-infected wounds in addition to other medical complications such as diabetes or 
hepatitis C (Herron-Olson et al., 2007b). In a hospital study in Taiwan 38% of patients 
presenting with necrotising fasciitis were found to be culture-positive for S. aureus and 60% 
of these isolates were found to be MRSA (Wilson et al., 2011). This demonstrates that S. 
aureus remains a serious clinical problem both in the hospital and in the community.  
 S. aureus is responsible for other life-threatening diseases including infective 
endocarditis (IE) and is the leading cause of this condition worldwide (Rozen, 2000, Enright 
et al., 2000). In the USA the increasing incidence of IE has been attributed to a higher 
incidence of S. aureus, and IE rates have increased by 27 % (1998 to 2009) mirrored by a 25 
% increase in S. aureus-associated IE cases (Tamura et al., 2007). IE occurs when the 
endocardium is damaged which can result from catheters, turbulent blood flow from vascular 
abnormalities or particulates from intravenous drug use (Ster et al., 2005). This damage 
results in the deposition of platelets and fibrin from the exposure of the subendothelial cells 
which leads to the formation of sterile vegetations (Wilson et al., 2011). These vegetations 
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can become infected and S. aureus is highly suited for this as it encodes a number of proteins 
that bind to components in the vegetation (Goddeeris and Morrison, 1988, Wilson et al., 
2011). The clinical consequences of this infection include severe cardiac damage and 
dysfunction, persistent fever and peripheral emboli (Wilson et al., 2011, Bremel, 1980).  
 The formation of IE often occurs after the development of S. aureus bacteraemia 
which has an incidence of 10 % to 30 % per 100,000 persons-years in developed nations 
(Ward and Schultz, 1973). There are a number of factors which pre-dispose patients to S. 
aureus bacteraemia including human immunodeficiency virus (HIV) infection, intravenous 
drug use and hospital procedures such as haemodialysis (Wilson et al., 2011).  SSTI 
infection can also progress to bacteraemia and the incidence of this has increased along with 
the incidence of CA-MRSA SSTIs (Luong et al., 2002).  
 S. aureus has been shown to be one of the leading causes of nosocomial pneumonia 
associated with 28 % to 40 % of infections in the USA (Herron-Olson et al., 2007b, Ono et 
al., 2008b). Incidence of S. aureus community associated pneumonia (CAP) is relatively low 
(2 % to 3 % of cases) (Lina et al., 2004a). However S. aureus CAP is associated with poorer 
outcomes for the patient, particularly when the disease manifests as necrotising pneumonia 
(Thomas et al., 2007). The emergence of necrotising pneumonia is associated with a number 
of S. aureus isolates including clinically-important strains such as the USA300 CA-MRSA 
clone (Orwin et al., 2002, Thomas et al., 2007, Lina G., 2004). The pathology observed in S. 
aureus pneumonia is primarily mediated by the hosts own immune response; it is 
characterised by a large leukocyte infiltration resulting in severe tissue damage from 
inflammation, and the activity of a number of toxins secreted by S. aureus including α-
haemolysin (Wilson et al., 2011, Fitzgerald et al., 2001a, Bramley et al., 1989). Mortality 
resulting from nosocomial S. aureus pneumonia can be as high as 50 % and mortality rates 
for S. aureus CAP were found to be equally high at 56 % (Somerville et al., 2002, Vojtov et 
al., 2002).     
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1.1.3 Community-associated methicillin resistant S. aureus (CA-MRSA) 
CA-MRSA was first identified in Australia in 1993, and has become a serious clinical 
problem worldwide (Fitzgerald et al., 2001a, Deringer et al., 1997). In the last 30 years since 
emerging, CA-MRSA has established itself and diversified in the human population 
(Deringer et al., 1996). CA-MRSA tends to affect patients who are seen as healthy and have 
no risk factors associated with MRSA. In contrast to HA-MRSA, people infected by these 
strains tend to be younger, with median age for CA-MRSA of 23 years versus 68 years 
median age for HA-MRSA (Wilson et al., 2011).  
 The pulse field gel electrophoresis (PFGE) CA-MRSA clone USA300 has become 
dominant in the USA (Fitzgerald et al., 2001a, Deringer et al., 1997, Wilson et al., 2011) and 
is the leading clone of S. aureus associated with SSTIs in the USA (Choi et al., 1989, 
Connelley et al., 2009, Elsik et al., 2009). USA300 isolates emerged from the multilocus 
sequence type (MLST) clonal complex (CC) 8, by acquisition of the staphylococcal 
chromosome cassette mec (SCCmec) type IV and are typically characterised by the presence 
of the Panton-Valentin leucocidin (PVL) gene (Tenover et al., 2006). The role of this toxin 
in S. aureus pathogenesis will be discussed in more detail in section 1.5.3.  
USA300 is the causative agent of a wide array of life threatening diseases including 
necrotising pneumonia, severe sepsis and necrotising fasciitis (Holtfreter et al., 2007). It has 
occurred in a variety of community settings including new-born nurseries, military barracks 
and amongst athletics teams (Guinane et al., Lowder et al., 2009a, Herron-Olson et al., 
2007a). It has been reported that USA300 isolates can spread within individual households 
and inferred to persist between 2-8 years (Smyth et al., 2009). This can help explain why 
some patients, who are susceptible to SSTI caused by USA300, keep suffering recurrent 
infections (Fitzgerald et al., 2001a). There is evidence to suggest that unlike other clinical S. 
aureus strains, the USA300 clone relies more on core-genome encoded virulence factors and 
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differential regulation of these factors rather than determinants encoded in the accessory 
genome (Gaskill and Khan, 1988, Tseng et al., 2004).  
Also associated with USA300 isolates is the carriage of the arginine catabolic 
mobile element (ACME) which may contribute to the success of USA300 (Regassa et al., 
1991). ACME in USA300 has been shown to have a very high level of homology to an 
element found in S. epidermidis and it is hypothesised that the transfer of ACME occurred 
from S. epidermidis into the USA300 lineage around the time the ancestor of this clone 
emerged (Derzelle et al., 2009, Guinane et al., 2008). The role of ACME in S. aureus 
pathogenesis has not been clearly defined but it has been reported the element encodes SpeG, 
an enzyme linked to the degradation of polyamines which are secreted by the skin and are 
toxic to S. aureus (Herron-Olson et al., 2007a, Shaw et al., 2006). 
 
1.2 Antibiotic resistance in S. aureus  
Methicillin resistance is mediated by the SCCmec element which contains mecA encoding 
penicillin binding protein 2A (PBP2A) which confers resistance to all β-lactam antibiotics 
(Guinane et al., 2008). Analysis of the S. aureus sequence type (ST) 5 demonstrates that this 
clone appeared to have evolved multiple times, in many countries, through acquisition of 
the SCCmec element by methicillin sensitive strains (Nubel et al., 2008). This suggests that 
methicillin resistance arises locally rather than spread over a geographical area of a single 
transformed clone (Kazmi et al., 2001, Broudy et al., 2001). SCCmec has diversified quite 
considerably, with at least 10 SCCmec types characterised to date (Kazmi et al., 2001, 
Broudy et al., 2001). As a result SCCmec can vary greatly in size and the type of resistance 
types of antibiotics other than β-lactams that they can confer resistance to. For example, the 
SCCmec type II can encode resistance to erythromycin, spectinomycin and tobramycin 
(Takei et al., 1993).  
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Vancomycin has been the gold standard antibiotic for managing serious MRSA 
infection for some time but due to its widespread use strains have emerged with decreased 
susceptibility (Ulrich, 2000, Holtfreter et al., 2004). These strains, termed vancomycin 
intermediate Staphylococcus aureus (VISA), have a minimum inhibitory concentration 
(MIC) above 2 mg/l (Holtfreter et al., 2004). Strains with MIC of more than 2 mg/l are 
associated with a much higher level of treatment failure for patients with severe MRSA 
infection (Wilson et al., 2011). The prevalence of these strains has increased from 2.6 % in 
2004 to 5.6 % in 2009 (Fitzgerald et al., 2001a, Jarraud et al., 2001a). High level 
vancomycin resistance can be conferred by the transfer of the VanA plasmid from 
Enterococcus species, although this is still rare (Johns and Khan, 1988, Fitzgerald et al., 
2001a). New antimicrobials have been tested and shown promise in the clinic including 
daptomycin (Jarraud et al., 2001a). These new compounds have also been developed 
alongside the deployment of new therapy strategies which include the use of combined 
administration of β-lactams with vancomycin or daptomycin and have been shown to 
improve patient outcomes for serious skin infections and pneumonia (Ono et al., 2008b, 
Johns and Khan, 1988). While novel antibiotics and strategies are being developed, the 
continued increase of antimicrobial resistance constantly threatens the efficacy of these 
treatments. 
 
1.3 S. aureus Evolution and Genetics 
1.3.1 Genome organisation of S. aureus 
Evolution of S. aureus has led to the generation of a diverse group of strains which can 
colonise a wide range of hosts, evade the immune system of these hosts and deploy an array 
of strategies to resist antibiotics (Lindsay and Holden, 2006, Ben Zakour et al., 2008). The 
genome of S. aureus can be divided into a core-, core variable- and an accessory region 
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(Fernandez et al., 2006). The core genome of S. aureus is composed of approximately 75 % 
of genes and includes all genes essential for growth, survival and some virulence and 
resistance genes found in all strains of S. aureus (Jarraud et al., 2001a, Thomas et al., 2006). 
The core variable component, making up approximately 10% of the S. aureus genome,  is 
composed of genes shared by strains of the same evolutionary lineage which may exhibit a 
higher rate of nucleotide substitution compared to core genes (Ho et al., 1989, Deringer et 
al., 1997). The core variable component often includes genes associated with niche adaption 
and host species specificity in colonisation and infection (Marr et al., 1993).     
The accessory genome is composed of genes that vary from strain to strain and 
contribute to non-essential functions such as antimicrobial resistance, alternative metabolic 
substrate utilization and virulence determinants (Marr et al., 1993). The accessory genome of 
S. aureus is composed of mobile genetic elements (MGE) such as prophages, plasmids and 
genomic islands including the S. aureus pathogenicity islands (SaPIs) (Fitzgerald et al., 
2001a). MGEs allow S. aureus to rapidly adapt to new niches and respond to new selective 
pressures such as antibiotics (Wilson et al., 2011, Lina et al., 2004b).  MGEs can be 
transferred through three major mechanisms: transformation (the uptake of naked DNA), 
transduction (bacteriophage mediated transfer) and conjugation (exchange of DNA through 
direct contact) (Lina et al., 2004b). 
 
1.3.2 Mechanisms of S. aureus evolution 
In S. aureus, point mutations have been show to outnumber recombination events leading to 
a clonal population structure (Ono et al., 2008b, Seo et al.). The generation time of bacteria 
allows successful alleles to become dominant relatively quickly throughout a clonal 
population (Thomas et al., 2009, Ono et al., 2008a). The non-synonymous mutations 
generated through this mechanism can help contribute to host adaption. For example, single 
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nucleotide polymorphisms (SNPs) in the dltB gene of S. aureus have been shown to allow 
human strains to adapt to the rabbit host in parallel in multiple lineages (Seo et al.). Point 
mutations have also been shown to contribute to the resistance of S. aureus to certain 
antibiotics including daptomycin, vancomycin and rifampicin (Thomas et al., 2009).  
Bacteriophages play a major role in disseminating genes across the S. aureus 
population and there are many examples of the dissemination of important virulence factors 
transmitted by the activity of phage in S. aureus (Ono et al., 2008a, Deringer et al., 1997). 
The genes LukSF which encode the leukocidin PVL have been shown to be transferred 
through S. aureus populations by a diverse group of bacteriophages (Fitzgerald et al., 2001a). 
The β-haemolysin converting phage carries the immune evasion cluster (IEC) which inserts 
into the β-haemolysin gene encoding the virulence genes scn, chp, sak and sea (Fitzgerald et 
al., 2001a). The acquisition of genes from phage can allow S. aureus to adapt to a new host 
as exemplified by ruminant adapted SaPIs (e.g. SaPIov2), which are transmitted by phage 
and can transmit host adapted alleles of important virulence factors such as the ruminant-
specific von Willebrand factor binding protein (vWBP) (Thomas et al., 2009).  
Plasmid-encoded antibiotic resistance has been well reported in S. aureus and these 
plasmids have been shown to be able to confer resistance to antimicrobials across many S. 
aureus isolates (Thomas et al., 2009). Plasmids have been shown to carry multiple resistance 
genes and virulence determinants in S.aureus. The plasmid-encoding exfoliative toxin B 
plasmid, pETB, has also been reported to carry multiple resistance genes which confer 
resistance to penicillin, erythromycin, aminoglycoside and gentamicin (Ferry et al., 2008). 
Other examples of plasmid-encoded virulence determinants include a number of 
superantigens which are found primarily on two plasmids, the pIB485-like plasmid 
(encoding sej, ser and sed) and the Pf5 plasmid (encoding ser, sej, ses and set) (Seo et al., 
Thomas et al., 2009, Connelley et al., 2009). S. aureus plasmids encoding the crf gene confer 
resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin 
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classes of antibiotics by methylation of the A2502 rRNA base in the 23S subunit of the S. 
aureus ribosome (Seo et al., 2010b).  Carriage of plasmids encoding crf has been reported in 
a number of important clinical lineages of S. aureus including USA300 and the livestock 
associated MRSA lineage CC398 and there is evidence to suggest further dissemination of 
plasmids carrying this gene into other clinical isolates and into other species of staphylococci 
(Thomas et al., 2009, Deringer et al., 1997, Ebling et al., 2001, Kuroishi et al., 2003).  
Large scale modifications of the S. aureus genome allowing for the evolution and 
adaption to new host species over time have been well reported (Ebling et al., 2001). 
However there has been recent evidence to suggest that S. aureus can exhibit a great deal of 
within-host diversity which can contribute to evolution and host adaption over the course of 
a single infection (Fitzgerald et al., 1997, Fitzgerald et al., 2000, Kuroishi et al., 2003). In a 
transmission network studied in a veterinary hospital the diversity of an S. aureus infection 
was examined and multiple isolates from a single canine host were sequenced (Dauwalder et 
al., 2009). This revealed that a number of SNPs had accumulated during the infection and 
non-synonymous changes were observed in genes including the agr quorum sensing gene 
regulator (Virtaneva et al., 2005). Lower activity of the agr regulator is associated with 
higher levels of antimicrobial resistance and indicates the bacterial population is responding 
to selective pressures in the host (Guinane et al., 2008, Tollersrud et al., 2006, Pellegrino et 
al., 2008).  
Evolution and adaption to new host environments has been demonstrated to require 
both the gain and loss of genes (Tollersrud et al., 2006). It has been shown that the 
acquisition of the IEC is critical for the CC398 LA-MRSA isolates to be able to transfer and 
adapt to the human host (Guinane et al., 2008). Conversely isolates of CC8 from bovine 
hosts were found to be devoid of the β-haemolysin converting prophage (Anderson, 1982). 
This demonstrates that the accessory genome of S. aureus is highly dynamic, acquiring genes 
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that will aid survival in a new environment and losing redundant genes that may have a high 
fitness cost or generating a strong immune response in the host.  
 
1.3.3 Restriction modification systems and other defences against foreign DNA 
Restriction modification (RM) systems present a barrier to mobile elements but are 
necessary to prevent the destruction of a bacterial population by a lytic phage (Herron-Olson 
et al., 2007b). Type I RM systems are found in the majority of isolates of S. aureus and are 
made up of three subunits which form a complex that mediates the addition of a methyl 
group on to adenosine bases of target sequences and prevents the degradation of the 
sequence from restriction enzymes (Kenny et al., 1992, Bramley et al., 1989). The complex 
is made up of a restriction subunit (hsdR), a modification subunit (hsdM) and a specificity 
subunit (hsdS) (C.M. Guinane, 2007). The hsdS subunit is highly stable in single lineages 
and this allows DNA within a CC to be exchanged without restriction, resulting in each 
lineage sharing many of the same MGEs (e.g. CC1, CC5 and CC8) and has led to the 
independent evolution of distinct S. aureus lineages (Brosnahan et al., 2009, Connelley et al., 
2009).  
Type II RM systems are endonucleases which target specific palindromic sequences 
about 4 nt to 8 nt in length. The presence of these enzymes has been reported in S. aureus but 
found to be extremely rare (Bosc and Lefranc, 2000). The Type IV RM systems are the most 
recent RM systems to have been identified and are widespread in S. aureus. They encode a 
single enzyme gene that can detect the methylation status of a DNA fragment and degrade it 
(Sriskandan et al., 2001). This system is unlike other restriction modification systems as it 
will degrade modified DNA rather than unmodified DNA (DaSilva et al., 2002, Yeung et al., 
1996). In addition to type I RM, the type IV RM system has presented a major barrier to 
genetic manipulation of S. aureus as DNA introduced directly from E. coli is degraded after 
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transfer (Faulkner et al., 2005, Peavy et al., 1970). Improved understanding of the type IV 
RM system has allowed the development of E. coli strains which amplify plasmids that can 
be directly transferred from E. coli into S. aureus without the need for an intermediate host 
such as S. aureus RN4220. This is achieved by directly modifying the DNA so it is not 
vulnerable to digestion by the type IV modification system (Park et al., 2004, Kelm et al., 
1997).  
The resistance to foreign elements is also mediated in S. aureus, like many other 
prokaryotes, by clustered regularly interspaced short palindromic repeats (CRISPRs) of 
which at least 45 loci have been identified (Ballingall et al., 2004).  CRISPR sequence with 
the CRISPR associated protein (Cas) system can identify and degrade exogenous DNA and 
block phage replication by the production of interfering RNAs (Ellis, 2004, Llewelyn et al., 
2006). In E. coli, the number and diversity of CRISPR loci had an inverse relationship with 
the pathogenicity of the isolate tested, which suggests that bacteria with a lower level of 
CRISPR diversity can acquire more mobile elements but this is balanced against a higher 
vulnerability to destruction by phage (Elsik et al., 2009). S. aureus has also been shown to 
exploit a mechanism that reduces the lytic activity of bacteriophages and confer resistance to 
foreign DNA, but still allows the transfer of mobile genetic elements (Le Maréchal C, 2009). 
The bacteriophage-associated satellite elements, SaPIs can interfere with the transcription of 
phage genes resulting in the production of a higher number of phage particles containing the 
SaPI element only, leading to a higher distribution of SaPIs in the bacterial population 
(Arden et al., 1995).  
 
1.4 Human Immune System 
To establish an infection in humans S. aureus must interact with the immune system and 
avoid destruction (Deringer et al., 1997). S. aureus has evolved numerous mechanisms 
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which contribute to avoidance of clearance by the human immune system, these factors will 
be discussed in detail after first considering some of the key mechanisms deployed in the 
human host to provide immunity to bacterial pathogens like S. aureus.  Innate mechanisms 
such as neutrophil phagocytosis or complement-mediated destruction are the main 
mechanisms with which the host can clear S. aureus before adaptive responses such as T-
lymphocytes are employed (Thomas et al., 2009).  
 
1.4.1 Neutrophil granulocyte 
The neutrophil or polymorphonuclear leukocyte (PMN) is the most common leukocyte 
circulating in the mammalian bloodstream and the activity of these cells is the primary 
mechanism of clearance of S. aureus (Seo et al., 2010b). Neutrophils are phagocytes that, 
when activated by signals such as IL-8, rapidly transmigrate to the site of infection and 
phagocytose invading organisms (Fig: 1.1) (Arnaud et al., 2004). Neutrophils also contain 
granules that can be released from the cell or fused with the lysosome (Bateman et al., 2001). 
They contain a range of enzymes such as elastase or serine proteases which can degrade 
microbial cells (Wilson et al., 2011). Neutrophils can also release a burst of reactive oxygen 
species such as hydrogen peroxide which are utilised to kill internalised microbes (Wilson et 
al., 2011). Another mechanism exploited by neutrophils is the formation of neutrophil 
extracellular traps (NETs). NETs are formed when the neutrophil releases extracellular DNA 
which forms a mesh that can trap invading microorganisms (JR Fitzgerald, 1997). When 
activated, neutrophils release a range of chemoattractants including host defensins that can 
exhibit antimicrobial functions and can amplify the recruitment of cells such as monocytes 
(Fitzgerald et al., 2001a). Unlike macrophages, neutrophils undergo apoptosis following 
phagocytosis which means they do not perform any antigen processing or presentation 
functions (Kreiswirth et al., 1983). Following apoptosis, neutrophils display an altered cell 
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surface which signals macrophages to take up the cells along with the degraded 
microorganisms inside (Holden et al., 2004, Baba et al., 2002). This process is termed 
efferocytosis and is a key step to clearing an infection and managing the response of 
neutrophils which can release a wide range of factors into the host that cause damage to host 
tissues and cells (Kuroda et al., 2001).   
 
1.4.2 Complement  
Complement is part of the humoral immune system and is made up of a number of proteins 
that can directly interact with invading pathogens leading to opsonisation, or killing by the 
formation of the membrane attack complex (MAC) which creates a destabilising pore in the 
surface of a pathogen (Kuroda et al., 2001). The Complement system is made up of three 
different pathways which differ in how they are initially activated; the classical pathway, 
alternative pathway and the lectin pathway. All three pathways activate homologues of the 
C3 convertase which cleaves the component C3 into C3a and C3b leading to a cascade of 
protein cleavage that leaves the surface of the invading cell coated with C3b and C5b 
opsonins for recognition by phagocytes and clearance (Fig 1.1) (Kuroda et al., 2001). The 
cleavage of C3 and C5 also release C3a and C5a which are powerful chemoattractants for 
PMNs (Fig 1.1) (Neoh et al., 2008). Deposition of C5b is also the first step in the formation 
of the MAC complex which is then followed by the deposition of C6, C7, C8 and then 
polymeric C9 which forms the majority of the pore (Lowder et al., 2009b). Lysis of the 
target can occur rapidly, although in nucleated targets the lysis can be resisted, but this leads 
to cell dysfunction and pro-inflammatory signal release (Diep et al., 2006).  
The classical pathway is activated by the binding of either IgM or IgG to the surface 
of the pathogen, then following this C1q binds to the antibodies and activates the formation 
of the C1-complex. The C1-complex is made up of C1q and two molecules each of C1r and 
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C1s. C1q can also bind to the surface of the pathogen independent of the immunoglobulins 
(Highlander et al., 2007). When formed in the C1complex, C1r, which is a serine protease, 
cleaves C1s (which is another serine protease) and activates it (Baba et al., 2008). The 
complex then in turn cleaves C4 and then C2 into C4a, C4b, C2a and C2b leading to the 
formation of the C4bC2a complex which is the version of C3 convertase used in this 
pathway (Gillaspy, 2006). Cleaved C3b later joins the C4bC2a to form the C5 convertase 
(Holden et al., 2004). The lectin pathway is homologous to the classical pathway except 
instead of antibodies and C1q, activation is initiated by the binding of bacterial 
carbohydrates by mannose-binding lectins and ficolins (Mwangi et al., 2007).  
 The alternative pathway is non-specific and does not require the binding of ligands 
prior to the cascade activation. C3 spontaneously splits by hydrolysis and can bind to 
hydroxyl or amino groups on the surface of pathogens (Mwangi et al., 2007, Guinane et al.). 
The cascade can be blocked by host proteins expressed to prevent cascade activation on host 
cells (Herron-Olson et al., 2007b). If it is not blocked C3b remains on the cell surface and 
can form the C3bBbp complex by the addition of factor B, D and P and forms the stable 
form of C3 convertase in this pathway (Gill et al., 2005a). This can cleave more C3 leading 
to the amplification of the signal on the surface of the pathogen and leads to the activation of 















Figure: 1.1a The role of neutrophils and complement in S. aureus clearance. Neutrophils 
circulating in the blood stream are activated and begin rolling on the surface of the 
endothelium. Once the cells have adhered to the endothelium they can transmigrate across 
the barrier and move by chemotaxis towards the site of infection. The humoral response can 
interact with invading S. aureus either opsonising the bacteria for phagocytosis with 























Figure 1.1b The molecular mechanisms involved in neutrophil responses to infection. 
This figure demonstrates the major molecular interactions involved in the neutrophil 
response to infection. (Activation) A neutrophil can be activated through a range of stimuli 
including pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide 
(LPS) or wall techoic acid (WTA) which are recognised by toll-like receptors (TLRs). Cells 
can also be activated by cytokines and chemokines such as IL-8 which signals the cell via 
the chemokine receptor CXCR1. (Chemotaxis) IL-8 is also an important chemokine 
involved in neutrophil chemotaxis along with GROα, pathogen associated molecules such as 
FLMP (Formyl-Methionyl-Leucyl-Phenylalanine) and anaphlatoxins such as C3a and C5a 
which are released as a result of complement deposition. (Rolling and Endocytosis) A 
neutrophil must roll along the inside of the endothelium and endocytose through the wall of a 
blood vessel to reach the site of infection once activated. During the immune response 
endothelial cells are induced to express P-selectin which binds to PSGL-1 expressed on the 
surface of neutrophils. This interaction allows the neutrophil to bind to the endothelial wall 
and begin the transmirgratory process. (Pathogen Recognition and Phagocytosis) At the 
site of infection the neutrophil can detect pathogens opsonised with either antibodies (such as 
IgG) which are detected by Fc receptors. Alternatively pathogen cell surfaces can be 
opsonised with deposited complement molecules such as C3b which are recognised by the 
complement receptor 1 (CR1) receptor. Neutrophils can respond to pathogen recognition by 
phagocytising the pathogen, releasing neutrophil granules containing antimicrobial 
compounds, releasing DNA which forms neutrophil extracellular traps (NETs) and releasing 









Human T-lymphocytes are an important group of cells which play a critical role in cell 
mediated immunity (Zhang et al., 2014, Zhu and Paul, 2008). There are many types T-cells 
which carry out different specialist functions as outlined in Table 1.1. The T-helper or CD4
+
 
T-cells become activated when the T-cell receptor (TCR) binds the major histocompatibility 
complex (MHC) class II on the surface of an antigen presenting cell (APC) (Krakauer, 
2010). Once activated the CD4
+
 cell can differentiate into a number of subtypes depending 
on the cytokines present (Fig 1.2). Th1 T-cell subtypes drive the cellular responses of the 
immune system by releasing cytokines such as interferon-γ (IFN-γ) and interleukin-2 (IL-2) 
which maximises macrophage-mediated killing,  induces the proliferation of CD8
+
 cytotoxic 
T-cells and drives B-cells to produce IgG (Zhang et al., 2014, Zhu and Paul, 2008). If the T-
helper cells are stimulated with IL-4 this will drive differentiation into the Th2 subtype which 
produces cytokines such as IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 that stimulate cells such 
as B-cells (to produce IgE), mast cells, basophils and eosinophils producing mediators such 
as histamine, serotonin and leukotriene (Hammad and Lambrecht, 2015, Zhu and Paul, 
2008). Helper T-cells can also interact directly with B-cells via TCR-MHC class II to 
stimulate the production of antibodies to specific antigens (Crotty, 2011). The cytokines 
produced by the Th1 response are inhibitory to the Th2 response and vice-versa resulting in a 
bias in the immune response depending on what type of pathogen has activated it i.e. bacteria 
and viruses are more commonly cleared by the Th1 response and extracellular pathogens 
such as helminths trigger the Th2 response (Hammad and Lambrecht, 2015, Zhang et al., 
2014). The Th17 response is a subset of T-helper cells that differentiate when antigen-
activated CD4
+
 T-cells are exposed to IL-6, IL-21, IL-23 or TGF-β (Bedoya et al., 2013). 
These cells produce IL-17a and IL-17F along with IL-21 and IL-23 which amplify the Th17 
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response (Bedoya et al., 2013). IL-17a and IL-17F are cytokines that have a proinflammatory 
effect and can induce the productions of other proinflammatory cytokines and chemokines 
including IL-8 and GRO-α which are chemoattractants of neutrophils (Matsuzaki and 
Umemura, 2007). It has been demonstrated that IL-17 contributes to S. aureus clearance in 


















Table 1.1 T-lymphocyte types and functions. 
T-Cell Type Molecular 
Marker 
Function Reference 
Helper CD4 TCR interaction with MHC class II 
loaded with processed antigen peptides 
activates specific T-cells and leads to the 
expression of cytokines that recruits the 
optimal response depending on which 
subtype the cells differentiates into. 
 
(Zhang et al., 
2014, Zhu and 
Paul, 2008) 
Cytotoxic CD8 TCR interacts with MHC class I on all 
nucleated cells. If foreign peptides are 
detected the T-cell induces apoptotic 
processes in the infected cell. This is the 
primary mechanism for removing virally 
infected or cancerous cells. 
 
(Zhang et al., 
2014) 
Memory CD4 or CD8, 
CD45RO 
Subset of antigen specific T-cells that 
can rapidly activate and expand when 
antigen specific to the cell is detected. 
These cells can express either CD4 or 
CD8 markers and revert to a helper or 
cytotoxic T-cell when activated. These 
cells are characterised by a high level of 
CD45RO expression. 
 
(Zhang et al., 











These cells recognize foreign/self-lipid 
presented molecules, such as CD1d, 
MR1, and CD1a. They act as a bridge 






CD4 These cells suppress inflammation at the 
end of an immune response to prevent 
excessive damage mediated by 
inflammatory processes. 
 
(Caramalho et al., 
2015) 
γδ T-cells TCR γδ TCR on these cells are made up of a γ 
and δ chain instead of α and β chains 
and are not restricted by MHC class I or 
II interactions. These cells recognize 
foreign/self-lipid presented molecules. 
They act as a bridge between the innate 



















Figure 1.2 Model of T-cell differentiation after stimulation with antigen. Processed 




 T-cells by the antigen presenting cell 
(APC). The stimulation of CD8
+
 T-cell sub-types with a specific antigen peptide and 
interleukin 2 (IL-2) results in the differentiation of cells into cytotoxic T-cells (Tc) which kill 
cells infected with intracellular pathogens. Stimulation of CD4
+
 T-cells results in the 
differentiation of T-cells into Th1 helper T-cells which can produce cytokines such as IL-2 
and interferon-γ (IFN-γ) which helps coordinate the Th1 cellular response. Exposure to IL-4 
during CD4
+
 T-cell stimulation drives differentiation of T-cells into Th2 helper cells which 
help activate B-cells to produce IgE. Th2 responses can be repressed by the IFN-γ when Th1 
response is activated and the Th1 response is repressed by the release of IL-4 and 
transforming growth factor-β when the Th2 response is activated. The Th17 response is 
activated by the exposure of CD4
+
 T-cell exposure to IL-6, IL-21, IL-23 or TGF-β. 
Stimulation of the Th17 cells with IL-6 and TGF-β drives the differentiation of regulatory 
cells and the factors IL-21 and IL-23 drive the differentiation of proinflammatory Th17 
which includes the production of IL-17A and IL-17-F which recruits and activates 







1.5 S. aureus pathogenesis  
S. aureus expresses a diverse array of both secreted and surface expressed virulence 
determinants. These factors allow S. aureus to adhere to the extracellular matrix molecules, 
spread in the host and evade the host immune response.  
 
1.5.1 Enzymes 
S. aureus secretes a wide range of exotoxins which enable the bacterium to survive in the 
host and contribute to virulence. These exotoxins include a large number of degradative 
enzymes such as nucleases, proteases and lipases which can be utilised by S. aureus to 
facilitate spread in the host by degrading tissue constituents (Koziel and Potempa, 2013). 
Examples of this are the cysteine proteases staphopain A and B which degrade fibrinogen 
and collagen, impair plasma clotting and may play a role in damaging the endocardium, the 
initial stage in the progression to endocarditis (Ohbayashi et al., 2011) Another protease that 
has been shown to play an important role in S. aureus pathogenesis is the metalloprotease, 
aureolysin (Cassat et al., 2013). Aureolysin, along with staphopain A and B and the serine 
protease V8 have been shown to interact with components of the complement system and 
contribute to the avoidance of complement killing (Jusko et al., 2014, Laarman et al., 2011). 
The protease-complement interaction may also contribute to S. aureus colonisation as V8 
and aureolysin interaction with C1q promotes deposition of C1q on the surface of S. 
epidermidis but not S. aureus giving S. aureus an advantage against this competitor (Jusko et 
al., 2014).  
Nucleases can be used by S. aureus to degrade DNA in neutrophil extracellular traps 
(NETs), which are deployed by neutrophils to restrict bacterial spread (Berends et al., 2010, 
Thammavongsa et al., 2013). S. aureus can also use the degradation of NETs to induce 
macrophage cell death, NETs are cleaved by nuclease and adenosine synthase which 
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produces deoxyadenosine and exposure to this molecule triggers the caspase-3 pathway in 
macrophages leading to macrophage apoptosis (Thammavongsa et al., 2013).  
Staphylocoagulase and vWBP can interact with the host enzyme, prothrombin, and 
manipulate its activity (McAdow et al., 2012).  Staphylocoagulase and vWBP can both bind 
to prothrombin and force a conformational change in prothrombin generating the formation 
of the staphylothrombin complex (Friedrich et al., 2003, Kroh et al., 2009). 
Staphylothrombin converts fibrinogen to fibrin which generates the formation of infected 
thrombi and assists in the establishment of infection in the host, and binding to the wall of 
blood vessels in a systemic infection (Claes et al., 2014, Panizzi et al., 2006, Bjerketorp et 
al., 2004). The fibrinogen conversion can also activate platelets which bind to fibrin formed 
by staphylothrombin and results in platelet aggregation (Vanassche et al., 2012). S. aureus 
can then interact directly with the platelets and establish infected thrombi (Vanassche et al., 
2012). The establishment of an infected fibrin network can modify the host response 
protecting S. aureus from direct interactions with leukocytes and allowing the bacteria to 
aggregate in a focal point which allows S. aureus to persist in vivo longer in comparison to a 
coagulase-deficient isogenic mutant (Loof et al., 2015, Vanassche et al., 2011). 
 
1.5.2 α-Haemolysin 
S. aureus also secretes other important exotoxins including the cytolytic toxins α-, β, γ- and 
δ-toxins which can lyse neutrophils aiding S. aureus evasion of the immune response 
(Alonzo and Torres, 2014). The α-toxin (Hla) secreted by S. aureus is a pore-forming toxin 
which is secreted as a single monomer and these monomers then assemble into a heptamer in 
the membrane of the target cell forming a β-barrel pore in the cell membrane resulting in 
cellular leakage and eventually lysis (Berube and Bubeck Wardenburg, 2013). This toxin has 
a wide target range of mammalian cells including monocytes and endothelial cells (Bhakdi 
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and Tranum-Jensen, 1991). It is critical to S. aureus pathogenesis and is encoded by the great 
majority of clinical isolates of S. aureus (Berube and Bubeck Wardenburg, 2013). The 
protein target for Hla is the ADAM-10 (a disintegrin and metalloprotease 10), a zinc-
dependent metalloprotease expressed as a transmembrane protein on a number of cell types, 
which explains how Hla can target a large number of cell types (Wilke and Bubeck 
Wardenburg, 2010). ADAM-10 binding by Hla allows the formation of the toxin pore which 
has been shown to be critical for Hla-induced tissue injury (Wilke and Bubeck Wardenburg, 
2010, Inoshima et al., 2011).  
Tissue disruption and damage to barriers such as skin, lung mucosa and vasculature 
is a feature of staphylococcal disease and much of this damage is attributed to the activity of 
Hla (Berube and Bubeck Wardenburg, 2013). The pore formed by the toxin can interfere 
with signalling pathways by causing an influx of Ca
2+
 ions into cells (Inoshima et al., 2011). 
The interaction of Hla with ADAM10 can also cause modifications to E-cadherin which 
together with pore formation can alter tight junctions and alter the integrity of epithelial and 
endothelial barriers (Powers et al., 2012).  Hla interaction with ADAM10 can also affect 
endothelial barriers by inducing inflammation via neutrophil activation and altering platelet 
activation. Inflammation of the endothelium can result in the reduction of wound repair and 
the formation of PMN-platelet aggregations in organs such as the lung leading to lethal 
sepsis (Powers et al., 2015). Hla has also been shown to contribute to the escape from the 
macrophage phagosome and then can prevent apoptosis of the infected cells by inducing the 
production of anti-apoptotic mediators such as myeloid cell leukemia-1 (MCL-1) allowing S. 







Leukocidins are toxins secreted by S. aureus as two distinct monomers, a slow (S) subunit 
and a fast (F) subunit based on the original purification of PVL (Finck-Barbancon et al., 
1991). When the monomers bind to their targets on the cell surface they assemble into an 
octomeric pore (composed of 4 F-subunits and 4 S-subunits) (Yoong and Torres, 2013). γ- 
toxin or HlgACB (expressed as either HlgAB or HlgBC) is a bi-component leukotoxin which 
is secreted as HlgA/C (S-subunit) and HlgB (F-subunit), the HlgA/C subunit binds to the cell 
first and then this is followed by the binding of the HlgB subunit (Kaneko et al., 1997). 
HlgACB is the only leukocidin that can lyse erythrocytes efficiently and is highly 
upregulated when S. aureus is incubated in blood, promoting survival (Malachowa et al., 
2011). HlgACB is encoded in most clinical isolates suggesting a critical role in pathogenesis 
(von Eiff et al., 2004) and has shown to be important in a murine model of sceptic arthritis 
demonstrating a role in vivo (Nilsson et al., 1999).  
Other bi-component toxins include the leukocidin A/B and E/D (LukAB and 
LukED).  LukAB was recently described and has been demonstrated to lyse neutrophils, 
monocytes, macrophage and dendritic cells (Dumont et al., 2011, Ventura et al., 2010, 
DuMont et al., 2013, Malachowa et al., 2012). LukAB is a bi-component cytotoxin which 
targets neutrophils by binding to the CD11b component of the MAC-1 complex (DuMont et 
al., 2013). Unlike other S. aureus bicomponent leukocidins LukAB forms heterodimers in 
solution rather than remaining as a monomer and the S subunit (LukA) includes extensions 
at the N- and C-terminus by 33 and 10 amino acids respectively (DuMont et al., 2014, 
Dumont et al., 2011, Badarau et al., 2015). Truncation of the C-terminal domain of LukA 
rendered the toxin inactive and more detailed study revealed a glutamic acid residue at 
position 323 was critical to toxicity, whereas deletion of the N-terminal domain only had a 
modest impact on cytotoxicity (DuMont et al., 2014). LukAB is the only leukocidin so far 
that has been reported to lyse neutrophils and monocytes after phagocytosis suggesting that 
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this toxin may contribute to escape from the phagosome (Dumont et al., 2011, Melehani et 
al., 2015).  
LukED targets neutrophils, lymphocytes, macrophages and dendritic cells by 
binding the CCR5, CXCR1 or CXCR2 receptors and by targeting these cells can promote S. 
aureus  survival during infection (Reyes-Robles et al., 2013, Alonzo et al., 2013). This toxin 
has been shown to promote bacterial growth in a murine model by targeting and destroying 
murine neutrophils, whereas deletion of the lukED genes or depletion of murine neutrophils 
abrogated the effect (Alonzo et al., 2012). LukED is highly conserved (100% amino acid 
identity found in all strains encoding this gene) and found in ~87% of clinical strains 
suggesting an important role in S. aureus pathogenesis (Alonzo et al., 2012). Another 
Leukocidin (LukMF’) was reported recently with specific toxicity for bovine neutrophils. 
The species-specificity is due to the binding partner of LukMF’, CCR1, which is expressed 
at high levels on bovine neutrophils but not on human neutrophils (Vrieling et al., 2015).  
PVL is another example of a bi-component β-pore forming cytotoxin which acts 
primarily on neutrophils (Kaneko and Kamio, 2004, Yoong and Torres, 2013). PVL is 
present in almost all CA-MRSA clones and heavily associated with necrotising skin lesions 
and pneumonia in CA-MRSA infections (Gillet et al., 2002, Bocchini et al., 2006, De Boeck 
et al., 2015). However some controversy surrounded the role of this toxin as contradictory 
evidence regarding its role in pathogenesis had been obtained from different animal models. 
In particular, murine models of infection had produced limited observable effects for this 
toxin (Diep and Otto, 2008, Voyich et al., 2006). Importantly PVL has been shown to be 
species-specific inducing rapid activation and cell death in human and rabbit neutrophils but 
not murine or simian cells (Löffler et al., 2010). Studies in rabbits have shown that PVL 
expression leads to more severe skin lesions (Lipinska et al., 2011), more severe and 
persistent osteomyelitis (Cremieux et al., 2009) and induces lung necrosis by activating and 
lysing PMNs (Diep et al., 2010). The target for PVL was identified as the C5a receptor on 
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the surface of neutrophils (Spaan et al., 2013). C5a exhibits variation among the animal 
species employed to investigate the role of PVL and explains the variation seen in these 
different studies (Spaan et al., 2013, Spaan et al., 2015). The host-specificity of PVL 
highlights the importance of understanding the molecular mechanisms involved in 
pathogenesis and using this information to select the most appropriate animal model.  PVL 
can act synergistically with  other haemolysins including β-toxin, LukED, γ-toxin and δ-
toxin and amplify both the cytolytic and proinflammatory effect of these toxins (Perret et al., 
2012). PVL can also induce the apoptosis of PMNs by targeting the mitochondria of these 
cells, PVL was shown to localise to the mitochondria in the cytosol in PMNs and it is 
suggested that the toxin forms pores in the mitochondria resulting the release of apoptogenic 
proteins cytochrome c and Smac/DIABLO (Genestier et al., 2005).  
Studies on the sublytic concentrations of leukocidins have indicated that these toxins 
have pro-inflammatory properties (Alonzo and Torres, 2014). Sublytic concentrations of the 
secreted toxins Hla, HlgACB, PVL and LukAB have all been found to activate the 
intracellular NOD-like Receptor (NLR) protein 3 (NLRP3) inflammasome in neutrophils, 
monocytes and macrophages leading to activation of Caspase 1 pro-inflammatory cytokines 
such IL-1β and IL-18, and induction of necrotic cell death (Davis et al., 2011, Holzinger et 
al., 2012, Melehani et al., 2015, Kebaier et al., 2012, Munoz-Planillo et al., 2009). This 
demonstrates that inflammation can be trigged by these toxins independent of pore formation 
(Holzinger et al., 2012). In a murine model, Hla induction of this caspase-1 inflammatory 
pathway was shown to induce abscess formation and lead to clearance of S. aureus (Cho et 
al., 2012). Conversely in the murine pneumonia model, the caspase-1 pathway activated by 
Hla resulted in more severe pathology (Kebaier et al., 2012). The activation of the NLRP3 
inflammasome is clearly an important function of haemolysins and leukocidins as these 
toxins overlap in their function (Yoong and Torres, 2013). However despite the functional 
overlap, it is not clear how the induction of inflammation enhances bacterial survival, one 
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possibility is that under certain conditions, inflammation and the associated tissue damage 
may allow S. aureus spread to different sites within the host (Vandenesch et al., 2012).  
 
1.5.4 Phenol soluble modulins 
Phenol soluble modulins (PSMs) are a group of short peptides made up of two groups, α-
PSMs (20-25 amino acids) and the longer β-PSMs (~44 amino acids) (Otto, 2014). In S. 
aureus 7 PSM peptides have been identified including δ-toxin (Otto, 2014). These short 
peptides form α-helices and this degree of helix formation appears to relate to the lytic 
potential of the peptide (Laabei et al., 2014). Increased production of PSMs has been 
associated with clinical isolates of MRSA from skin and soft tissue infections (SSTIs) and 
suggests these peptides play an important role in the pathogenesis of SSTIs (Berlon et al., 
2015).  The lytic activities of these peptides are readily inactivated in serum which suggests 
that extracellular cell lysis does not have a role during infection (Surewaard et al., 2012). 
These peptides have been shown to be expressed inside the phagosome, in PMNs, facilitating 
S. aureus escape from the phagosome and lysing cells from the inside (Surewaard et al., 
2013, Grosz et al., 2014). PSM peptides have been shown to induce the release of pro-
inflammatory cytokines from a range of cells including dendritic cells (DC) and regulatory 
T-cells (T-regs). Stimulation of DCs and T-regs in this way can lead to the release of the IL-
10 resulting in the dampening of the immune response (Schreiner et al., 2013). The PSM δ-
toxin was also shown to activate mast cells by inducing calcium flux into the cell which 
results in the release of mast cell granules promoting IgE and IL-4 production (Nakamura et 
al., 2013). Allergic skin diseases are characterised with a high level of δ-toxin and the 
dysregulation of mast cells which may provide a mechanism for the link between S. aureus 
colonisation and allergic skin disease (Nakamura et al., 2013) 
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PSMs have also been suggested to play a role in prosthetic joint infections. In the 
early stages of biofilm formation the expression of PSMs is low due to the low activity of the 
agr locus (Queck et al., 2008, Dastgheyb et al., 2015). As cell numbers increase PSMs are 
expressed and act as surfactants disrupting interactions between polysaccharide molecules 
such as polysaccharide intercellular adhesin (PIA) resulting in release of the bacteria from 
the biofilm and dissemination in the host (Dastgheyb et al., 2015). PSMs are also thought to 
play a key role in colonisation owing to their surfactant properties aiding growth at an 
oil/water interface (Otto, 2014). PSMs have shown to aid the spread of S. aureus growth 
over a wet surface aiding colonisation (Tsompanidou et al., 2013).  Furthermore, PSMs have  
been demonstrated to contribute to the formation of extracellular fibrils which stabilise S. 
aureus biofilms (Schwartz et al., 2012). There is also some evidence to suggest that PSMs 
may have antimicrobial activity as PSMα1 and PSMα2 have been demonstrated to exhibit 
anti-streptococcal activity, this may assist S. aureus to out-compete other bacteria at the site 
of colonisation (Joo et al., 2011).  
 
1.5.5 Other secreted immune modulatory proteins 
S. aureus secretes a battery of immunomodulatory proteins that can interfere with the 
function of both complement and neutrophils. Chemotaxis inhibitory protein of 
staphylococcus (CHIPS) functions by binding the formylated peptide receptor and the C5a 
receptor on neutrophils, blocking cheomtaxis to the site of infection (Postma et al., 2004). 
SCIN interacts with C3 convertases bound to the bacterial surface and prevents C3b 
deposition and phagocytosis (Rooijakkers et al., 2005). CHIPS and SCIN are both expressed 
at an early stage during S. aureus infection and blocks essential steps in the acute immune 
response (Rooijakkers et al., 2006). The formyl peptide receptor-like 1 inhibitor (FLIPr) and 
its homologue FLIPr-like have been shown to both have anti-inflammatory properties by 
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antagonising the formylated peptide receptor but also can bind to Fcγ receptors and interfere 
with IgG-mediated phagocytosis of neutrophils (Prat et al., 2006, Stemerding et al., 2013).  
The extracellular adherence protein (EAP) can mediate interaction between the bacterial cell 
wall and matrix proteins such as fibronectin and has also been shown to have a number of 
immunomodulatory effects such as the inhibition of the activity of neutrophil serine 
proteases including neutrophil elastase (Stapels et al., 2014, Geisbrecht et al., 2005). EAP 
has also been shown inhibit both the lectin and classical complement pathways by binding to 
the C4b component and blocking the formation of the C3 convertase (Woehl et al., 2014). 
EAP has also been shown inhibit both the lectin and classical complement pathways by 
binding to the C4b component and blocking the formation of the C3 convertase (Woehl et 
al., 2014). The extracellular fibrinogen binding protein (Efb) of S. aureus can bind to 
fibrinogen and prevent platelet aggregation (Shannon and Flock, 2004). Efb can also bind to 
complement component C3 simultaneously with plasminogen which in turn leads to the 
degradation of C3, this functional process is also seen in surface immunoglobulin-binding 
protein (Sbi) and contributes to the inactivation and removal of C3b from the surface of the 
bacteria (Koch et al., 2012). The combination of complement and fibrinogen binding 
interactions for Efb is suggested to create an ‘immune capsule’ around the bacteria which 
can reduce opsonophagocytosis of S. aureus (Ko et al., 2013). 
 
1.5.6 Staphylococcal superantigen-like proteins 
One of the largest groups of immune modulators is the family of 14 staphylococcal 
superantigen-like toxins (SSLs) which share a similar structure to staphylococcal 
superantigens (SAgs), but lack mitogenic activity (Fraser and Proft, 2008b). Instead they 
appear to have alternative roles in modulating the immune response (Table 1.2)  
(Thammavongsa et al., 2015). The ssl genes 1-11 are found in the VSaα region which is a 
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highly variable region of the chromosome of S. aureus. This region has been identified in all 
strains so far and can vary in size from 12 to 17 kB encoding at least 7 of the ssl genes 
(Fitzgerald et al., 2001b, Fraser and Proft, 2008b, Kuroda et al., 2001). The other three ssl 
genes are found at a distinct genomic region 0.7 MB upstream of vSaα (Fraser and Proft, 
2008b, Kuroda et al., 2001).  
The SSl-proteins studied so far have shown a range of functional properties that 
include inhibition of both the humoral and cellular immune response. For example, SSl7 was 
demonstrated to bind to complement factor C5 and the immunoglobulin IgA, and is therefore 
suspected to play a role in immune evasion in the mucosa (Langley et al., 2005, Bestebroer 
et al., 2010). SSl7 was shown to enhance the survival in blood of Lactococcus lactis when 
SSl7 was transformed into the bacteria (Lorenz et al., 2013). SSl7 was shown to reduce 
neutrophil migration in a peritoneum infection model with heat-killed S. aureus and C5 
binding capacity of SSl7 was shown to be critical to this function as a C5-binding mutant 
was incapable of blocking the migration of neutrophils (Lorenz et al., 2013). SSl10 can 
interact directly with IgG and block the association of C1q, a critical component in the 
classical complement cascade (Itoh et al., 2010b), whereas SSl8 binds to tenascin-C and 
attenuates the interaction between this molecule and fibronectin (Itoh et al., 2013). If 
tenascin-C cannot interact with fibronectin, keratinocyte motility is reduced and this effect 
reduces the speed of wound recovery (Itoh et al., 2013). 
To date, SSl5 is the best characterised neutrophil-binding SSl-protein with a number 
of distinct functions identified. For example, SSl5 can bind to neutrophils via the P-selectin 
glycoprotein ligand-1 (PSGL-1) which is used by the neutrophil to facilitate rolling on the 
surface of the endothelium prior to transmigration outside of the blood vessel (Bestebroer et 
al., 2007). The interaction of SSl5 with this target blocks neutrophil rolling, inhibits platelet 
adhesion and can reduce the formation of thrombi (Armstrong et al., 2012, Walenkamp et al., 
2010). The binding of SSl5 can also have an effect on neutrophil activation by inhibiting 
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calcium mobilisation after stimulation with the chemokines C3a, C5a and CXCL8 
(Bestebroer et al., 2009). SSl5 can also bind factors secreted by activated neutrophils such as 
the matrix metalloprotease 9 (MM9) which SSl5 can bind to and inhibit (Itoh et al., 2010a). 
Inhibition of MM9 may affect neutrophil migration as this enzyme is involved in regulation 
and migration of neutrophils over the basement membrane (Opdenakker et al., 2001). SSl5 
contains a binding motif that shares homology with conserved sialic acid binding proteins 
from other bacteria and viruses and can interact with human glycans (Baker et al., 2007). 
This binding site was found to be conserved in SSl2, SSl3, SSl4 SSl6 and SSl11 suggesting 
that these proteins can bind glycans expressed on immune cells (Baker et al., 2007). Despite 
these shared glycan binding sites being similar between these SSl-proteins, they do exhibit 
differential binding to glycans which suggests they have distinct tropisms to receptors 
expressed on the surface of cells (Baker et al., 2007, Hermans et al., 2012, Chung et al., 
2007).  
Functions identified for other neutrophil binding SSl-proteins include TLR-2 
antagonism by SSL3, and induction of phagocytosis of erythrocytes by SSl6 binding via 
CD47 (Bardoel et al., 2012, Fevre et al., 2014, Koymans et al., 2015). One feature of SSl-
proteins 4, 5 and 11 is that following glycan binding they are rapidly internalised into 
vesicles in neutrophils and macrophages (Chung et al., 2007, Hermans et al., 2012), which 
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Chemotaxis inhibition (Chung et al., 2007) 
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13 NK NK  
 
14 NK NK  
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1.5.7 Cell wall anchored proteins 
S. aureus encodes a diverse range of cell wall anchored (CWA) proteins that contribute to 
pathogenesis and to date at least 24 different proteins have been identified (Foster et al., 
2014). These proteins are important virulence factors as they can be used to adhere to host 
tissue components, bind proteins in blood, mediate host cell invasion and contribute to 
resistance against phagocytosis (Foster et al., 2014). Many CWA proteins bind extracellular 
matrix molecules and as such are termed MSCRAMMs (matrix surface components 
recognising adhesive matrix molecules) (Foster and Hook, 1998). The major MSCRAMMs 
that have been characterised (Table 1.3) include clumping factors (Clf) A and B and 
fibronectin binding proteins (FnBP) A and B.  Other groups of CWA proteins include the 
near iron transporter (NEAT) motif family, three helical bundle family and the G5-E repeat 
family (Table 1.3) (Foster et al., 2014).  
FnBPA and B both bind fibronectin, fibrinogen and elastin which are recognised and 
bound by the GPIIb/IIa integrin on resting platelets and can result in platelet activation and 
aggregation (Fitzgerald et al., 2006, Keane et al., 2007). S. aureus internalisation has also 
been shown to be dependent of FnBPs (Sinha et al., 2000). The FnBPs have also been 
associated with the formation of S. aureus biofilms and it is proposed that bacterial cell to 
cell interactions mediated via the FnBPs result in the accumulation of cells leading to the 
formation of a biofilm (McCourt et al., 2014, Herman-Bausier et al., 2015) 
Staphylococcal protein A (SpA) is a CWA protein that has been classically shown to 
bind the Fc region of IgG blocking the interaction between IgG and the Fcγ receptor on 
phagocytic cells (Deisenhofer, 1981). Blocking the Fc region prevents the opsonisation of 
the bacterial cell and reduces the rate of phagocytosis (Clarke and Foster, 2006). SpA has 
also been shown to bind von Willebrand factor (vWF) (a serum protein that mediates platelet 
adhesion at sites of endothelial damage) which may contribute to the formation of infected 
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thrombi (Hartleib et al., 2000, O'Seaghdha et al., 2006). SpA can also be released from the 
cell wall into the extracellular matrix allowing the protein to interact directly with human B-
cells (Becker et al., 2014). SpA can bind to the human VH clan III-encoded (VH3) B-cell 
receptor (BCR) which makes up about 50 % of VH genes and allows SpA to interact with 
over 30% of human B-lymphocytes (Silverman et al., 1993, Graille et al., 2000). This 
interaction of SpA and the BCR appears to drive the proliferation of VH3 B-lymphocytes 
(Kristiansen et al., 1994). This has been shown to occur in vitro, and supraclonal expansion 
of VH3 B-cell can also been observed in the murine sepsis model (Palmqvist et al., 2005). 
The superantigenic function of SpA can induce clonal deletion of non VH3 B-cell subsets and 
immunodominance of the VH3 subset which limits the host response to S. aureus infection 
by diminishing the B-cell repertoire (Pauli et al., 2014). SpA is critical to S. aureus 
pathogenesis as the IgG binding and B-lymphocytes interactions help S. aureus avoid 
immune surveillance and prevent the maturation of B-cell subsets that produce 
immunoglobulins that can inactivate or opsonise S. aureus (Falugi et al., 2013).   
ClfA is a protein that can bind fibrinogen and is the dominant protein involved in 
activation of platelets at the stationary phase of growth, contributing to the formation of 
infected thrombi (Foster et al., 2014). These molecules can engage resting platelet 
glycoprotein GPIIb/IIIa, aided by bound IgG molecules triggering activation of GPIIb/IIIa 
and aggregation of platelets (Loughman et al., 2005). A ClfA mutant, unable to bind 
fibrinogen, demonstrated that ClfA is able to induce platelet activation independent of 
fibrinogen by the deposition of complement (Loughman et al., 2005).  Complement 
association of ClfA can  also contribute to immune evasion as ClfA can bind to complement 
control factor 1 and increase C3b cleavage on the surface of the S. aureus cell wall resulting 
in reduced opsonophagocytosis and complement-mediated killing (Hair et al., 2010). Like 
ClfA, ClfB also binds fibrinogen and can meditate the activation of resting platelets 
(Miajlovic et al., 2007). Unlike ClfA, ClfB is only expressed in early exponential growth 
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phase, can bind cytokeratin 10 and plays a role in host colonisation on the skin and in the 
nasal passage (Weidenmaier et al., 2012, Schaffer et al., 2006, Mulcahy et al., 2012). It has 
also been shown that ClfB can contribute to biofilm formation in the absence of calcium 
(Abraham and Jefferson, 2012). By binding host fibrinogen, ClfA and ClfB may aid in the 
evasion of the host immune system by restricting the access of opsonins to the bacterial cell 
surface (Foster, 2005, Higgins et al., 2006).  
In addition to ClfA a number of CWA proteins have been shown to bind to 
components of the complement system. The collagen binding protein (Cna) interacts with 
both collagen in the extracellular matrix and has also been shown to be able to interact with 
C1q from the classical pathway of the complement system reducing complement activation 
in response to S. aureus infection (Kang et al., 2013). Bone sialoprotein-binding protein 
(BbP) can bind to the C4b binding protein and can inhibit bacterial killing and opsonisation 
by reducing the association of C3 complement fragments on the surface of the bacterial cell 
wall (Hair et al., 2013).  The iron uptake protein IsdH has also been associated with 
complement modification, although no ligand has been identified (Visai et al., 2009). A 
deletion mutant of IsdH in S. aureus demonstrated reduced virulence in a sepsis model and 
was engulfed at a higher rate by human neutrophils, these observations were linked to a 
higher level of C3b degradation on the surface of S. aureus in the presence of IsdH (Visai et 
al., 2009). Serine-aspartate repeat protein E (SdrE) can also manipulate complement 
activation by binding to complement factor H which resulted in a higher level of conversion 
of C3b to iC3b (inactive C3b) on the surface of the bacterial cell and preventing the 
activation of the complement cascade (Sharp et al., 2012).  
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Table 1.3 Major characterised CWA proteins from S. aureus and their ligands (adapted from Foster et al. (2014)). 
CWA protein Ligands Function Reference 
MSCRAMMs    
Bone sialoprotein-binding protein (Bbp) 
 
Bone sialoprotein, C4b binding 
protein, fibrinogen 
Adhesion to ECM, Immune evasion by blocking 
C3 deposition 
 
(Hair et al., 2013, Vazquez et al., 
2011) 
Clumping Factor A (ClfA) 
 
 
Fibrinogen and complement 
regulator factor I 
Adhesion to ECM, Immune evasion by 
degradation of C3b 
(Hair et al., 2010, Ganesh et al., 
2008) 
Clumping Factor B (ClfB) Fibrinogen, loricrin and 
cytokeratin 10 
Adhesion to ECM, Nasal colonisation (Ganesh et al., 2011, Xiang et al., 
2012) 
 





Collagen and C1q 
 
Adhesion to collagen rich tissue, immune 




(Ross et al., 2012, Kang et al., 
2013) 
Fibronectin Binding protein A (FnBPA) Fibronectin, fibrinogen and 
elastin 
Adhesion to ECM, host cell invasion (Keane et al., 2007, Stemberk et al., 
2014, Bingham et al., 2008) 
 
Fibronectin Binding Protein B (FnBPB) Fibronectin , fibrinogen and 
elastin 




Serine-aspartate repeat protein C (SdrC) Desquamated epithelial cells 
and β-neurexin 
Potential role in nasal colonisation (Corrigan et al., 2009, Barbu et al., 
2010) 
Serine-aspartate repeat protein D (SdrD) Desquamated epithelial cells  Potential role in nasal colonisation (Corrigan et al., 2009) 
Serine-aspartate repeat protein E (SdrE) Complement Factor H Immune evasion by degradation of C3b (Sharp et al., 2012) 
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CWA protein Ligands Function Reference 
 
Three Helical Bundle 
   
Staphylococcal Protein A (SpA) IgG, IgM (B-cell receptor) and 
von Willebrand factor 
Opsonophagocytosis avoidance, B-cell 
superantigen and a mediator of endovascular 
infection 
(O'Seaghdha et al., 2006, Foster, 
2005) 
 
NEAT motif family    




Haem, cytokeratin 10, 
fibronectin and fibrinogen 
Iron uptake, adhesion to desquamated epithelial 
cells, resistance to lactoferrin immune evasion 
by conferring resistance to host defensins and 
antibacterial lipids 
 
(Clarke et al., 2004, Clarke et al., 
2007, Clarke et al., 2009, Clarke 
and Foster, 2008) 
Iron Regulated Surface determinant B 
(IsdB) 
 
Haem, Haemoglobin and β3 
integrins 
Iron Uptake and invasion of host cells (Miajlovic et al., 2010, Pishchany et 
al., 2014, Zapotoczna et al., 2013, 
Pilpa et al., 2009) 
 
Iron Regulated Surface determinant H 
(IsdH) 
 
Haem, haemoglobin and an 
unknown complement 
component 
Iron uptake and accelerated degradation of C3b  (Visai et al., 2009, Pilpa et al., 
2009) 
G5-E repeat family    
S. aureus surface protein G (SasG) 
 
Not determined Adhesion to desquamated epithelial cells and 
biofilm formation 
(Roche et al., 2003, Geoghegan et 
al., 2010) 
Plasmin-sensitive surface protein (Pls) Not determined Adhesion to desquamated epithelial cells (Roche et al., 2003) 
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1.5.8 S. aureus host cell invasion  
S. aureus has conventionally been considered to be an extracellular pathogen, but in 1986 it 
was first observed internalised in non-professional phagocytes (Hamill et al., 1986, Vann et 
al., 1986). S. aureus internalisation has been found to be mediated by FnBPA and B by 
forming a bridge via fibronectin to host cell α5-β1 integrin (Foster et al., 2014). Extracellular 
adherence protein (EAP) has also been demonstrated to be an invasin and can promote the 
invasion of S. aureus and other staphylococci into keratinocytes (Sinha and Fraunholz, 2010, 
Bur et al., 2013). The iron regulated surface determinant B (IsdB) can also mediate S. aureus 
invasion into host cells independent of fibronectin and the fibronectin binding proteins of S. 
aureus (Zapotoczna et al., 2013).  
 Once S. aureus has been internalised into the host cell it can survive for a prolonged 
period (up to two weeks) in the invaded cell. But it is unclear how the bacterium persists 
inside the cell (Garzoni and Kelley, 2009). Transcriptome analysis has suggested extensive 
modifications in bacterial gene expression post-invasion (Garzoni et al., 2007). Of note gene 
expression of metabolic genes, indicative of nutrient restricted conditions, see increased 
activity which is in contrast to several haemolytic toxins including hla (Garzoni et al., 2007). 
It is suggested that small colony variants (SCV), a phenotypic variant of some S. aureus 
strains, could be better adapted to the intracellular environment (Sendi and Proctor, 2009). 
SCVs produce less factors that might damage host cells, such as Hla, and have a reduced 
growth rate allowing these bacteria to persist in host cells for longer periods (Proctor et al., 
2006). Once S. aureus has been taken up into host cells it can manipulate host cell apoptosis 
through EsxA and then can mediate release of the bacteria through the activity of EsxB 
(Korea et al., 2014). 
The importance of host cell invasion by S. aureus is unclear but it is likely S. aureus 
invades cells to avoid the host immune response and establish a chronic infection (Sendi and 
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Proctor, 2009, Kalinka et al., 2014). It has also been shown that S. aureus internalisation was 
necessary to induce endothelial cell apoptosis (Haslinger-Loffler et al., 2005). This may 
contribute to entry or exit from the vasculature, which allows localised infections to become 
systemic (Clarke and Foster, 2006).  
 
1.6 Superantigens 
The SAgs are a family of non-glycosylated proteins secreted by pathogens which induce 
non-specific T-cell proliferation (Spaulding et al., 2013). SAgs bind MHC class II  and the 
T-cell receptor (TCR) forming a trimeric complex which bypasses normal antigen 
presentation and activation (Fig 1.3) (Baker and Acharya, 2004, Fraser and Proft, 2008b). 
SAgs have been identified in a number of different bacterial species including Streptococcus 
spp., Yersinia enterocolitica and Mycoplasma arthritidis in addition to some viruses such as 
Epstein-Barr virus and gammaherpes virus  (Fraser and Proft, 2008b, O'Flaherty et al., 
2015). The staphylococcal SAgs represent the best characterised group with over 25 
identified to date (Table 1.3) (Ono et al., 2015, Spaulding et al., 2013). In general the 
primary function of SAgs is to subvert adaptive immune recognition and cause significant 
damage to the host, permitting the progression of infection (Stach et al., 2014). SAgs are 
generally heat and protease resistant and can also maintain functional activity after exposure 
to weak acids and weak bleach solutions, allowing the staphylococcal enterotoxins (SEs) to 
survive the harsh conditions of the gut and cause food poisoning (McCormick et al., 2001, Li 



















SEA 27.1 + 1, 5, 6, 7, 9, 15, 16, 18, 
21, 22, 24 
LAS+HAS  ɸSa3n 
SEB 28.3 + 3, 12, 13, 14, 15, 17, 20 LAS SaPI 
SEC 27.5 + 3, 12, 13, 14, 15, 17, 20 LAS SaPI 
SED 26.4 + 1, 3, 5, 8, 9, 12, 14 LAS+HAS Plasmid (pIB485-like) 
SEE 26.4 + 5, 6, 8, 9, 13, 16, 18, 21 LAS+HAS Integrated Plasmid 
SEG 27 + 3, 12, 13, 14, 15 LAS vSAβ 
SEH 25.2 + Vα8, Vα10 LAS+HAS Transposon 
SEI 24.9 + 1, 5, 6, 23 LAS+HAS Plasmid (pF5) 
SEJ 28.5 + 8, 21 LAS+HAS SaPI/ɸSa3n/Plasmid 
(pF5/ pIB485-like) 
SEK 26 + 1, 5, 6 LAS+HAS SaPI 
SEL 26 + 1, 5, 7, 16, 22, 23 LAS+HAS vSAβ 
SEM 24.8 + 8, 9, 18, 21 LAS+HAS vSAβ 
SEN 26.1 + 7, 8, 9, 17 LAS+HAS vSAβ 
SEO 26.7 + 5, 7 LAS+HAS vSAβ 
SEP 27 + 5, 8, 16, 18, 21 LAS+HAS ɸSa3n 
SEQ 28 + 6, 21 LAS+HAS SaPI/ɸSa3n 
SER 27 + 3, 12, 14 LAS Plasmid (pF5/ pIB485-
like) 
SES 26.2 + 9, 16 LAS+HAS Plasmid (pF5) 
SET 22.6 + NK LAS Plasmid (pF5) 
SElU 27.1 NK 13, 14 LAS vSAβ 
SElW 26.7 NK NK LAS vSAβ 
SElV 25 NK 6, 18, 21 LAS+HAS vSAβ 
SElX 19.3 NK 1, 6, 18, 21 NK Core genome 
SElY 22.5 + NK NK NK 
TSST-1 22 - 2 LAS SaPI 
a
 NK, Not known 
b
 Data compiled from references: (Argudin et al., 2010, Spaulding et al., 2013, Omoe et al., 
2013, Seo et al., 2010a, Ono et al., 2015) 
c














Figure 1.3 Superantigens induce T-cell proliferation by by-passing normal antigen 
presentation. (A.) Conventional antigen presentation and specific T-cell activation.  An 
antigen presenting cell (APC) processes antigen and loads an antigen peptide onto the 
binding site of the MHC class II molecule which in turn is presented to a specific T-cell 
receptor (TCR). (B.) SAgs crosslink the MHC class II and TCR which induces non-specific 
activation of T-cells. The SAg binds to the MHC class II outside the antigen presentation site 











1.6.1 SAg structure and binding  
The staphylococcal SAg protein family ranges in size from 19 kDa to 29 kDa and they have 
two major domains including an N-terminal domain which displays a characteristic 
oligosaccharide/oligonucleotide binding (OB) fold, and a C-terminal domain which adopts a 
β-grasp motif (Fig 1.4) (Spaulding et al., 2013). These two domains are divided by a solvent 
accessible α-helix which spans the centre of the molecule (Fraser and Proft, 2008b). A 
feature seen in many SAgs is a highly flexible disulphide loop located in the N-terminal 
domain which is implicated in both the emetic activity of SEs and binding to certain TCR Vβ 
chains (Fig 1.4) (Hu and Nakane, 2014, Spaulding et al., 2013). 
Another common feature among SAgs are zinc binding sites, which vary in 
arrangement and may be used as an alternative MHC class II binding site (Fig 1.4) (Li et al., 
2001, Sundstrom et al., 1996). Zinc binding sites have also been shown to be important in 
the dimerization of staphylococcal enterotoxins such as SED or SEC (Chi et al., 2002, 
Sundström et al., 1996), and there is evidence to suggest that zinc binding may play a role in 
the high level of thermostability exhibited by many SAgs (Baker and Acharya, 2004, 
Cavallin et al., 2000a).   
Staphylococcal SAgs also share a common dodecapeptide sequence which is located 
within β-strand(8)/hinge/α-helix(4) domain of SAgs and has been demonstrated to interact 
with epithelial cells and induce the production of cytokines, such as IL-8 (Shupp et al., 
2002). This mechanism is termed outside-in signalling and it is proposed that it is exploited 
by SAgs to attract immune cells to the sub-mucosa upon which SAg can exert their activity 
(Brosnahan and Schlievert, 2011, Stach et al., 2014). Binding of co-receptors to the trimeric 
complex induced by SAgs has not been well characterised to date. However recent work 
conducted on SEB demonstrates this SAg not only binds the TCR and MHC but also the co-
stimulatory receptor CD28 (Arad et al., 2011). The interaction between CD28 and SEB is 
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mediated through the SAg dodecapeptide implicated in outside-in signalling (Arad et al., 
2011). Binding of this receptor was required to induce the release of pro-inflammatory 
cytokines suggesting that the mechanism of SAg-induced T-cell proliferation is not 
necessarily restricted to TCR-MHC interactions as previously assumed (Arad et al., 2011). 
Two distinct sites have been identified on MHC class II that bind to SAgs. The first 
is referred to as the generic binding site and is located on the α chain of MHC-class II. The 
other type is located on the β-chain of the MHC class II and is termed the high affinity site, 
due to its ~100 fold greater affinity for SAg binding than the generic binding site. Binding at 
the high affinity site is mediated by zinc (Fig 1.4) (Baker and Acharya, 2004, Papageorgiou 
and Acharya, 1997, Papageorgiou and Acharya, 2000). The presence of multiple sites of 
interaction with MHC class II produces a great deal of diversity among these toxins as many 
SAgs, including TSST-1 and SEB bind to MHC class II molecules that express HLA-DR 
alleles while some other SAgs such as SEC, SpeA and SSA bind predominantly to HLA-DQ 
alleles (Jardetzky et al., 1994, Kim et al., 1994, Papageorgiou and Acharya, 2000, Patel et 
al., 2010).   
Almost all SAgs interact with the Vβ chain of the TCR resulting in stimulation of up 
to 20% of resting T-cells (Spaulding et al., 2013). Highly specific interactions occurs 
between the active side chains in the SAg and complementarity determining regions 1 and 2 
(CD1 and CD2) and hypervariable region 4 (HV4) of the TCR Vβ chain (Fields et al., 1996) 
and altering a single residue in the TCR binding site is enough to alter the Vβ-specificity (Li 
et al., 1998). Binding of the TCR by SAgs results in clustering of TCRs which in turn 
facilitates the acquirement of intracellular components required for signal transduction 
(Lavoie et al., 2001). This clustering may occur in two ways; firstly by direct clustering of 
the TCR or by the binding of SAg homodimers to multiple MHC class II molecules which 
would also promote TCR clustering (Fig 1.5) (Baker and Acharya, 2004, Lavoie et al., 
72 
 
2001). Of note, SEH is the only staphylococcal SAg demonstrated to interact with the Vα 
























Figure 1.4 The two domain structure of SAgs. The staphylococcal SAg consists of two 
protein domains demonstrated by TSST-1 (i) . The crystal structrure of SEA reveals a 
number of features associated with SAgs (ii). The features are colured and residues involved 







1.6.2 Role of SAgs in S. aureus pathogenesis 
SAg induced T-cell proliferation elicits a response that is primarily inflammatory. CD4 and 
CD8 T- lymphocytes proliferate and a range of cytokines can be released including IL-1, IL-
2, IL-6, tumour necrosis factor-α (TNF-α), IFN-γ, macrophage inflammatory protein 1α 
(MIP-1α), MIP-1β, and monocyte chemo- attractant protein 1 (MCP-1) (Krakauer, 1999, 
Fraser and Proft, 2008b). This uncoordinated release of cytokines is the main cause of 
damage associated with SAg induced toxicity (Spaulding et al., 2013). SAgs can cause 
rashes, fever, multi-organ damage, coma and death from severe shock (Schlievert, 1995). 
These toxins have been implicated in a wide range of diseases ranging from staphylococcal 
food poisoning to severe toxic shock (Murray et al., 1995, Schlievert, 1995). SAgs have also 
been implicated in a range of autoimmune conditions including Kawasaki disease, multiple 
sclerosis, arthritis and diabetes (Torres et al., 2001, Stauffer et al., 2001).  
SAg-induced T-cell proliferation leads to a pro-inflammatory response which causes 
damage to the host and impedes the effectiveness of the immune response by creating a bias 
towards the Th1 response and inducing memory T-cell deletion or anergy (Watson et al., 
2012). Prolonged exposure to SAgs results in the production of IL-4 and IL-10 and can lead 
to deletion or anergy of stimulated T-cells decreasing the repertoire available to interact with 
S. aureus infections (Miller et al., 1999, Watson et al., 2012). The production of IL4 and  IL-
10 act to decrease the immune response with affects such as a reduction in IFN-γ and 
depletion of MHC Class II which results in memory T-cells that are unresponsive to antigen 
stimulation (Miller et al., 1999, Sundstedt et al., 1997, Watson et al., 2012). Regulatory T-
cells (Tregs) are also affected by SAg-induced T-cell proliferation and are unable to mitigate 
the inflammation caused by toxic shock syndrome (TSS) (Tilahun et al., 2014).  SAgs have 
been shown to manipulate cytokine expression during infection and subvert the innate 
immune response by inducing the infiltration of neutrophils into murine livers forming 
abscesses via the induction of cytokine release (Xu et al., 2014). Taken together the effects 
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induced by SAgs are likely to cause significant deficiency in the ability of the adaptive 
immune response to respond effectively to infection by the uncontrolled release of 
cytokines leading to global immune dysregulation.  
SAgs can also play a role in disrupting mucosal barriers and mediating immune 
inflammation at these locations (Brosnahan and Schlievert, 2011). The outside-in signalling 
dodecapeptide motif has been implicated in this mechanism as it has been shown to mediate 
transcytosis of SEA, SEB and TSST-1 through epithelial monolayers (Shupp et al., 2002). 
The mechanism proposed is that SAgs can interact directly with epithelial cells and stimulate 
the release of chemokines such as IL-8 and MIP-3α which recruits immune cells to the 
submucosa and the lumen, particularly neutrophils and T-lymphocytes (Peterson et al., 
2005). The influx of neutrophils into the lumen can result in severe pathology as observed in 
a murine pneumonia model of intranasal exposure to SEB (Rajagopalan et al., 2006). The 
influx of immune cells results in disruption of the epithelial barrier allowing the SAg to 
diffuse into the submucosa (Rajagopalan et al., 2007). At this point the SAg can interact with 
T-lymphocytes, both in the submucosa and with lymphocytes that have migrated thorough 
the epithelium, and induce further inflammation (Spiekermann and Nagler-Anderson, 1998). 
The stimulation of the mucosal surface by SAgs results in inflammation and barrier 
disruption which can lead to invasion by S. aureus and in some cases allows the SAg to enter 
the blood stream resulting in systemic toxic shock (Brosnahan and Schlievert, 2011).  
S. aureus is a major cause of the food poisoning in humans and this is characterised 
by the rapid onset of vomiting and is mediated by the emetic SAgs (Table 1.4) (Hu and 
Nakane, 2014, Hennekinne et al., 2012). The first staphylococcal SAgs to be described were 
SEA and SEB, which were initially identified as enterotoxins before the superantigenic 
function of the protein was elucidated (Balaban and Rasooly, 2000). SEA is still the most 
common SE associated with staphylococcal food poisoning and much of the research to 
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understand the mechanisms of emesis induced by SEs have been performed with SEA (Hu 
and Nakane, 2014). SEA can translocate from the gastrointestinal tract (GI) lumen through 
the intestinal epithelium into the submucosa possibly using the same outside-in signalling 
mechanism observed for TSST-1 (Hu et al., 1999, Brosnahan and Schlievert, 2011). It has 
been shown that SEA can interact with mast cells in the submucosa and induce 5-HT 
serotonin release by the degranulation of mast cells (Ono et al., 2012). The release of 5-HT 
serotonin can stimulate vagal afferent nerves in the submucosa by binding the 5-HT3 
receptors (Hu et al., 2007). The binding of 5-HT serotonin to vagal nerves can induce nerve 
depolarisation which can stimulate the medulla oblongata leading to the vomiting reflex 
(Darmani and Ray, 2009). Emesis induced by enterotoxins occurs rapidly, these toxins can 
enter and progress through the GI tract independently of S. aureus bacteria owing to the high 
level of structural stability exhibited by SEs (Hennekinne et al., 2012, Li et al., 2011).   
SAgs have been shown to be important in the onset of necrotizing pneumonia most 
likely by stimulating infiltrating CD4
+
 T-cells inducing proliferation and the production of 
pro-inflammatory cytokines including IL-6, IL-1β and TNF resulting in tissue damage 
(Parker et al., 2015, Strandberg et al., 2010). SAgs has been shown to be critical in the 
establishment of IE as TSST-1- negative isogenic isolates of a USA200 clone were unable to 
establish IE in rabbits unlike TSST-1 positive isolates that were able to establish severe IE at 
a much higher frequency (Pragman et al., 2004).  Anti-SEC therapy also reduced the severity 
of disease in a rabbit IE model (Mattis et al., 2013). In this disease the role of SAgs is 
unclear but there is evidence to suggest a number of mechanisms including direct toxicity of 
the endothelium cells, immune dysregulation preventing clearance of the vegetation or 
capillary leakage induced SAgs all could be responsible (Lee et al., 1991b, Lee et al., 1991a, 




1.6.3 Distribution of S. aureus SAg Genes 
The distribution of SAgs in S. aureus is highly variable and each strain can secrete anywhere 
between one and 23 of 25 serologically distinct SAgs (Spaulding et al., 2013). 80 % of 
human nasal isolates were found to encode at least one SAg (in addition to SElX), and of this 
number 50% were found to have the enterotoxin gene cluster (egc) suggesting the majority 
of human clinical isolates encode on average 5 SAg genes (Omoe et al., 2005). The 
prevalence of SAg genes is higher in MRSA than in MSSA as the SCCmec element can 
contain SAg genes (Hu et al., 2011, Hu et al., 2008). The diversity of SAg carriage results 
largely from of almost all SAg genes being associated with MGEs such as prophages, 
plasmids and SaPIs (Table 1.4) (Argudin et al., 2010). SaPIs can range in size from 14 kbp 
to17 kbp and can encode a variety of different SAgs depending on the SaPI (Suzuki et al., 
2015, Argudin et al., 2010).  The mobility of these elements are mediated by phage, for 
example, SaPI2 containing the tst-1 gene is excised from its chromosomal location and 
transmitted during the growth of the phage 80α (Subedi et al., 2007, Ubeda et al., 2009). The 
enterotoxins SED and SEJ are both found associated with the same plasmid termed sed-
encoding plasmid (Zhang et al., 1998). SEA is encoded on the IEC, which includes the genes 
for the immune modulators SCIN and CHIPS and the IEC is transferred by β-haemolysin 
converting phage (van Wamel et al., 2006). The enterotoxin genes seg, sei, selm, seln, and 
the two pseudogenes ψent1 and ψent2 have been demonstrated to form the chromosomal 
operon egc (enterotoxin gene cluster) which is located within the vSaβ genomic 
island (Jarraud et al., 2001b). The egc of S. aureus appears to have been formed through the 
duplication and diversification of a SAg ancestor, and phylogenetic analysis of this cluster 
and other SAg genes in S. aureus suggested that all these genes are related (Jarraud et al., 
2001b).  It has been demonstrated that the vSaβ element was transferred by multiple 
overlapping bacteriophage transduction resulting in the diversification of this element in 
different S. aureus strains (Moon et al., 2015). This mechanism may also explain how newly 
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diversified SAg were transferred from the egc nursery to other parts of the S. aureus genome. 
The presence of the egc cluster can enhance the fitness of the bacteria and is found in many 
clinical isolates of S. aureus, although animal studies have suggested that this cluster may 










Figure 1.5: Different SAgs can bind to the MHC class II molecule through a variety of 
mechanisms. Schematic diagram of how Superantigens (SAgs) can interact with the MHC 
class II molecule (blue, made up of both an α-chain and β-chain) (brown sphere represent 
Zn
2+
 ion); (i) Zinc independent binding through low affinity site on α chain (e.g. TSST-1). 
(ii) Zinc dependent binding to the β chain through the high affinity site (e.g. SEI). (iii) 
Binding to both sites (e.g. SEA). (iv) Dimerization of SAgs via zinc binding (e.g. SED). (v) 







1.7 Regulation of virulence determinants in S. aureus 
The coordinated regulation of virulence factors is essential to be able to establish an 
infection and evade the host immune system. To regulate gene expression, S. aureus utilises 
two major groups of regulators, transcription factors and two-component regulation systems 
(of which S. aureus has at least 16) (Table 1.5)(Cheung et al., 2004) These systems allow S. 
aureus to respond effectively to different environmental and host factors and act as an 
efficient opportunistic pathogen (Cheung et al., 2004). For example sae and agr deletion 
mutants of highly pathogenic USA300 strains are less virulent in a mouse model of 
necrotizing pneumonia and skin infection (Montgomery et al., 2010). These same regulators 
have been shown to be activated during interactions with neutrophils (Wright et al., 2005, 
Voyich et al., 2009).  
The agr locus is largely responsible for growth phase dependent gene expression in 
S. aureus. It is a quorum sensing system which responds to the concentration of an auto-
inducing peptide (AIP) (Painter et al., 2014). The locus is divided into two RNA transcripts, 
RNAII contains the operon agrBDCA and RNAIII is a regulatory RNA which acts as the 
effector of the agr cascade (Painter et al., 2014). The agr locus is a critical regulator for a 
large number of virulence determinants, up-regulating secreted factors such as hla and down-
regulating cell associated determinants such as spa (Bronner et al., 2004, Kong et al., 2006). 
Agr can be activated during uptake into the phagosome by neutrophils, as the concentration 
of the auto-inducing peptide is higher in the lower volume of the phagosome. This can lead 
to the production of proteins that aid intracellular survival such as PSMs and Hla (Pang et 






Table 1.5 Characterised two-component regulators of S. aureus. 
Regulator Activation Function Reference 
AgrCA Auto-inducing 
peptide (AIP) 
Growth Phase dependent expression of 
virulence determinants 
(Painter et al., 2014) 
SaeRS Stimuli from 
phagocytes 
Regulates the expression of virulence 
determinants in response to phagocytic 
signals and elements of the humoral 
response. SaeRS can also work 
synergistically with sarA to repress 
proteolytic activity to promote biofilm 
formation. 
(Mrak et al., 2012, 
Liang et al., 2006, 
Voyich et al., 2009, 
Geiger et al., 2008) 
lytRS Unknown Regulates autolytic pathways in the 
bacterial cell which play a role in cell wall 
turnover and biofilm formation 
(Brunskill and 
Bayles, 1996, 





Down-regulates virulence determinants 
under anaerobic conditions. Up-regulates 
genes involved in nitric oxide resistance. 
(Kinkel et al., 2013, 
Ulrich et al., 2007) 
HssRS Heme System is activated by heme resulting in the 
up-regulation of the ABC transporter HrtAB 
which mediates heme uptake. 
(Stauff and Skaar, 
2009) 
WalKR Unknown Regulation of cell wall maintenance, 
autolysis genes and biofilm formation. 
(Dubrac et al., 2007) 
AirSR Anoxic 
conditions 
Regulates virulence expression under anoxic 
conditions and can promote S. aureus 
survival in blood. Regulates cell 
homeostasis. 
(Hall et al., 2015, Sun 
et al., 2012) 
ArlRS Unknown Regulation of autolysis and proteolytic 
enzyme release along with regulation of 
agglutination. 
(Walker et al., 2013, 






Regulation of resistance to both antibiotics 
and bactreiocins by the activation of a 
corresponding ABC transporter that 
mediates detoxification 
 
(Hiron et al., 2011, 




Activates the expression of the vraFG ABC 
transporter and confers resistance to some 
cationic antimicrobial peptides 
 
(Yang et al., 2012) 
HptRS Hexose 
phosphates 
Mediates the expression of the system 
required for uptake of hexose as a carbon 
source 
(Park et al., 2015) 
    
VraRS Antimicrobials Contributes to resistance against β-lactams 
such as oxicillin but independent of mecA 
regulation 






The sae locus is a two-component system critical for the optimal expression of 
exoproteins and is made up of four open reading frames (ORF), saeS, saeR, saeQ and saeP 
(Cheung et al., 2004). The ORFs saeS and saeR encode the two-component system; where 
saeS encodes a histidine kinase and saeR encodes the cytoplasmic response regulator 
(Giraudo et al., 1999). The presence of saeQ and saeP has been demonstrated to be essential 
for this locus to function correctly through the enhancement of phosphatase activity by the 
SaeS sensor kinase (Adhikari and Novick, 2008, Jeong et al., 2012). The expression of SaeQ 
and SaeP can lead to differential expression of SaeR targets (Adhikari and Novick, 2008, 
Jeong et al., 2012). In USA300 strain LAC, SaeR up-regulates virulence-associated genes 
sharing a consensus sequence found in the promoter regions (Nygaard et al., 2010). The 
SaeRS system is critical for the regulation of factors involved in innate immune evasion and 
if deleted S. aureus virulence is highly attenuated (Voyich et al., 2009, Montgomery et al., 
2010). SaeRS has been shown to be activated by signals indicative of phagocytes including 
hydrogen peroxide and low concentrations of α-defensins (Geiger et al., 2008). Examples of 
immune evasion factors regulated by SaeRS include the SSl-proteins which are upregulated 
when SaeRS is activated together with Rot (Repressor of toxins) (Benson et al., 2012). 
SaeRS can also coordinate with the post-transcriptional repressor SarA and repress the 
expression of proteolytic enzymes allowing the formation of S. aureus biofilm (Mrak et al., 
2012).   
Rot is a post-transcriptional repressor, which is a member of the SarA family. It has 
been shown to repress the α-toxin gene, hla, along with a large group of other virulence 
factors including SAgs genes like seb (Manna and Ray, 2007, Tseng and Stewart, 2005) . In 
addition to its role as a toxin repressor Rot has been shown to be a global regulator of 
virulence that can promote expression of genes encoding SSl-proteins (Benson et al., 2011, 
Said-Salim et al., 2003). The activity of Rot is required for biofilm formation of USA300 
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strains by supressing the activity of proteases secreted during the planktonic phase (Mootz et 
al., 2015).   
Global regulators do not operate independently; the saeRS system coordinates with 
the agr locus, combining environmental and quorum sensing signals to regulate virulence 
expression (Fig 1.6). An example of this interaction between global regulators is the 
expression of hla, which has been shown to be co-ordinated by a combination of factors 
including agr, saeRS and rot (Xiong et al., 2006). A further example of a virulence factor 
regulated by a combination of different global virulence regulators working in tandem is 
TSST-1 which in addition to being regulated by RNAIII also has been shown to be under the 
influence of sigma factor B, Rot and SarA (Andrey et al., 2015). The complex regulation of 
virulence determinants allows for differential expression of virulence factors so they can be 














Figure 1.6: S. aureus virulence regulators coordinate to ensure correct expression of 
virulence determinants.  Major regulatory inputs in the expression of hla and ssl11 are 
shown. (1) The Agr quorum-sensing system is activated when AIP reaches a high 
concentration as a result of high bacterial density, leading to AgrA-dependent activation of 
the P3 promoter, which encodes the regulatory RNA, RNAIII. RNAIII negatively regulates 
the translation of the hla repressor and ssl11 activator Rot, leading to increased HlA 
production and reduced SSl11production. (2) The global regulator SarA indirectly facilitates 
expression by positively regulating the expression of the P3 promoter in the agr locus, 
leading to a similar repression of Rot translation and increased Hla production. (3) Rot is 
believed to bind directly to promoters to inhibit toxin gene expression. (4) The SaeRS two-
component system recognizes external stimuli from the environment, leading to direct 
binding of SaeR to hla and ssl11 promoters and subsequent enhancement of gene expression. 






1.8 Staphylococcal enterotoxin-like toxin X (SElX) 
SElX is a SAg encoded in the core genome of 95% of S. aureus strains (Wilson et al., 2011). 
This is unique as all other SAgs characterised from S. aureus to date are associated with 
MGEs. SElX has demonstrated the typical properties of SAgs including, Vβ-specific T-cell 
mitogenicity, pyrogenicity and enhancement of LPS toxicity (Wilson et al., 2011). Sequence 
analysis of selx revealed 17 different allelic variants of this toxin, which have been generated 
by a combination of point mutation and assortative recombination (Wilson et al., 2011).  
Western blot analysis of human, bovine and ovine serum from clinical cases and human 
volunteers found that the majority of serum samples were positive for anti-SElX antibodies. 
This suggests that SElX is expressed during S. aureus infection and induces a humoral 
immune response (Wilson et al., 2011). Importantly SElX from the USA300 clone was 
shown to contribute to lethality in a rabbit model of necrotising pneumonia (Wilson et al., 
2011). Global transcription studies of USA300 strain LAC have demonstrated that selx is up 
regulated when S. aureus is incubated in blood and serum unlike the other SAgs encoded by 
USA300 LAC and selx is expressed at similar levels to immune evasion proteins such as the 
ssls (Malachowa et al., 2011). Further study examining temporal expression of S. aureus 
virulence determinants during soft tissue infection in rabbits demonstrated SElX was 
regulated 1 day post infection in a similar fashion to known virulence factors such as PVL 
and Hla (Malachowa et al., 2015). The promoter region of selx contains a consensus 
sequence that mediates binding of SaeR and suggests that selx is regulated by this important 
2-component regulator. SElX can interact directly with the surface of neutrophils which was 
demonstrated recently using a phage display approach (Fevre et al., 2014). The neutrophil 
interaction was shown to be of high affinity and could be abolished if the neutrophils were 
treated with neuraminidase suggesting the interaction was dependent upon sialic acid 
residues on the neutrophil surface (Fevre et al., 2014). An antibody blocking screen 
suggested the PSGL-1 can interact with SElX although a very high level of SElX protein was 
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required to see this (Fevre et al., 2014). It is likely given that the discrepancy of between 
SElX affinity for neutrophils and its relatively low affinity for PSGL-1, there is one or more 
targets for SElX still to be identified, along with any functional consequences for the 
neutrophil when SElX binds to it.  
  
1.9 Staphylococcal enterotoxin-like toxins Y and Z (SElY and SElZ) 
The toxin SElY was recently reported and shown to be able to induce emesis in the house 
musk shrew model and induce proliferation of human lymphocytes (Ono et al., 2015). The 
protein is predicted to have a molecular weight of 22.5 kDa and the amino acid sequence has 
a 32% sequence identity with the superantigen SET (Ono et al., 2015). SElZ is a putative 
SAg identified by Wilson (2010) in the bovine mastitis strain of RF122, which shares a 98% 
nucleotide identity with a putative SAg found in the capsule type 1 element SCCcap1 in S. 
aureus strain M. The closest related SAg is SEG which shares a 58% homology with SElZ 
(Wilson, 2010). Recombinant SElZ prepared from RF122 was able to induce bovine T-cell 




The SAgs SElX, SElY and SElZ have all been recently identified and further examination of 
these SAgs is required to enhance our understanding of the role these proteins play in S. 
aureus pathogenesis. SAgs are produced by all clinical isolates and can modulate the host 
immune response by inducing T-cell activation, inducing damage through uncontrolled 
cytokine release and the induction T-cell anergy all contributing to pathogenesis. The SAgs 
secreted by S. aureus are highly diverse yet functionally very similar and as a result SAgs 
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may overlap in the T-cell groups that they activate. The SAgs are a large group of proteins 
probably reflecting the diversity of interactions with the adaptive immune response. 
However the energy cost of producing a group of virulence factors that have related immune 
modulatory functions is presumably high and it is therefore feasible that SAgs exhibit other 
functions to mitigate the energy costs. Given the structural relatedness of SAgs and SSls, it is 
possible that some SAgs have evolved to exhibit functions related to those of the SSl-
proteins. SElX is a good candidate for exploring this further as it is one of the most closely 
related SAgs to the SSl-proteins and it has already been demonstrated to interact with PSGL-
1 on the surface of neutrophils (Wilson et al., 2011, Fevre et al., 2014). The functional 
consequences of this interaction are yet to be investigated but may provide new insights into 
the interaction between SAgs and leukocytes within the immune system.  
 
1.10 Project aims 
The aim of this project is to investigate the functions of the staphylococcal SAgs SElX, SElY 
and SElZ and further elucidate the role of SAgs in S. aureus disease by:  
 Investigating the structure of SElX, SElY and SElZ to inform our understanding of 
function 
 Defining the emetic potential of SElX, SElY and SElZ to determine if these toxins 
can play a role in staphylococcal food poisoning 











































2.1 Human blood sampling ethical review  
For the isolation of human leukocytes, blood was sampled from healthy donors recruited by 
passive advertising. Written informed consent was obtained from all subjects and blood was 
obtained by venepuncture. Recruitment and sampling procedures were reviewed by the 
national research ethics service (NRES) committee London City and East under the research 




2.2 Bacterial culture conditions 
S. aureus strains were grown in tryptone soya broth (TSB) or brain heat infusion broth (BHI) 
(Oxoid, UK) with shaking at 200rpm, or on tryptone soya agar (TSA) (Oxoid, UK) at 37°C 
for 16 h unless otherwise stated. E. coli strains were grown in Luria broth (LB) (Melford 
laboratories, UK) with shaking at 200rpm, or on LB-agar (Melford laboratories, UK) at 37°C 
for 16 h unless otherwise stated. Media was supplemented, where appropriate, with 
antibiotics. Strains were stored in appropriate liquid culture media containing 40 % (v/v) 
glycerol (Sigma-Aldrich, UK) in cryovials (Nunc, Thermo Scientific, UK) at -80°C.  
 
2.3 Genomic DNA extraction 
Genomic DNA (gDNA) was extracted from 0.5 ml of an overnight culture of S. aureus 
strains using the PurElute™ Bacterial Genomic Kit (Edge Biosystems, MD, USA) as 
described in the manufacturer’s protocol, except for the addition of 100 µg/ml of lysostaphin 
(AMBI products LLC, NY, USA) to spheroplast lysis buffer and incubation for 30 min at 
37°C. gDNA pellets were re-suspended in 50µl of EB buffer (Qiagen, Manchester, UK).  
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2.4 Plasmid and DNA isolation 
Plasmids were isolated from 5 ml overnight cultures of E. coli using the QIAprep Spin 
Miniprep kit (Qiagen, Manchester, UK) as described in the manufactures protocol. DNA 
fragments were purified from agarose gels using the QIAquick gel extraction kit (Qiagen, 
Manchester, UK) according to the manufacturer’s specifications. PCR products were cleaned 
up using the QIAquick PCR purification kit (Qiagen, Manchester, UK) according to the 
manufactures protocol.  
 
2.5 DNA quantification 
DNA concentration (ng/µl) was determined using a nano-drop ND-1000 spectrophotometer 
(Thermo scientific, USA) by measuring the absorbance at a wavelength at 260nm. Sample 
purity was assessed by comparing the ratios at wavelengths of 230/260 and 280/260.  
 
2.6 Restriction digestion 
Plasmid DNA was digested with appropriate high fidelity restriction enzymes and buffers as 
outlined in the manufacturer’s protocol (New England Biolabs, Herts, UK). 50 ng of plasmid 
DNA was digested in a 20µl reaction containing 1x reaction buffer, 1U restriction 









2.7 Polymerase chain reaction (PCR) 
Oligonucleotide primers were designed using the primer design tool on the NCBI website 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and synthesised by Invitrogen custom 
oligo service (Life Technologies, Paisley, UK). PCR reactions were carried out in 
Mycycler™ thermal cycler (Biorad, UK) and contained 100 nM forward and reverse primers 
and 250 nM dNTP (Promega, Hampshire, UK), either Go Taq G2 polymerase enzyme 
(Promega, Hampshire, UK) or PfuUltra II Fusion DNA polymerase (Agilent technologies, 
UK) at 1 U per reaction, PCR buffers for each enzyme were provided with the kit and used at 
a 1 x concentration. 10 ng of template DNA was added and ddH2O was added to a final 
volume of 50 µl. Colony PCR was carried out by boiling single colonies for 10 min in 20 µl 
of ddH2O. Unless otherwise stated, the thermal programme was; 1 cycle at 95°C for 3 min, 
30 cycles at 95°C for 1 min, 54°C for 1 min, 72°C for 1 min per kb (Taq) or 15 s per kb 
(Pfu), followed by a final extension of 72°C for 10 min. 
 
2.8 Agarose gel electrophoresis 
Agarose gel electrophoresis of DNA fragments was carried out in 1 % (w/v) agarose gels 
(Melford Laboratories, UK), with 1 x Tris-acetate-EDTA (TAE) buffer (Thermo Scientific, 
UK) containing either 1 x SYBR safe DNA gel stain (Life Technologies, Paisley, UK) or 1 x 
Gel Red DNA stain (Biotium Limited, Cambridge Biosciences, UK). Promega loading dye 
(Promega, UK) was added to DNA samples before they were loaded onto the gel alongside a 
1 kb DNA ladder (Promega, UK). Electrophoresis was carried out at 120 V for 60 min. Gels 






2.9 DNA sequencing 
Sequencing reactions were carried out by Edinburgh Genomics (King’s Buildings, 
University of Edinburgh, UK). Reactions contained 5 µl (approximately 50 ng) of purified 
DNA with 100 nM sequencing primers. Big Dye terminator reactions were performed as part 
of the sequencing services using the Bigdye™ Terminator v3.1 Ready Cycle reaction 
sequencing kit and performed according to the manufacturer’s protocol (Life Technologies, 
UK). Samples were analysed on an ABI3730 capillary DNA analyser (Life Technologies, 
Paisley, UK).  
 
2.10 Gene Cloning 
Gene templates were amplified by PCR using PfuUltra II Fusion DNA polymerase (Agilent 
technologies, UK) with primers stated in each chapter. PCR products were checked by gel 
electrophoresis to ensure robust amplification and then the PCR inserts were used in the 
Strataclone blunt cloning kit (Aglient technologies, UK). The PCR insert was cloned into the 
pSC-B plasmid as described in the manufacturer’s protocol. Following cloning the pSC-B 
plasmids were isolated using the QIAprep minikit (Qiagen, Manchester, UK) and the 
purified plasmid was then digested with restriction enzymes. The inserts were purified from 
a gel and ligated into the desired plasmid (digested with the same enzymes as the inserts) 
with T4 DNA ligase (New England Biolabs, Herts, UK) for 16 h at 16°C. The ligations were 
dialysed on 0.025 µm filter discs (Merk Millipore, Germany) and transformed into E. coli 
strains DH5α or XL-1 blue. For the plasmids transformed into DH5α cells, the plasmids 





2.11 Preparation of electo-competent cells and electroporation 
E. coli electro-competent cells were prepared by inoculating 250 µl of an overnight culture 
into 25 ml of LB and incubated at 37°C with shaking at 200 rpm, until an OD600 of 0.6 was 
reached. Cells were washed once in an equal volume of ddH2O, after centrifugation at 4000 
x g for 10 min, at 4°C. The cells were then washed twice in a ½ volume of ice cold 10 % 
(v/v) glycerol and once in ¼ volume of ice cold of 10 % glycerol. Cells were pelleted as 
before and re-suspended in 250 µl of 10 % glycerol. Electro-transformation was carried out 
with approximately 1 µg of plasmid added to 50 µl of competent cells in an electroporation 
cuvette with a 0.2 cm gap (Sigma-Aldrich, UK). Electroporation was carried out at 100 Ω, 25 
µF and 2.5 kV and immediately following pulsing 250 µl of super optimal broth (SOB) was 
added and the suspension was then incubated at 37°C for 1 h with shaking at 200 rpm. Cells 
were plated onto LB-agar supplemented with selective antibiotics and incubated for 18 h at 
37°C. 
 
2.12 Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were resolved by sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
(SDS-PAGE). 12 % (w/v) polyacrylamide resolving proteins gels were prepared using a 
mini-protean casting apparatus (Biorad, Hemel Hempstead, UK). The polyacrylamide gel 
was prepared with 4 ml of ddH2O, 2.5 ml of 1.5M TrisHCl (pH 8.8), 100 µl 10 % (w/v) 
Sodium-dodecylsulphate (SDS) (Melford, UK), 3.3 ml 40 % (w/v) Acrylamide/Bis-
acrylamide (Sigma-Aldrich, UK), 100 µl 10 % (w/v) Ammonium persulphate (APS) (Sigma-
Aldrich, UK) and 10 µl Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, UK) and 
sealed using 1 ml isopropanol. The gel was allowed to polymerise for at least 30 min before 
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a 4% (w/v) stacking gel was added which contained  6.30 ml of ddH2O, 2.5 ml of 0.5 M 
TrisHCl (pH 6.8), 100 µl 10% (w/v) SDS, 1 ml 40% (w/v) Acrylamide/Bis-acrylamide, 100 
µl 10% (w/v) APS  and 10 µl TEMED. A comb was inserted once the stacking gel was 
added and the gel was allowed to polymerise. The protein gel was then assembled in the 
mini-protean tetra-cell running apparatus (Biorad, Hemel Hempstead, UK) and covered with 
1 x running buffer (5 x stock containing; 124 mM Tris hydroxymethyl (methylamine) base 
(Tris) (Fisher Scientific, UK) 960 mM glycine (Sigma-Aldrich, UK) and 17 mM SDS). 
Protein samples were boiled in 1 x protein sample buffer (Laemmli, Sigma-Aldrich, UK) for 
10 min, loaded into wells and electrophoresed at 200 V for 40 min. A pre-stained 
Pageruler™ 180kDa to 10 kDa (Life Technologies, UK) molecular marker was included for 
protein size estimation. SDS-PAGE gels were stained for 1 h at room temperature with 
Instant Blue coomassie stain (Expedeon, Cambridge, UK). 
 
2.13 Recombinant protein purification 
2.13.1 Protein induction 
E. coli expression strains containing plasmid constructs for protein expression were cultured 
in LB containing selective antibiotics and induced in mid-exponential phase of growth 
(OD600 = 0.6), with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) (Formedium Ltd., 
Norfolk, UK) for 4 h at 37°C or 18 h at 16°C. Once induced, cells were harvested by 
pelleting the cells at 4000 x g for 20 min and stored at -20°C if not processed immediately.  
 
2.13.2 Affinity chromatography 
Recovered cells were defrosted and re-suspended in binding buffer (either native or 
denaturing buffer depending on the protein) (Table 2.1), before lysis in a One-Shot cell 
disruptor (Constant Systems, Northants, UK). 6 x HIS-tagged recombinant proteins were 
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purified by automated immobilized metal affinity chromatography (IMAC) with Ni-NTA 
superflow resin (Qiagen, Manchester, UK) along with employing the buffers listed in Table 
2.1. Purification was performed on an AKTA fast protein liquid chromatography (FPLC) 
OPC900 P920 machine (GE Healthcare, Buckinghamshire, UK). If a second purification 
step was required ion exchange chromatography protein purification was also performed 
using an SP sepharose column (GE Healthcare, Buckinghamshire, UK) (Binding and wash 
buffer 50mM HEPES and elution buffer 50mM HEPES+1M NaCl). Proteins were dialysed 
in 1 x phosphate buffered saline (PBS) (pH 7.3) using Spectra/Por Float-A-Lyzer tubing with 
an 8000 to 10000 molecular weight cut off (MWCO) (Spectrum Laboratories, CA, USA), 
and LPS was removed using ProteoSpin endotoxin removal kit (Norgen Biotek, ON, 
Canada).  
 
2.13.3 Protein quantification 
Proteins were quantified using a nano-drop ND1000 spectrophotomer (Thermo scientific, 
USA) set on the A280 program. After the protein solution spectra were obtained, the 
concentration of the protein was calculated at an absorbance of 280 nm and the extinction 
coefficient calculated from the protein sequence as described previously (Gill and von 









Table 2.1 Protein purification buffers 
Protocol Buffer Recipe Final pH 
Native conditions Binding Buffer 50 mM NaH2PO4 
300 mM NaCl 
10 mM imidazole 
 
8 
Native conditions Wash Buffer 50 mM NaH2PO4 
300 mM NaCl 
20 mM imidazole 
 
8 
Native conditions Elution Buffer 50 mM NaH2PO4 
300 mM NaCl 





Binding Buffer 100 mM NaH2PO4 
10 mM Tris·Cl 





Wash Buffer 100 mM NaH2PO4 
10 mM Tris·Cl 





Elution Buffer 100 mM NaH2PO4 
10 mM Tris·Cl 









2.15 Western Immunoblot analysis 
Proteins were separated by SDS-PAGE, as described in section 2.12 and transferred to 
nitrocellulose membranes (Amersham Hybond™ ECL™, GE Healthcare, Slough, UK) using 
Towbin transfer buffer (20 mM Tris, 154 mM Glycine and 20 % (w/v) Methanol (Fisher 
Scientific, UK)) and the Trans-Blot Turbo™ Blotting system (Bio-Rad, Hemel-Hempstead, 
UK), according to the manufacturer’s specifications. Following transfer the membrane was 
incubated in 1 x PBS (pH 7.3) containing 8 % (w/v) powdered milk (Sigma-Aldrich, UK), at 
4°C overnight. The membrane was incubated for 2 h with primary antibody at dilutions 
stated in each chapter then washed 3 times with washing buffer (1 x PBS (pH 7.3) containing 
1 % (w/v) powdered milk and 0.05 % Tween 20 (v/v) (Sigma-Aldrich, UK). The membrane 
was then incubated with horse radish peroxidase-conjugated (HRP) secondary antibody for 1 
h at the dilutions stated in each section. The membrane was washed and then incubated with 
ECL reagent for 5 min (ECL solution was composed of equal volumes of ECL 1 and ECL2, 
ECL1 contained 1 ml Luminol (Fluka, UK), 250 mM dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, UK), 0.44 ml p-Coumaric acid (Sigma-Aldrich, UK) 100 mM TrisHCl, with ddH2O 
to a final volume of 100 ml. ECL solution 2 contained 64 µl 30 % H2O2 (Sigma-Aldrich, 
UK), 100 mM TrisHCl and ddH2O to a final volume of 100 ml). Following incubation the 
membrane was visualized by exposing to Hybond ECL film (Amersham systems, 
Buckinghamshire, UK) for 20 s and processed in an X-ray developer (SRX-101A, Konic 
Minolta, Japan).  
 
2.16 Isolation of human PMN and PBMC 
50 ml tubes of venous blood was drawn and mixed with 6 ml of acid-citrate-dextran 
(ACD) (25 g D-glucose (Sigma-Aldrich, UK) and 20.5 g trisodium citrate (Sigma-







(Gibco, UK) and 25 ml was layered onto a dual layer Ficoll gradient (12 ml of a density 
1.119 g/ml histopaque solution (Sigma-Aldrich, UK) in a 50 ml tube with 10 ml of 
density 1.077 g/ml ficoll-hypaque solution (GE healthcare, Buckinghamshire, UK) 
layered on top), prior to centrifugation for 20 min at 396 x g without brakes. Plasma was 
aspirated before the PBMC and PMN layers were recovered and each cell type was 
washed with RPMI 1640 (Gibco, UK) containing 0.05 % (v/v) human serum albumin 
(RPMI+HSA) (Sigma-Aldrich, UK), cells were pelleted by centrifugation at 400 x g for 
10 min at 4°C. Contaminating red blood cells were removed from the PMN pellet by 
hypertonic lysis; the pellet was re-suspended in 9ml of ice cold ddH2O and was incubated 
for 30 s. Isotonic conditions were restored by the addition of 1 ml of 10 x PBS (Gibco, 
UK) before washing in RPMI+HSA followed by centrigugation at 400 x g for 10 min at 
4°C. Cells were counted using a TC20 automated cell counter (Biorad, UK) and re-




2.17 T-cell proliferation assays 
Human PBMC were adjusted to a concentration of 1x10
6
 cells/ml in RPMI 1640 (Sigma 
Aldrich, UK) supplemented with 10% (v/v) foetal calf serum (Gibco, UK), 100 U/ml 
penicillin, 100 µg/ml streptomycin and 292 µg/ml L-glutamine. (PSG) (Gibco, UK). Cells 
were cultured in 96 well low-bind round bottomed tissue culture plates (Nunc, Fisherbrand, 
UK) at 37°C in humidified air with 5 % CO2. Proteins samples were tested in triplicate and 
added before incubation at the concentrations described in each chapter. Cells were cultured 
in medium only or with 5 µg/ml of Concanavalin A as negative and positive controls 
respectively. Proliferation of cells was determined using the incorporation of [
3
H]-thymidine, 
by pulsing with 1 µCi/well of [3H]-thymidine after a 72 h incubation and harvested after 18 h 
using a Tomtec Mach III M Harvester 96 (Hamden, USA) onto Wallac A filters (Perkin 
99 
 
Elmer, MA, USA). A Meltilex A wax scintillant strip (Perkin Elmer, MA, USA) was melted 
onto the filter pad and the [
3
H]-thymidine incorporation into cellular DNA was determined 
by scintillation counting using a β-radiation counter (Wallac 1450 Microbeta PLUS, Perkin 




















































Analysis of SElX, 


























The family of SAgs contains a number of characteristic motifs and structural features. To 
form the trimeric complex with the TCR and MHC class II each SAg contains a TCR 
binding site and MHC class II binding which cross link these receptors. SAgs contain one or 
both, of a low affinity MHC class II binding site and a high affinity site which uses zinc to 
coordinate binding (Fraser and Proft, 2008b). Recently a number of reports have suggested 
the existence of co-receptors on the surface of T-cells such as CD28 and CD40 which can 
contribute to T-cell activation (Brosnahan and Schlievert, 2011, Arad et al., 2011). All SAgs 
have also been shown to contain a motif termed the outside-in sequence, which is a 
dodecapeptide sequence at the base of the central α-helix involved in transcytosis of some 
SAgs across epithelial layers (Brosnahan and Schlievert, 2011).  
 A number of staphylococcal SAgs have also been demonstrated to induce emesis 
and are classified as staphylococcal enterotoxins (SEs). A common feature of SEs is a 
polypeptide cysteine loop framed by a di-sulphide bridge located in the N-terminal domain 
of the protein (Hu and Nakane, 2014). However the presence of this feature within the 
structure of a protein does not neccesarily correlate with emetic activity (Balaban and 
Rasooly, 2000, Hu and Nakane, 2014). Another property of SEs and staphylococcal SAgs is 
that they exhibit a high level of stability when exposed to varying temperature and pH 
conditions which enable the protein to transit through the human GI tract and retain activity 
(McCormick et al., 2001, Li et al., 2011).  
 An emerging theme in staphylococcal pathogenesis is that virulence determinants 
often exhibit more than one function (see section 1.5). There is a wide diversity in the SAgs 
encoded by S. aureus and it is possible that these proteins perform alternative functions 
independent of their T-cell mitogenicity during S. aureus infection. The SSl-proteins are a 
functionally diverse group of proteins that are structurally similar to SAgs but are non-
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mitogenic (Fraser and Proft, 2008b). Accordingly it is feasible that SAgs may have some 
functional properties in common with SSl-proteins which could be reflected by conserved 
functional motifs.  
 In this study the structure of SElX, SElY and SElZ are analysed for the presence of 
motifs common to other SAgs. The proteins are also screened for motifs that could indicate 
functions other than superantigenicity. The regulation of expression of selx is also analysed 
to determine which gene regulators control selx expression and what signals may be involved 
in regulation during infection. 
 These aims will be achieved by:  
 Building protein models and performing structural analysis of SElX, SElY and SElZ 
to determine the presence of features of SAgs and functional motifs found in other 
proteins  
 Performing stability assessment and emetic studies to determine if any of these SAgs 
are enterotoxigenic   












3.2 MATERIALS AND METHODS 
3.2.1 Bacterial strains and culture conditions 
S. aureus strains (Table 3.1) were grown in tryptone soya broth (TSB) or brain heat infusion 
broth (BHI) (Oxoid, UK) shaken at 200rpm, or on tryptone soya agar (TSA) (Oxoid,  UK) at 
37°C for 16 h unless otherwise stated. E. coli strains were grown in Luria broth (LB) 
(Melford laboratories, UK) shaken at 200 rpm, or on LB-agar (Melford laboratories, UK) at 
37°C for 16 h unless otherwise stated. Media was supplemented, where appropriate, with 
antibiotics. For selection transformed E. coli 100 µg/ml ampicillin was used. For the 
selection of S. aureus  muntants containing insertion sequences tetracycline (5 µg/ml) or 
erythromycin (10 µg/ml) were added to the media as required.  Strains were stored in 
appropriate liquid culture media containing 40% (v/v) glycerol (Sigma-Aldrich, UK) in 
cryovials (Nunc, Thermo Scientific, UK) at -80°C.  
 
3.2.2 Cloning and purification of recombinant protein 
Gene templates were amplified by PCR using the proof reading polymerase Pfu fusion II 
polymerase (Agilent technologies, UK) with primers stated in Table 3.2. Genomic DNA 
from S. aureus strains MSA2020 and MSA1695 were used as templates for sely and selz 
respectively. The sea gene was amplified from wild type S. aureus Newman and tst was 
amplified from the ED84 isolate (Table 3.1).  The PCR product was cloned into the pSC-B 
plasmid using Strataclone blunt cloning kit (Aglient, technologies, UK) as described in the 
manufacturer’s protocol. Following cloning the pSC-B plasmids were isolated using the 
QIAprep minikit (Qiagen, Manchester, UK) and digested with appropriate restriction 
enzymes. The inserts were gel-purified after agarose gel electrophoresis using the Qiaquick 
gel purification kit (Qiagen, Manchester, UK) and ligated into the desired plasmid with T4 
DNA ligase (New England Biolabs, Herts, UK) for 16 h at 16°C. The ligations were dialysed 
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on 0.025 µm filter discs (Millipore, Watford, UK) and transformed into E. coli strains DH5α 
or XL-1 blue. For recombinant protein expression the plasmids were and transformed into E. 
coli BL21 DE3 by electroporation according to the general methods section 2.11.  
Plasmid pET15b and pQE30 constructs containing SAg genes were used for the 
expression of recombinant proteins (Table 3.3). Proteins expression was induced as outlined 
in section 2.13.1. All recombinant proteins were purified using the native purification 
protocol outlined in section 2.13.2 except SElX and SSl5. SElX was purified using the 
denaturing protocol outlined in section 2.13.2 followed by a second purification step using 
IEC also described in section 2.13.2. SSl5 was purified with a hybrid purification protocol as 
follows; induced cells were lysed and bound to the affinity column with denaturing protocol 
buffers (Table 2.1) using the protocol described in section 2.13.2 and then washed with the 
denaturing wash buffer as described in 2.13.2. Protein is then refolded on the column by 
adding native protocol wash buffer over a gradient (30 min to 100% at a flow rate of 1 
ml/min). The protein was eluted with native protocol elution buffer (Table 2.1).  
 
3.2.3 Phylogenetic and amino acid sequence analysis  
The sequences of SAgs and SSl-protein genes were obtained from GenBank (Table 3.4). The 
Nucleotide sequences were aligned using BLOSUM (Blocks substitution matrix) 62 in 
MEGA 5.2 software. The sequence alignment was used to construct maximum-likelihood 
phylogeny. Predicted structural models were built using the I-TASSER server (Roy et al., 
2011) and crystal structures were downloaded from the RCSB PDB databank. Structural 






Table 3.1 Bacterial strains used in this study. 
Strain Description Source/ Reference 
S. aureus   
Newman Wild type (agr+) 
 
(Duthie and Lorenz, 1952) 
VJT 7.17 
 
Newman agr::tet (Benson et al., 2011) 
VJT 9.98 
 
Newman rot::Tn917 (Benson et al., 2011) 
VJT 10.03 
 
Newman agr::tet rot::Tn917 (Benson et al., 2011) 
VJT 12.22 
 
Newman saeS::bursa (Benson et al., 2011) 
VJT 17.25 Newman agr::tet 
saeS::bursa 
(Benson et al., 2011) 
   
USA300 LAC 
 
WT Erythromycin sensitive (Benson et al., 2011) 
AH1292 USA300 LAC agr::tet (Benson et al., 2011) 
VJT 16.37 USA300 LAC agr::tet 
rot::Tn917 
(Benson et al., 2011) 
VJT 28.25 USA300 LAC saeS::bursa (Benson et al., 2012) 
MSA2020 
 
Human SSS clinical isolate, 
France 
 
(Musser and Selander, 1990) 
MSA1695 Human SSS clinical isolate, 
Japan 
 
(Musser and Selander, 1990) 
ED84 Chronic cystic fibrosis 
infection 
(McAdam et al., 2011) 
   
E. coli   
DH5α 
 
Cloning strain Invitrogen, Paisley, UK 
BL21 DE3 
 
Expression strain  Invitrogen, Paisley, UK 
XL-1 blue 
 
Cloning and expression 
strain 
Agilent Technologies, UK 
Strataclone SoloPack™ lacZΔM15 mutation, endA, 
recA deficient 
Agilent Technologies, UK 






 Restriction sites incorporated are underlined
Table 3.2 Oligonucleotide primers used in this study. 








   
seapET 
 
CCCCATATGAGCGAAAAAAGCGAAG CCCGGATCCTTAGCTGGTATACAGATAAAT NdeI and BamHI 
tstpET 
 
CCCCATATGTCTACAAACGATAATATAAAGG CCCCTCGAGTTAATTAATTTCTGCTTC NdeI and XhoI 
selyhupET 
 
GCGCCATATGAAAACAACTGGATTGATTA GCGCGGATCCCTATTTCATATAAATATC NdeI and BamHI 
selzhupQE 
 
TAGCGGATCCGAGACACAAAATGATCCAAA GCGCCTGCAGCTACTTTTTAGTTAAGT BamHI and PstI 
qRT-PCR 
 
   
16rRNA 
(Wilson et al, 
2011) 
 
TATGGAGGAACACCAGTGGCGAAG TCATCGTTTACGGCGTGGACTAAC  
selxq 
(Wilson et al, 
2011) 
 
AGCAGACGCGTCAACACACAAA GGTCTCTCTGAATAAACCCAATTCC  
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Table 3.3 Plasmids used in this study. 
Plasmid  Description Source/ Reference 
   
pET15b Overexpression plasmid 
encoding an N-terminal 6 x 
HIS-tag 
Invitrogen, Paisley, UK 
pET15b::selx2 
 
selx2 cloned into pET15b (Wilson et al., 2011) 
pET15b::sea 
 
sea cloned into pET15b This Study 
pRSETB::ssl5 
 
ssl5 cloned into pRSETB (Bestebroer et al., 2007) 
pET15b::ssl7 
 
ssl7 cloned into pET15b (Wilson et al., 2011) 
pET15b::selyhu 
 
selyhu cloned into pET15b This Study 
pet15b::tst 
 






encoding an N’ terminal 6 x 
HIS-tag 
Qiagen, Manchester, UK 
pQE30-xa::selzhu 
 














3.2.4 Circular dichroism analysis 
Far UV circular dichroism (CD) spectra of protein samples was recorded in 0.1 x PBS (pH 7.3) 
on the Jasco J-710 (Japan Spectroscopic Co. Ltd, Japan). Spectra of the proteins, at a 
concentration of 0.4 mg/ml to 1 mg/ml, were recorded between 190 nm to 250 nm using a 
cuvette with a path length of 0.05 mm. For analysis the precise molar concentration was 
determined for each protein and used in the Jasco software to normalise each protein spectra 
before the data was analysed in further detail.  
 
3.2.5 Thermal shift analysis 
To monitor protein unfolding, the fluorescent dye Sypro orange (Life technologies, UK) was 
used. The unfolding process exposes the hydrophobic region of proteins and results in a large 
increase in fluorescence that can be used to monitor the protein-unfolding transition. The 
thermal shift assay was conducted in a Lightcycler 480 (Roche, West Sussex, UK) using the 
melt curve function determined from 25°C to 95°C.  Solutions of 5 μM recombinant 
staphylococcal protein were mixed with Sypro orange dye diluted 1/125 of the stock dye. The 
plate was heated from 25°C to 95°C with a heating rate of 0.1°C/sec. The fluorescence intensity 
was measured with excitation/emission: 465/510 nm.  
 
3.2.6 Western blot analysis 
Supernatants from stationary phase (16 h) cultures of S. aureus strains grown in BHI broth were 
concentrated with Amicon Ultra-15 Centrifugal Filter units (10000 MWCO) (Millipore, 
Watford, UK). Concentrated secreted proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membranes using the Trans-Blot Turbo™ Blotting system (Bio-Rad, Hemel 
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Hempstead, UK), according to the manufacturer’s specifications. The membrane was incubated 
in 1 x PBS (pH 7.3) containing 8 % (w/v) powdered milk (Sigma-Aldrich, UK), at 4°C 
overnight. The membrane was incubated with primary antibody (Anti-SElX chicken IgY), at a 
concentration of 1:1000 for 2 h. Anti-SElX IgY was obtained from immunised hen’s eggs using 
the Eggspress™ IgY purification kit (Gallus immunotech, NC, USA) according to the 
manufacturer’s instructions. Following primary antibody incubation the membrane was washed 
3 times with washing buffer, 1 x PBS (pH 7.3) containing 1 % (w/v) powdered milk and 0.05 % 
(v/v) Tween 20 (Sigma-Aldrich, UK). The membrane was then incubated with horse radish 
peroxidase-conjugated (HRP) secondary antibodies (goat anti-chicken-IgY IgG (Source 
Bioscience, Nottingham, UK)), diluted 1:10000 in washing buffer, for 1 h, followed by a further 
3 washes and then incubated with ECL reagent for 5 min. The blot was then exposed on 
Hybond ECL film (Amersham, Systems, Buckinghamshire, UK) for 20 s and developed using 













Table 3.4 S. aureus whole genome sequences, plasmids and gene sequences examined from 
publically available sources. 







Newman strain NC_009641.1 UK, 1950 8 (Duthie and Lorenz, 
1952) 
RF122 strain NC_007622 Ireland, 1993 151 (Herron-Olson et al., 
2007b) 
ED98 strain NC_013450.1 UK, 1996 5 (Lowder et al., 
2009b) 
COL strain  NC_002951.2 UK 250 (Gill et al., 2005b) 
FPR3757 strain NC_007793.1 USA, 2003 8 (Diep et al., 2006) 
Mu50 strain  NC_002758.2 Japan, 1997 5 (Kuroda et al., 2001) 
MW2 strain NC_003923.1 USA, 1998 1 (Baba et al., 2002) 
pSK67-M1 Plasmid HF937104.1 Denmark, 2003  (Larner-Svensson et 
al., 2013) 
pF5 plasmid  NG_036541.1 Japan, 2008  (Ono et al., 2008a) 
selv gene EF030427.1   (Thomas et al., 2006) 
seu gene AY205305.1   (Letertre et al., 2003) 
see gene  M21319.1   (Couch et al., 1988) 







3.2.7 qRT-PCR analysis 
3.2.7.1 RNA extraction from S. aureus  
Total RNA was extracted from post-exponential phase (OD600 = 4.0 to 7.0) S. aureus cultures 
using the RNeasy miniprep plus kit (Qiagen, Manchester, UK) according to the manufacturer’s 
specification except for a modified lysis step, that involved the re-suspension of the washed 
cells in Tris-EDTA (TE) buffer with 100 µg/ml lysostaphin (Ambi Products, USA) and 
incubation at 37°C for 30 min. RTL buffer from the RNeasy miniprep plus kit (Qiagen, 
Manchester, UK) was added to the cells and they were disrupted using the FastPrep® FP 120 
machine (MP Biomedicals, UK) in tubes containing lysis matrix B (MP Biomedicals, UK). 
Following disruption tubes were centrifuged at 13,000 x g for 1 min to remove the matrix and 
then RNA was isolated from the supernatant using the RNeasy plus kit (Qiagen, Manchester, 
UK). RNA was treated with the Turbo-DNA-Free kit (Ambion, Life Technologies, UK) as 
described in the manufacturer’s protocol. 1% (w/v) agarose gel electrophoresis of RNA samples 
was carried out to verify the integrity of the RNA. RNA was quantified and purity was 
determined using a nano-drop ND1000 spectrophotometer (Thermo scientific, UK). 
 
3.2.7.2 Quantitative reverse transcriptase-PCR  
qRT-PCR reactions were performed using the power SYBR green® RNA-to-Ct™ 1-step kit 
(Life technologies, UK) with a lightcycler 480 (Roche, West Sussex, UK). qRT-PCR primer 
sequences and their concentrations were obtained from previously published work (Table 3.2). 
Each primer set is designed to amplify a DNA fragment between 150 bp and 200 bp, and 50 ng 
of isolated RNA was used as a template in a 25µl reaction. RNA samples were processed in 
triplicate with a no template control (NTC), no RT controls and gDNA standards. The 
thermocycling conditions were 48°C for 30 min for 1 cycle, 10 min at 95°C for 1 cycle, 
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followed by 45 cycles of 20 s at 95°C, 20 s at 55°C and 20 s at 72°C with fluorescence 
measured at the end of each annealing step.  
 
3.2.8 House musk shrew model of emesis 
To determine the emetic capacity of SElX and SElZ, recombinant proteins were tested in a 
house musk shrew model of emesis at the Hirosaki University as previously described (Hu et 
al., 2003). Briefly, emetic assays were performed with healthy adult (2 to 10 m-old) house musk 
shrews (Suncus murinus) weighing 50 g to 70 g (male) and 40 g to 50 g (female). Each animal 
was placed in a separate cage, fed on commercial feed formulated for S. murinus (Nihon Clea, 
Tokyo, Japan), and provided water ad libitum. Purified proteins were diluted in 0.01 M PBS 
(pH 7.2), and 200 µl volumes of proteins at an appropriate dilution were administered 
intraperitoneally to the house musk shrews. The animals were observed for emesis for 3 h after 
the intraperitoneal administration of proteins. The number and times of vomiting, the time to the 











3.3 RESULTS  
3.3.1 Distribution and genetic relation of SElY and SElZ. 
The staphylococcal SAgs are a genetically diverse group with sequence homology ranging from 
86 % (SEA versus SEE) to 26 % (SEA versus TSST-1) identity. Despite this the staphylococcal 
SAgs form distinct groups when analysed phylogenetically (Spaulding et al., 2013). Alignments 
of all characterised SAgs and the recently identified SAgs sely and selz were analysed by 
constructing a maximum likelihood tree (Fig 3.1). This phylogeny demonstrates that selx 
segregates outside the major groups of SAgs with an outlier group more closely related to the 
SSl-proteins as previously reported by Wilson et al. (2011). This outlier group includes tst, set 
and sely, and is more closely related to the SSl-proteins than to other SAgs. SSl-proteins 
classically exhibit diverse immune modulatory functions and the possibility that selx and sely 
exhibit these functions warrants further investigation. 
 Further sequence analysis was performed on sely using an in-house database of 813 
sequenced S. aureus genomes. The gene sequence of sely was compared against whole genome 
sequences available using BLAST (basic local alignment search tool) This analysis 
demonstrated 91 out of 813 S. aureus genomes (11.1%) carried the sely gene. The dataset also 
identified 20 different allelic variants of sely and 39 positions varied within the protein 
sequences of the different alleles (Appendix 1.1). The most diverse allelic variants were found 
to share 91.442 % identity (SElY1 versus SElY19) (Appendix 1.1). The in house data base 
contains genome sequences from S. aureus isolated from a range of species and the sely gene 
was found in strains associated with many of these different host species including humans, 
cattle and rabbits.   
The novel SAg selz is most closely related to seg (41 % identity) and this SAg falls 
within the group II SAgs (Fig 3.1). This group exhibits 2 zinc binding sites and many members 
of this group have been shown to be emetic. The relatedness of selz to SAgs like seg, ser and 
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sec suggest that sely is a more classical SAg compared to selx and sely. Using the in-house S. 
aureus genome database the selz gene was identified in 54 out of 813 S. aureus genomes (6.7%) 
using BLAST. Sequence analysis of the SElZ protein demonstrated there were 11 allelic 
variants of this protein and the gene appears to be highly conserved (Appendix 1.2) as the most 
diverse variants were found to share 94.981 % identity (SElZ3 versus SElZ10). There are 19 
positions within the SElZ protein sequence that exhibit variation and 7 of these occur in the 
signal sequence region of the protein (Appendix 1.2), if this region of the protein region is 










Figure 3.1 Phylogenetic analysis of selx, sely, and selz.  The genetic relatedness of 
staphylococcal SAgs and SAg-like proteins was inferred by using the Maximum Likelihood 
method based on the Tamura-Nei model (Tamura and Nei, 1993). The tree with the highest log 
likelihood (-14825.7934) is shown. Initial tree(s) for the heuristic search were obtained 
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise 
distances estimated using the Maximum Composite Likelihood (MCL) approach, and then 
selecting the topology with superior log likelihood value. The analysis involved 40 nucleotide 
sequences. Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing 
gaps and missing data were eliminated. There were a total of 402 positions in the final dataset. 
Analyses were conducted in MEGA5 (Tamura et al., 2011). Genes are coloured according to the 
group classification described  previously (Spaulding et al., 2013).  Blue genes denote the SSl 
proteins, red show the group I SAgs, green genes denote the group II SAgs, group III SAgs are 
coloured purple and group V SAgs are coloured orange. The branches for selx, sely and selz 
have been coloured red to highlight their position in the tree. 
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3.3.2 SElX, SElY and SElZ exhibit features associated with other SAgs. 
The crystal structure of SElX, SElY and SElZ have yet to be determined, so structure 
predictions of the proteins were made using the I-Tasser server (Roy et al., 2011). Protein 
motifs in the sequences of SElX, SElY and SElZ were determined by aligning the amino acid 
sequences with that of characterised SAgs. Analysis of the protein models was combined with 
protein alignments to look for analogous residues and motifs from other SAgs that may 
contribute to the function of the protein (Fig 3.2 and Fig 3.3). The models of SElX, SElY and 
SElZ all exhibit the two domain structure of other SAgs as typified by the crystal structure of 
TSST-1 (Fig 3.2 and Fig 3.3). Sequence alignments demonstrate that all three SAgs analysed 
share residues that could interact with the T-cell receptor (Fig 3.2). Each of the SAgs encode a 
variant of the outside-in signalling motif which has been implicated in co-receptor signalling in 
T-cell activation (Fig 3.2, Fig 3.3 and Fig 3.4) (Arad et al., 2011, Brosnahan and Schlievert, 
2011, Spaulding et al., 2013). This motif is found at the base of the conserved central alpha 
helix in SElX, SELY and SElZ, similar to all other SAgs examined to date (Fig 3.4).  
 The position of predicted MHC class II binding residues is more diverse in the three 
SAgs analysed. SElX is predicted to encode only the low affinity MHC class II site found 
within the N-terminal OB domain. This domain is predicted to be highly truncated in SElX 
suggesting that a novel MHC class II interaction may occur. SElZ is predicted by the I-TASSER 
software to interact with zinc, indicative of a SAg that binds to the MHC class II via the high 
affinity site (Abrahmsen et al., 1995, Hudson et al., 1995). The location of the zinc binding site 
is predicted to be in the C-terminal grasp domain as observed in other zinc binding SAgs such 
as SEA and SEC. A second zinc binding site was also predicted in the OB fold domain of SElZ. 
SAgs with two zinc-binding sites such as SEC have been shown to form dimers that allow for 
cross linking of MHC class II complexes on the surface of APC cells (Chi et al., 2002). SElZ 
exhibits a loop structure in the N-terminal domain which is framed by two parallel cysteine 
residues (Fig 3.3) a characteristic feature of many emetic SAgs (Balaban and Rasooly, 2000). 
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This suggests SElZ may behave as an enterotoxin. SElY is predicted to encode the low affinity 
MHC class II binding site in the OB domain. This protein is predicted to exhibit a structure very 
similar to TSST-1 (Fig 3.2 and 3.3) 
 
3.3.3 SElX contains a conserved sialic acid binding motif. 
If SAgs perform alternative functions during S. aureus infection then it is possible they contain 
protein motifs associated with these functions. Sequence alignments of SElX with previously 
characterised SSl-proteins revealed a conserved sialic acid binding motif (Fig 3.5) (Baker et al., 
2007, Chung et al., 2007, Hermans et al., 2012). The motif in SElX has a 54% amino acid 
sequence identity with the same motif found in SSl5. Of note, this motif is commonly found in 
staphylococcal proteins that interact with neutrophils (Hermans et al., 2012). Within the motif  
are 4 amino acid residues that have been demonstrated to interact with sialic-Lewis X (sLEX) 
(Hermans et al., 2012), and 3 of these residues (E4, K7, and Q10) are conserved in all 5 proteins 
identified to date that contain this motif (Fig 3.5). The fourth residue shown to interact with 
sLEX in crystallography studies varies among the SSl-proteins and allelic variants of SElX 
suggesting that this residue may confer some level of specificity to the protein but is not 













Figure 3.2 SElX and SElY share a number of common features with other characterised 
SAgs.(i) Model structure of SElX. (ii) Model structure of SElY. Front and rear views (right and 
left respectively) are shown in surface and cartoon forms (top and bottom respectively). Key 
features of the proteins are coloured and described in the key. Alignments of protein sequences 













Figure 3.3 SElZ shares a number of common features with other characterised SAgs. (i) 
Model structure of the SAg SElZ. (ii) The crystal structure of TSST-1. Front and rear views 
(right and left respectively) are shown in surface and cartoon forms (top and bottom 
respectively). Key features of the proteins are coloured and described in the key. Alignments of 
protein sequences showing the position of the residues within the proteins sequences are shown 









Figure 3.4 SElX, SElY and SElZ all encode the outside-in signalling sequence.  (i) Amino 
acid sequence alignments of the outside-in signalling sequence (coloured red) of TSST-1, SElX, 
SElY and SElZ showings the relative position of this motif in the sequence. (ii) Ribbon 
diagrams of three staphylococcal SAgs demonstrate the outside-in motif (coloured yellow) is 
consistently located at the base of the central α-helix. (iii) Amino acid residues within the 
outside-in signalling sequence from all characterised SAgs including SElX, SElY and SElZ 
were used to show the conservation of specific residues among various proteins. Residues more 
likely to be at each position appear larger than their less common counterparts. Image generated 
using the free weblogo 3.4 program located at http://weblogo.threeplusone.com/. 







Figure 3.5 SElX protein sequence encodes a conserved sialic acid binding motif. (i) Amino 
acid sequences of characterised SSl-proteins and SElX reveal a conserved glycan binding motif 
(coloured red). (ii) The sialic acid binding motif is conserved in all 17 alleles of SElX. (iii)  
Amino acid residues within the sialic acid binding region of 7 staphylococcal neutrophil binding 
proteins (SSl2, SSl3, SSl4 SSl5, SSl6, SSl11 and SElX) were used to show the conservation of 
specific residues among various proteins. Residues more likely to be at each position appear 
larger than their less common counterparts. Image generated using the free weblogo 3.4 
program located at http://weblogo.threeplusone.com/. Chemical property colour scheme: green 




3.3.4 SElX, SElY and SElZ circular dichroism analysis suggest novel features. 
The models of SElY and SElZ suggest they may have a structure similar to that of previously 
characterised SAgs. In contrast SElX is predicted to contain a truncated N-terminal domain 
which suggests a novel mechanism of MHC class II interaction.  Recombinant proteins were 
prepared and tested for the ability to induce non-specific human T-cell proliferation by 
thymidine incorporation (Fig 3.6). The five SAgs; SElX, SElY, SElZ, SEA and TSST-1 were all 
demonstrated to be able to induce non-specific T-cell mitogenicity (Fig 3.6). All the SAgs 
except SElX proved to be highly potent to the point that they were capable of inducing T-cell 
proliferation at concentrations as low as 100 pg/ml (Fig 3.6). SElX induced T-cell proliferation 
at concentrations higher than 10 ng/ml, indicative of lower potency compared to other SAgs. 
This is the first time that SElZ has been demonstrated to be mitogenic for human T-
lymphocytes.  The 5 SAgs were then analysed using circular dichroism (CD) to examine 
secondary structure content (Fig 3.7). By including structurally characterised SAgs in this 
analysis the CD spectra may provide an insight into the structures of SElX, SElY and SElZ.  
  The secondary structure content of the 5 SAgs and SSl7 was determined by CD. All 6 
proteins tested exhibited varying CD spectra which are indicative of variable structures (Fig 
3.7). The data acquired from this analysis was found to be unreliable below 200nm due to the 
buffer conditions and equipment used, the lamp used was a standard Xe lamp and buffers were 
not degassed prior to use which can both contribute to noise below 200 nm (Kelly et al., 2005). 
Due to these limitations, accurate estimation of secondary protein structure was not possible. 
However these data can still be compared to spectra from proteins that exhibit 100 % of each 
secondary structure (Greenfield, 2006).  Overall SSl7 gave a relatively weak spectrum and it is 
difficult to determine which secondary structure predominates but it appears to be distinct from 
the other proteins analysed (Fig 3.7). The CD spectra of TSST-1 indicated a mixture of helices, 
beta sheets and a strong signal for random coil (signal observed between 200 and 210nm), 
which is demonstrated in the crystal structure of TSST-1 (Fig 3.3 and Fig 3.7). This 
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demonstrates that the CD spectrum gives an accurate reflection of secondary structure in these 
recombinant proteins. For SElX the predicted structure is predominated by random coils and for 
SElY the structure is predicted to be more mixed between different secondary structures (Fig 
3.2). The models of SElX and SElY were built using a variety of Sag and SSls as a template. 
Given that neither of these proteins exhibit a CD spectra remotely close to that seen for TSST-1 
or SSl7 it suggests that these proteins exhibit a different structure than that predicted (Fig 3.7). 
SElX and SElY CD spectra suggest proteins that exhibit a structure predominated by α-helices 
which does not reflect the models (Fig 3.7). SElZ and SEA CD spectra both indicate proteins 
predominated by β-sheets which is similar to the secondary structure predicted in the model for 
SElZ and shown by the crystal structure of SEA (Fig 3.7 and Fig 3.3). These proteins display a 
diverse range of secondary structure and the analysis has demonstrated that the predicted 
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Figure 3.6 Recombinant staphylococcal superantigen proteins tested induce T-cell 
proliferation. Human PBMC proliferation assay after 72 h exposure to recombinant SAgs, as 
indicated by the incorporation of [
3
H] thymidine. Results shown are the means of triplicate 
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Figure 3.7 Staphylococcal SAgs exhibit distinct CD spectra. Recombinant staphylococcal 
proteins were used to generate far UV CD spectra of secondary structure. Each spectrum was 
normalised to the precise molar concentration analysed and compared to spectra from the other 
recombinant proteins.  
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3.3.5 SElX, SElY and SElZ exhibit a high level of stability. 
Staphylococcal SAgs have classically demonstrated a very high level of stability in response 
to variations in pH and temperature (Li et al., 2011). This property of the staphylococcal 
enterotoxins facilitates survival in the human GI tract prior to the induction of emesis (Hu 
and Nakane, 2014). In the current study, to determine if the novel SAgs also exhibit this 
property, staphylococcal proteins (SElX, SElY, SElZ, SEA, TSST-1 and SSl5) were dialysed 
in PBS buffer of varying pH (4 to 9). The thermostability profile of each protein under each 
condition was determined using thermal shift analysis (Fig 3.8), demonstrating distinct 
spectra under different pH conditions.  
The most stable proteins are SElY and TSST-1, as measured by a lack of a phase 
shift in fluorescence up to 50°C. The most unstable protein is SSL5 as this protein exhibited 
spectra indicative of complete degradation above pH 5. The other three proteins (SElX, SElZ 
and SEA) all gave more intermediate profiles. A feature of the SEA and SElZ profiles was 
biphasic protein degradation across the pH spectrum implying that there are structures within 
the protein that are more thermostable than others (Fig 3.8).  SElX and TSST-1 also exhibit 
biphasic profiles but these only occur under certain pH conditions (Fig 3.8).  
The Tm of each protein under each condition was calculated (this is defined as 50% 
of maximum unfolding) and in the event of biphasic degradation the Tm was calculated for 
the first phase of the degradation only. These data were plotted against pH (Fig 3.9) 
indicating that the melting temperature varies only slightly over the pH range tested (Fig 
3.9). SEA was the only protein to demonstrate any relationship between stability and pH 
with a slight increase in Tm at the higher pH buffers tested (Fig 3.9) and the other proteins 
remain stable over a wide pH range. SElY and TSST-1 are the most stable proteins tested 
with a mean Tm in excess of 50°C. SElX and SElZ demonstrate a high level of resistance to 
changing pH conditions as the Tm of these proteins exhibit little variation from pH 4 to pH 9. 
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Taken together the SAgs SElX, SElY and SElZ all exhibit a Tm in excess of 40°C and 
demonstrate resistance to variations in pH, conditions that a potentially emetic protein may 
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Figure 3.8 Staphylococcal SAgs exhibit a high level of tolerance to pH variation. 
Thermal shift analysis of staphylococcal proteins buffered with PBS at varied pH. Profiles 
were performed in triplicate and the mean fluorescence was plotted against temperature 
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Figure 3.9 SAgs demonstrate limited variation in stability at different pH. Mean 
fluorescence spectra of SAg thermal shift profiles at different pH were used to determine the 
Tm (50% of protein unfolding) of each protein under each condition. If a Tm was not 




3.3.6 SElZ demonstrates zinc-dependent binding. 
Zinc ions can be utilised by SAgs to interact with the MHC class II complex (Spaulding et 
al., 2013). If zinc binds to SAgs it may alter the stability of the proteins and change the 
thermal shift profile. Here, 5 µM of recombinant protein was co-incubated with differing 
concentration of zinc sulphate and the divalent cation chelator EDTA. Zinc compounds will 
precipitate in neutral and alkaline solutions and in PBS so all profiles were obtained in 50 
mM HEPES at pH 6. The thermostability profiles of TSST-1, SElX and SElY were 
unchanged between 10 µM to 0 µM of Zn2+ and for the protein incubated with EDTA (Fig 
3.10). The thermal profiles of TSST-1, SElX and SElY demonstrate instability when 
incubated with the higher concentrations of zinc. Taken together these data are consistent 
with a lack of a biologically relevant interaction for TSST-1, SElX and SElY with zinc. SSl5 
shows an inverse relationship between zinc and thermostability (Fig 3.10) as thermal profiles 
of SSl5 exhibited more rapid degradation when more zinc was added. The most stable SSl5 
profile was exhibited when SSl5 was incubated with EDTA, which suggests that SSl5 is 
sensitive to the presence of divalent cations like zinc.  
 SEA has been demonstrated to interact with zinc during the interaction between 
MHC class II and the high affinity binding site on the protein (Hudson et al., 1995). Here we 
demonstrate that SEA stability increases as more zinc is added indicative of zinc binding. 
The thermostabilty profiles of SElZ are more varied exhibiting the highest level of stability 
at 1 µM of zinc. The second highest level of SElZ stability was exhibited by the protein 
suspended in EDTA. This suggests that SElZ binds to zinc but this interaction has an optimal 
concentration and can be destabilised by higher concentrations of the cation. This suggests 
that SElZ binds zinc cations and could be used by the protein to form dimers or bind to the 
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Figure 3.10 Zinc binds differentially to staphylococcal SAgs. Thermal shift experiments 
of different staphylococcal proteins co-incubated with different zinc sulphate concentration. 





3.3.7 SElX and SElZ do not exhibit emetic activity. 
SElX and SElZ exhibit a high level of stability and SElZ contains a cysteine loop, a 
characteristic of potential emetic activity. It is important to identify the potential to induce 
emesis as staphylococcal enterotoxins are a leading cause of food poisoning in humans 
(Hennekinne et al., 2012). Activity has traditionally been assessed in non-human primate 
models which are expensive and ethically questionable. Recently an alternative rodent model 
of emesis in the house musk shrew (Suncus murinus) has been developed (Hu et al., 2003). 
The animals were assessed for emesis following intraperitoneal administration of protein. 
500 µg/ml of SElX and SElZ was injected into 4 and 5 animals respectively. Emesis was not 
observed after 3 h and no behavioural changes noted. The dose was increased to 1mg/ml for 
each protein and again no emesis or behavioural changes were observed demonstrating that 
these proteins are not emetic in this model. These experiments were performed at Hirosaki 
University, Japan, by Dr. Hisaya Ono and supervised by Prof. Akio Nakane. SElY was found 
to be emetic independently of this study (Ono et al., 2015).  
 
3.3.8 Regulation of SElX expression is dependent on the sae locus. 
The importance of SElX in a rabbit model of USA300-induced necrotizing pneumonia and 
abscess models demonstrates up-regulation of expression during infection (Malachowa et al., 
2015, Wilson et al., 2011). In order to examine the regulation of expression of SElX, 
insertion mutants of selected global regulators were assessed for SElX gene and protein 
expression in strains Newman and USA300 LAC. Similar mutants for strains encoding SElY 
and SElZ were not available at this time so this analysis was not performed for these SAgs. 
Supernatants and bacterial cells from the two wild type S. aureus strains and 8 global 
virulence regulator mutants (Table 3.1) attenuated for expression of regulators agr, saeRS 
and rot were analysed by Western blot and qRT-PCR analysis for SElX expression (Fig 
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3.11). The expression of the selx gene was analysed at post-exponential phase (OD600= 7.0 
for Newman and OD600= 4.0 for LAC) as this is the peak point of expression of selx 
previously reported in liquid media (Malachowa et al., 2011). Fold change data was 
calculated based on the transcription of selx from the wild type after the each data point was 
normalised using the internal control (16srRNA). Western blot analysis was performed on 
supernatants from bacterial cultures grown for 16 h. The disruption of the agr locus resulted 
in increased selx expression in strain Newman, a trend that was not significant in USA300 
LAC (Fig 3.11), consistent with a strain-dependent role for agr as a repressor of selx 
expression. When the rot gene is disrupted there is no effect on selx transcription or protein 
expression suggesting this locus has no direct impact of SElX expression (Fig 3.11).  In 
contrast, the loss of sae expression resulted in a massive reduction in levels of SElX protein 
for both strain Newman and USA300 LAC (Fig 3.11). In Newman the disruption of sae 
resulted in SElX being undetectable in both the single sae and double sae and agr mutants 
(Fig 3.11). In LAC SElX expression was greatly diminished in the sae insertion mutant (Fig 
3.11). When the transcript analysis was performed on the sae mutants it was found that selx 
transcripts were significantly lower in the sae mutant of LAC and reduced in Newman, 
although not significantly (Fig 3.11). However there was a significant reduction in selx 
transcripts when comparing the agr sae combination mutant compared to the agr only 
insertion mutant of Newman. Taken together these data demonstrate that the sae locus is a 















Figure 3.11: Expression of selx is regulated by the two component sensor system saeRS. 
Expression analysis of global regulator insertion mutants from S. aureus strains Newman (i) 
and USA300 LAC (ii) by western blot and qRT-PCR analysis. Western blots were 
performed on concentrated overnight supernates and detected using anti-SElX IgY. RNA 
was purified from bacteria grown to OD600 = 7.0 for strain Newman and OD600 = 4.0 for 
USA300 LAC and analysed by SYBR™ green qRT-PCR. Data was normalised to fold 
change from the wild type (ΔΔCt) and the results shown are the means of four independent 










In this study the SAgs SElX, SElY and SElZ all were shown to contain motifs found in other 
SAg which have been demonstrated to be involved in SAg function. The phylogenetic 
analysis demonstrated that selx and sely are more closely related to the SSl-proteins than 
they are to the majority of SAgs. The predicted models all suggest SElX, SElY and SElZ 
exhibit the classical two domain arrangement and encode residues in the expected regions of 
the protein that can mediate TCR and MHC class II binding. All three SAgs were found to 
encode a variant of the outside-in signalling motif which is found in all other SAgs 
(Brosnahan and Schlievert, 2011). This motif appears to be a critical component of SAg 
structure, in a similar fashion to the TCR and MHC class II binding sites (Brosnahan and 
Schlievert, 2011, Stach et al., 2014). The alignment of this motif from different SAgs shows 
that the dodecapeptide is diverse in amino acid sequence (Fig 3.4) and may mediate 
specificity to different cell surface receptors. The motif has been implicated in transcytosis 
of SAgs like TSST-1 and may also be the binding site for tertiary binding partners involved 
in T-cell activation such as CD28 and CD40 which have been implicated in cytokine 
activation by SAgs (Arad et al., 2011, Brosnahan and Schlievert, 2011, Stach et al., 2014).  
The sequence analysis of SElY and SElZ demonstrates that these SAgs are 
distributed among S.aureus strains at a level comparable to other staphylococcal SAgs (5 % 
to 25 %) (Fraser and Proft, 2008b, Spaulding et al., 2013). Both SAgs were found in S. 
aureus strains isolated from a range of host species including humans, cattle and rabbits. For 
both SAgs a number of allelic variants were identified and further work should be conducted 
to examine their distribution across the S. aureus population and the potential functional 
significance of the allelic variation.   
SElX is predicted to exhibit a unique structure for a staphylococcal SAg in that it has 
a truncated N-terminal domain made up of loop structures (Wilson et al., 2011). This is 
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contrary to the CD spectra obtained which suggests that the predominant secondary structure 
in the protein is α-helices. The prediction software used to prepare the model of SElX 
utilised the crystal structure of TSST-1 and other SSl-proteins as templates. Given the vast 
difference in the CD spectra of SElX, TSST-1 and SSl7 it suggests the model for SElX is 
inaccurate and that the structure of SElX maybe unique. The OB fold is the location of the 
low affinity binding site for MHC class II. As SElX does not to bind to zinc and given the 
novel structure of the OB domain, it remains unclear how SElX interacts with the MHC class 
II complex. This data may be linked to the lower potency of SElX relative to other SAgs. 
Further analysis of SElX demonstrated that it contains a sialic acid binding motif, a 
common feature of many SSl-proteins. This protein motif mediates the binding of many SSl-
proteins to neutrophils and maybe the site of interaction between SElX and neutrophils 
previously reported (Fevre et al., 2014). This motif is identical in 11 of the 17 identified 
allelic variants of SElX with the six variants that are not identical demonstrateing only a 
single amino acid difference in position 12 (Fig 3.4), a residue previously demonstrated to 
interact with sLEX in crystallography studies (Hermans et al., 2012). Unlike the three other 
residues demonstrated to bind to sLEX, position 12 varies among the SSl-proteins and so far 
histidine, aspartic acid and asparagine have all been identified at this site in different SSl-
proteins suggesting a possible role in tropism to specific sugars or glycoproteins.  The 
conservation of the sialic acid binding motif in all variants of SElX associated with strains 
infecting multiple hosts suggests that sugar interactions may be an important general 
function for SElX in the pathogenesis of human and animal species.  
The thermal shift assay demonstrated that four (SElX, SElY, SSl5 and TSST-1) of 
the six proteins tested did not interact with zinc and suggest that SElX and SElY do not 
encode the MHC class II high affinity binding site and likely interact with MHC class II 
through the low affinity site only, similarly to TSST-1 (Spaulding et al., 2013). SEA 
demonstrates an increase in stability when the zinc ligand is added, which may suggest why 
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SEA exhibits such a low tolerance to pH variations, as the assay was performed in the 
absence of zinc. For SElZ the data from the zinc binding assays were not conclusive as 1µM 
of zinc increased the stability of SElZ, but other concentrations either conferred a limited 
increase in stability or destabilised the protein (Fig 3.12). Another possibility for the limited 
zinc binding observed in SElZ is the presence of the HIS-tag. This motif is controlled for as 
it is presenet in all the proteins tested but it could still contribute to an increase in zinc 
binding. Given that SElZ is predicted to encode two zinc binding sites, it is likely that there 
is a genuine interaction with zinc and binding to MHC class II can occur via the high affinity 
binding site.   
The data obtained in this study suggests that SElZ exhibits the structural and 
functional traits of a classical group II SAg. The T-cell proliferation assay demonstrated that 
this protein was also a potent mitogen for human T-cells.  It was also shown to exhibit high 
level of stability to variation in temperature and pH. During the stability study it exhibited a 
biphasic degradation profile similar to that observed for SEA. SEA contains the cysteine 
loop structure in the OB domain of the protein which SElZ is also predicted to contain. The 
biphasic profile seen may be indicative of this structure in both SEA and SElZ as the first 
phase of unfolding is associated with regions of the protein not associated with the loop 
structure. As the cysteine loop is a more stable structure, a second peak in fluorescence is 
observed as the temperature reaches a level high enough for degradation of the loop. Despite 
exhibiting a stable structure and containing a cysteine loop, SElZ was non-emetic in the 
house musk shrew model. This model has been shown to be able to demonstrate emesis for 
potent enterotoxins like SEA but may behave inconsistently for less potent emetic proteins 
(Omoe et al., 2013). It is feasible that SElZ is emetic at high concentrations in humans, and 
to investigate this SElZ should be examined in a non-human primate model. 
SElY has been demonstrated to be a highly stable protein in this study and is 
predicted to share a structure similar to TSST-1. Further, SElY is emetic in the house musk 
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shrew model (Ono et al., 2015). This suggests that SElY is capable of mediating food 
poisoning in humans. Like SElX there is a discrepancy between the predicted model and the 
similarity between the CD spectra of SElY and TSST-1. The SElY spectrum is indicative of 
more α-helical structure than that predicted in the model and crystallography studies should 
be performed to understand the structure of this SAg. SElY is phylogenetically related to 
SET which uniquely does not have a Vβ T-cell profile and may induce T-cell proliferation 
independent of the Vβ region of the TCR. SElY is a potent T-cell mitogen in humans but the 
Vβ profile is still to be determined and it may prove to behave in a similar way to SET. 
In the case of both SElX and SElY the CD data varied significantly from the 
predicted model of both proteins. In both cases the templates used to prepare the model were 
TSST-1 and a number of SSl-proteins including SSl7. The CD spectrum of both SSl7 and 
TSST-1 were found to be completely different from that seen for SElX or SElY, there was 
strong indication for the presence of the random coil and less α-helices in the secondary 
structure of TSST-1. In SSL7 the CD spectra generated gave a relatively weak signal 
compared to the other proteins examined but the spectra was more suggestive of a secondary 
structure made up of an equal amounts of  α-helices and β-sheets.  SElX and SElY CD 
spectra suggest two protein structures predominanted by α-helices and may suggest a novel 
arrangement compared to other SAgs. The presence of the outside-in signalling motif 
suggests the central α-helix is likely still present and may still separate the protein into two 
separate domanins as seen in other SAgs. The structural analysis of these proteins highlights 
the limitations of protein modelling and that the accuracy is highly dependent on the 
availability of crystal structures from closely related proteins. The group I superantigens are 
a disparate group and sequence identity within this group is low (<20%) and it is 
unsurprising that the models generated from using TSST-1 and other less closely related 
proteins such as SSl-proteins do not necessarily reflect the reality. 
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The expression data demonstrates that selx expression is globally regulated by both 
the agr and saeR/S locus. The agr locus is acting as a repressor of selx expression as RNA 
transcripts were significantly increased in the Newman strain when agr was disrupted. To 
date many SAgs have been shown to be positively regulated by the agr locus suggesting that 
selx is not employed by S. aureus during infection in the same way as other SAgs. The 
saeR/S locus is an activator of selx expression as the disruption of this locus saw a very large 
reduction in selx expression in both backgrounds tested. Like other genes regulated by the 
saeR/S locus selx was found to encode a consensus sequence in the promoter region of the 
gene which SaeR can bind to directly and up regulate expression (Nygaard et al., 2010). The 
saeR/S locus has been implicated in the response of S. aureus to phagocytic signals although 
it is not clear precisely which signals can activate the pathway and there is evidence to 
suggest the pathway can be activated differentially by different signals (Geiger et al., 2008, 
Voyich et al., 2009). The saeRS regulon included a wide number of different virulence 
determinants including the SSl-proteins 5 and 7, CHIPS and FLIPr (Nygaard et al., 2010).  
This study has shown that selx is regulated by a locus that responds to phagocytic signals and 
activates expression of virulence determinants that have been shown to contribute to the 
evasion of phagocytes. Taken together with the presence of the sialic acid binding motif 
within SElX there is a case to further explore if SElX can interact with neutrophils and other 











































So far in this study we have demonstrated that SElX contains characteristic motifs of both 
SAgs and SSl-proteins. The regulation of selx also suggests it may be expressed as part of 
the S. aureus response to the innate immune system given its co-regulation with other innate 
immune modulators such as CHIPS, SCIN and the SSl-proteins (Nygaard et al., 2010, 
Rooijakkers et al., 2006).  It has already been demonstrated that SElX can interact directly 
with human neutrophils and at very high concentrations interact with the glycoprotein 
PSGL-1 (the same target as SSl5) (Fevre et al., 2014, Bestebroer et al., 2007). This 
interaction is unlikely to be the only target of SElX on neutrophils as the concentration 
required to bind PSGL-1 is at a physiologically irrelevant concentration (Fevre et al., 2014). 
Taken together these data suggests SElX may act as innate immune modulator by binding to 
neutrophils.  
SElX was found in the previous chapter to contain a predicted sialic acid binding 
motif, a motif found in the SSl-proteins, SSl4, SSl5, and SSl11 which coordinates the 
binding of sialic acid decorating proteins on the surface of neutrophils (Baker et al., 2007, 
Chung et al., 2007, Hermans et al., 2012). SSl3 also contains the sialic acid binding motif but 
binds to its target on the neutrophil (TLR2) independent of the glycan binding motif 
demonstrating that SSl-proteins can interact with neutrophil through mechanisms 
independent of sialic acid (Koymans et al., 2015).  The characterisation of neutrophil binding 
SSl-proteins has demonstrated that these proteins have a range of targets on the surface of 
the neutrophil (Table 1.2). The binding of SSl-proteins to the surface of a neutrophil can 
directly antagonise the target and block its function (Bestebroer et al., 2007), but binding 
may also lead to internalisation of the protein which could have an intracellular function 
(Chung et al., 2007).  
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The SAgs TSST-1 and SElY also have been shown to be phylogenetically more 
closely related to the SSl-proteins than the majority of SAg and therefore warrant further 
study for any potential innate immune inhibitory functions. Potential neutrophil interactions 
should also be analysed with SElY and TSST-1 to determine if the SAg-neutrophil 
interaction is a property limited to SElX. Here we will characterise the binding of SElX and 
other SAgs to neutrophils by:  
 Comparing the binding of SElX and other SAgs to leukocytes from different 
mammalian species 
 Using site directed mutagenesis to determine the residues involved in SElX binding 
to neutrophils  
















4.2 MATERIALS AND METHODS 
4.2.1 Neutrophil isolation from different mammalian species 
Human PMNs and PBMC were isolated from human blood as outlined in section 2.16. 
Murine bone marrow derived PMNs were isolated from femurs of 10 to 16 week old 
BalbC mice, as described previously (Mocsai et al., 2003). Femurs were harvested after 





UK) supplemented with 20 mM Na-HEPES (Fisher Scientific, UK) (pH 7.4) and 0.5% 
FCS (Sigma Aldrich, UK)) to remove any muscle tissue. Bone marrow was flushed from 
the femurs with excess murine-preparation buffer, homogenised and then passed through 
a 70 µm cell strainer (BD bioscience, Oxford, UK) to remove bone fragments. The 
suspension was then pelleted by centrifugation at 400 x g for 5 min and re-suspended in 
10 ml of 0.2 % (w/v) NaCl to lyse red blood cells for 30 s to 40 s. Osmolarity was 
restored with 10 ml 1.6% (w/v) NaCl and the cells were again pelleted by centrifugation 
at 400 x g for 5 min. Percoll (GE, healthcare, Buckinghamshire, UK) was mixed with 
murine-preparation buffer to prepare a 62.5 % (v/v) gradient and 5 ml was added to a 15 
ml conical tube. The cells were re-suspended in 5 ml murine-preparation buffer and 
layered onto the 62.5 % Percoll. The suspension was then centrifuged for 30 min at 1000 
x g with the centrifuge brake off. At the end of the centrifugation the neutrophil pellet was 
harvested (diffuse layer found in the middle of the 62.5 % percoll). The pellet is washed 
twice with murine-preparation buffer and then re-suspended in 1 ml of assay buffer for 
counting with the TC20 automated cell counter (Biorad, Hemel Hempstead, UK) and re-
suspended to a concentration of 1 x 10
7 
cells/ml. Neutrophil phenotype was confirmed 
using Lys6C and Lys6G staining by incubating the samples of the isolated neutrophils 
individually with 1:500 dilutions of with Rat anti-Lys6C PerCP-Cy5.5 (BD Bioscience, 
Oxford, UK) and Rat anti-Lys6G PE-Cy7 (BD Bioscience, Oxford, UK)  for 30 min on 
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ice before the cells were analysed by flow cytometry (FACSCalibur; Becton Dickinson, 
Franklin Lanes, NJ). Phenotype was confirmed by a high fluorescent signal for Lys6G 
and Lys6C. 
Bovine PMNs were isolated from Holstein-Friesian cattle aged 18 to 36 months 
via jugular vein puncture (6 ml 10 x PBS/EDTA (100 mM KH2PO4, 9 % (w/v) NaCl, and 
2 mg/l EDTA in sterile H2O adjusted pH to 7.4) anticoagulant used for 50 ml of blood). 
Animals were reared indoors and maintained on a ration of hay and concentrates. PMNs 
were isolated from bovine blood using a protocol described previously (Siemsen et al., 
2007). 50 ml blood was pooled into a conical 50 ml polypropylene centrifuge tube (BD 
bioscience, Oxford, UK) and centrifuged at 740 x g for 10 min at room temperature with 
low brake. The upper plasma layer and buffy coat (found at the plasma–red blood cell 
interface) were removed and the remaining red blood cell layer was split equally between 
5 polypropylene centrifuge tubes. Red blood cells were lysed by adding 10 ml of sterile 
H2O to each tube and gently inverted for 20 s at room temperature. Osmolarity was 
restored by adding 1 ml of 10 % (w/v) NaCl solution to each tube. The leukocyte pellet 
was recovered by centrifugation at 585 x g for 10 min at room temperature with low 




free). Histopaque gradients were prepared by first layering 15 ml of Histopaque 1077 
(Sigma-Aldrich, UK) onto 15 ml Histopaque 1077/1119 solution (1:1 solution of 
Histopaque 1119 and Histopaque 1077 (Sigma-Aldrich, UK)) in a conical 50 ml 
centrifuge tube. The leukocyte suspension was layered on top of the Histopaque and 
centrifuged at 440 x g for 25 min at room temperature with no brake. The neutrophil 
pellet was harvested and washed by re-suspending the cells in 50 ml of HBSS and 
centrifuging at 585 x g for 10 min at room temperature. The cells were then counted with 
a TC20 automated cell counter (Biorad, Hemel Hempstead, UK) and re-suspended to a 
concentration of 1 x 10
7 
cells/ml in the desired assay buffer. 
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Rabbit PMNs were isolated from whole rabbit blood (using ACD (see section 2.16) 
as an anticoagulant) purchased from the National Transfusion Centre, Moredun Institute, 
Midlothian, UK.  Leukocytes were isolated using an equal volume of red blood cell (RBCs) 
lysis buffer (10 x buffer contained; 155 mM NH4Cl, 10 mM KHCO3 and 100 µM EDTA in 
ddH2O). RBCs were lysed in 1x Buffer for 10 min at 37°C and the remaining cells were 




free) (Gibco). This 
was repeated until the pellet was clear of red cells and the cells were then counted with a 
TC20 automated cell counter (Biorad, Hemel Hempstead, UK) and re-suspended to a 
concentration of 1 x 10
7 
cells/ml in the desired assay buffer.  
 
4.2.2 Protein expression and purification 
Plasmid pET15b and pQE30 constructs containing SAg genes previously prepared in 
Chapter 3 were used to prepare recombinant proteins (Table 3.3). Protein expression was 
induced as outlined in section 2.13.1. All recombinant proteins were purified using the native 
purification protocol outlined in section 2.13.2 except SElX and SSl5. SElX was purified 
using the denaturing protocol outlined in section 2.13.2 followed by a second purification 
step using IEC also described in section 2.13.2. SSl5 was purified with a hybrid purification 
protocol; induced cells were lysed and bound to the affinity column with denaturing protocol 
buffers (Table 2.1) using the protocol described in section 2.13.2 and then washed with the 
denaturing wash buffer as described in 2.13.2. Protein was then refolded on the column by 
adding native protocol wash buffer over a gradient (30 min to 100 % at a flow rate of 1 






4.2.3 Cell binding experiments 
For binding of recombinant proteins to leukocytes, neutrophils (5 × 10
6
 cells/ml) and 
PBMCs (5 × 10
6 
cells/ml) were incubated with increasing concentrations of 6 x HIS-tagged 
recombinant proteins in RPMI 1640 (Gibco, UK) and 0.05 % HSA (Human serum albumin) 
(Sigma-Aldrich, UK) (RPMI-HSA) for 30 min on ice. For lymphocyte binding experiments 
the cells were also co-incubated with lymphocyte subset–specific antibodies including anti-
CD4, -CD8, and, -CD19 (PE labelled) (BD bioscience, Oxford, UK). Cells were washed 
with RPMI-HSA and pelleted at 400 x g for 10 min at 4°C. Binding of the proteins was 
detected with a FITC-labelled monoclonal mouse anti-HIS tag monoclonal antibody (LS 
Bioscience, WA, USA), antibodies were incubated with cells for 30 min on ice, washed with 
RPMI-HSA and pelleted at 400 x g for 10 min at 4°C. Following washing, cells were re-
suspended in 200 µl of RPMI-HSA and leukocyte populations were identified based on 
forward and sideway scatter on a flow cytometer (FACSCalibur; Becton Dickinson, Franklin 
Lanes, NJ), and fluorescence was measured.  For neuraminidase experiments isolated 
leukocytes (2 × 10
6
 cells/mL) were pre-treated with 0.2 U/ml neuraminidase (from Vibrio 
cholerae; Sigma-Aldrich, UK) at 37°C for 45 minutes at pH 6.0, prior to washing and 
subsequent incubation.  
 
4.2.4 Site-directed mutagenesis  
Site-directed mutagenesis was performed to replace amino acids in the sequence of SElX by 
introducing mutations into the pET15b::selx2 construct using PCR reactions with 
oligonucleotide primers listed in Table 4.1. The reactions were performed using the PfuUltra 
II Fusion HS DNA polymerase (Agilent Technologies, UK) as described in section 2.7. 
Primers were used at a final concentration of 250 nM along with 2 mM dNTPs (Promega, 
Hampshire, UK). Vector DNA was added to a final concentration of 5 to 30 ng and the PCR 
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reactions were performed on a MyCycler™ thermal cycler (Biorad, Hemel Hempstead, UK); 
1 cycle at 95°C for 2 min, 30 cycles of 95°C for 20s, 50°C for 20s and 72°C for 90s, 
followed by a final extension of 3 min at 72°C. Following the PCR amplification DpnI 
endonuclease (New England Bioscience, Herts, UK) was added to a final concentration of 
0.8 U/µl, the reaction was then incubated for 1 h at 37°C followed by an enzyme 
deactivation step of 10 min at 65°C. Following digestion, 1µl of the amplified vector product 
was transformed into E. coli Solopack™ cells from the Strataclone blunt cloning kit (Aglient 
technologies, UK). The ligated mixture was transformed into the defrosted competent cells 
and pre-incubated on ice for 20 min, followed by a heat shock at 42°C for 45s before 
returning to ice for 2 min. 250 µl of pre-warmed LB was added to the cells to recover for an 
hour at 37°C before 100 µl of the bacterial suspension was plated onto LB agar containing 
100 µg/ml of ampicillin.  
Plates were grown overnight at 37°C and screened for transformed colonies which 
were randomly selected for Sanger sequencing. Briefly, transformed colonies were grown 
overnight in liquid culture and the plasmids were purified using the Qiaprep miniprep kit 
(Qiagen, Manchester, UK) according to the manufacturer’s specifications. Plasmid 
constructs were sequenced by Edinburgh Genomics Sanger sequencing service (University 
of Edinburgh, UK). When the mutations were confirmed the plasmid constructs were 
transformed into BL21 DE3 E. coli cells for protein expression and purification (see section 
2.13). To ensure that protein folding and stability was not affected by the mutagenesis, CD 
and thermal shift analysis was carried out. 
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Table 4.1 Oligonucleotide Primers used for site directed mutagenesis of pet15b::selx2. 
Primer 
Name 

































499 GAG>GCT  
508 AAA>GCA  







 Positions relative to selx2 allele
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4.2.5 Circular Dichroism analysis 
Far UV CD spectra of protein samples was recorded in 0.1 x PBS (pH 7.3) using the Jasco J-
710 (Japan Spectroscopic Co. Ltd, Japan).  Spectra of the proteins, between a concentration 
of 0.4 to 1 mg/ml, were recorded between 190 nm to 250 nm using a cuvette with a path 
length of 0.05 mm. For analysis the precise molar concentration was determined for each 
protein and used in the Jasco software to normalise each protein spectra. 
 
4.2.6 Thermal shift analysis 
To monitor protein unfolding, the fluorescent water sensitive dye Sypro orange (Life 
Technologies, UK) was employed. The thermal shift assay was conducted in the Lightcycler 
480 (Roche, West Sussex, UK), the melt curve function of this system was used and a melt 
curve was determined from 25°C to 95°C. 25µl of 5 μM recombinant protein was incubated 
with Sypro orange dye diluted 1/125 of the original stock dye, with heating from 25°C to 95 
°C at a heating rate of 0.1°C/sec. The fluorescence intensity was measured with 
excitation/emission at 465/510 nm.  
 
4.2.7 Affinity precipitation and mass spectrometry analysis 
This analysis was performed at the New York University Medical Centre by Dr David James 
and supervised by Prof. Victor Torres. Detergent-solubilized proteins from primary human 
neutrophils were incubated with 6 x HIS-tagged SElX and interacting proteins were purified 
using Ni-NTA resin (Qiagen, Manchester, UK). Proteins eluted from Ni-NTA resin were 
separated on a precast 4 % to 15 % gradient SDS-PAGE gel (Bio-Rad, Hemel Hempstead, 
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UK) and stained with SYPRO-Ruby (Life Technologies, UK). Gels were imaged and the 
lanes were excised for trypsin digestion, protein extraction and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis. 
The gel was de-stained with 1:1 solution of 10 mM ammonium bicarbonate and 100 
% (v/v) acetonitrile solution followed by 100 % (v/v) acetonitrile. The solvent was removed 
and the gel pieces were covered with trypsin digestion buffer (13 ng/μl trypsin (porcine 
sequencing grade (Promega, Hampshire, UK)) in 10 mM ammonium bicarbonate containing 
10% (v/v) acetonitrile) and the buffer was allowed to saturate for 2 h on ice. Digestion was 
carried out overnight at 37°C.   
The protocol for protein extraction is as follows; slurry of R2 20 µm Poros beads 
(Life Technologies, UK) in 5 % (v/v) formic acid and 0.2 % (v/v) trifluoroacetic acid (TFA) 
was added to each sample at an volume equal to that of the ammonium bicarbonate added for 
digestion,  followed by shaking at 4˚C for 3 h.  The beads were loaded onto equilibrated C18 
ziptips (Millipore) by centrifugation for 30 s at 6000 rpm.  Gel pieces were rinsed three times 
with 0.1 % TFA and each rinse was added to its corresponding ziptip followed by 
centrifugation.  The extracted porous beads were further washed with 0.5 % (v/v) acetic acid 
and peptides were eluted by the addition of 40 % acetonitrile in 0.5% acetic acid followed by 
the addition of 80 % (v/v) acetonitrile in 0.5 % (v/v) acetic acid. The organic solvent was 
removed using a SpeedVac concentrator and the sample reconstituted in 0.5 % (v/v) acetic 
acid. 
Samples were ready for LC-MS/MS analysis and 1/3 of each sample was analysed 
individually by Liquid chromatography separation connected with MS using the autosampler 
of an EASY-nLC 1000 (Thermo Scientific, USA). Peptides were gradient eluted from the 
column directly to Q Exactive mass spectrometer using a 1 h gradient (Thermo Scientific, 
USA). High resolution full MS spectra were acquired with a resolution of 70,000, an 
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automatic gain control (AGC) target of 1e6, with a maximum ion time of 120 ms, and scan 
range of 400 to 1500 m/z.  Following each full MS twenty data-dependent high resolution, 
higher-energy C-trap dissociation (HCD) MS/MS spectra were acquired. All MS/MS spectra 
were collected using the following instrument parameters: resolution of 17,000, AGC target 
of 5e4, maximum ion time of 250ms, one microscan, 2 m/z isolation window, default charge 
state of +3, fixed first mass of 150 m/z, and normalised collision energy (NCE) of 27.  
MS/MS spectra were searched using a Uniprot Human database using Sequest within 
Proteome Discoverer (Thermo Scientific, UK).   
 
4.2.8 Enzyme-linked immunosorbent assay (ELISA) validation of protein-
protein interaction 
96-well ELISA plates (Maxisorb; Nunc, Thermo, UK) were coated with 10 µg/ml 
recombinant SElX WT, SElX EKQD-A, SSL5 or SSl7 in carbonate/bicarbonate buffer 
(50mM Na2CO3 and NaHCO3) diluted 1/10 in PBS. The plates were incubated overnight at 
4°C. Plates were washed with PBS-0.05 % (v/v) Tween-20 (Sigma-Aldrich, UK) and 
blocked with PBS-0.05 % (v/v) Tween-20 and 8% (w/v) skimmed milk powder 
(microbiology grade; Sigma-Aldrich, UK) for 1 h at 37°C. Plates were washed with PBS-
0.05 % (v/v) Tween20 and incubated with different concentrations of PSGL-1-HIS, CD50-
HIS and CD16b-HIS (all purchased from Life Technologies, UK) for 1 h at 37°C. Bound 
HIS-tagged proteins were detected using mouse monoclonal antibodies for each target 
protein (AbD Serotec, Biorad, UK) followed by a peroxidase-conjugated rabbit-anti-mouse 
monoclonal antibody (Abcam, Cambridge, UK). Peroxidase activity was detected with TMB 
(Sigma-Aldrich, UK) for 40 s and the reaction was stopped using 1M H2SO4. Absorbance 





4.3.1 Characterisation of binding of SAgs to human cells. 
In order to test the hypothesis that SAgs can bind to human leukocytes the four SAgs; SElX, 
SElY, SElZ and TSST-1 were incubated with human leukocytes isolated from blood taken 
from healthy donors. Binding was detected by determining the fluorescent signal from a 
(FITC labelled) anti-HIS tag antibody so binding of all recombinant proteins tested can be 
compared directly. The SSl-protein SSl5 has previously been demonstrated to bind to 
neutrophils and monocytes previously (Bestebroer et al., 2007) and here we could reproduce 
those findings at concentrations below 20 nM of protein. SSl7 did not demonstrate any cell 
binding. Importantly SElX bound to human neutrophils and monocytes with a similar 
affinity and protein concentration to SSl5 (Fig 4.1). At higher concentrations SElX exhibited 
a higher binding signal than SSl5 when incubated with neutrophils, suggesting that SElX 
may have a higher affinity for human neutrophils than SSl5. In contrast the binding curves of 
SSl5 and SElX for monocytes was consistent with a similar affinity.  Also observed was a 
lower affinity interaction between SElY and human neutrophils and monocytes, which was 
detectable above a 100 nM protein concentration. There was a higher signal for SElY-
monocyte binding versus neutrophils binding which may indicate SElY has a higher affinity 
for monocytes.  The SAgs SElZ and TSST-1 did not demonstrate binding to any of the 
human cells tested. 
A variable low affinity interaction was observed between SElX and lymphocytes in 
some experiments, and co-staining of SElX and lymphocyte markers revealed (Fig 4.2) that 




 T-lymphocytes subsets but not to B-lymphocytes (CD19). 




4.3.2 SElX interacts with PMNs from different mammalian species. 
S. aureus can infect a broad range of mammalian hosts (Fitzgerald, 2012). To determine if 
the observations made in the human cell binding analysis could be extended to different host 
species, neutrophils from 3 additional mammalian species (murine, laprine and bovine) were 
analysed for binding to the staphylococcal SAgs tested earlier on human neutrophils. The 
species were selected as S. aureus is a major pathogen of cattle, and both rabbits and mice 
are commonly used as models for S. aureus infections. In this experiment, only the SElX2 
recombinant protein was tested, which is an allele found only in human isolates of S. aureus 
(Fig 4.3). Murine cells demonstrated a high affinity for SElX, which was greater than that 
observed for human cells. Bovine and laprine cells exhibited lower binding but SElX and 
SSl5 binding could still be observed at a concentration below 100 nM (Fig 4.3). Overall 
SElX was capable of binding with PMNs isolated from the three species tested with an 
affinity that exceeded that of SSl5.  SElY was the only other SAg tested that demonstrated 
binding to human neutrophils, but activity was not observed for cells from the additional 
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Figure 4.1 SElX and SElY bind to human monocytes and neutrophils. Flow cytometry 
analysis of binding of recombinant staphylococcal proteins to isolated human white blood 
cells. Binding to human cells was detected using Mouse anti-HIS-FITC IgG binding to the 6 
x HIS-tag on the recombinant proteins. Mean median fluorescence of three donors is shown 











Figure 4.2 SElX binding to different lymphocyte subpopulations. Two-colour flow 
cytometry was used to analyse SElX binding to different lymphocyte subpopulations. To 





B-lymphocytes were concurrently stained with PE-conjugated antibodies directed against 
CD4, CD8, or CD19. SElX binding was determined using a FITC conjugate mouse anti-HIS-
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Figure 4.3 SElX interacts with neutrophils from a range of mammalian species. Flow 
cytometry analysis of binding of recombinant staphylococcal proteins to isolated human (i), 
murine (ii), bovine (iii) and laprine (iv) neutrophils. Binding to cells was detected using 
mouse anti-HIS-FITC IgG binding to the 6 x HIS-tag on the recombinant proteins. Mean 
median fluorescence of three donors is shown ± standard error of the mean. SSl5 and SSl7 







4.3.3 SElX binding to PMNs is dependent on the predicted sialic acid binding 
motif.   
SElX was demonstrated in chapter 3 to contain a sialic acid binding motif which has been 
reported to mediate the interaction between some SSl-proteins and neutrophils. To test if the 
SElX interaction with PMNs is sialic acid-dependent, binding assays were performed on 
neuraminidase-treated cells, as previously reported (Fevre et al., 2014). Neuraminidase 
treatment of neutrophils prior to incubation with SElX abolished neutrophil binding 
suggesting that binding involves a sialic acid interaction (Fig 4.5). In order to confirm the 
role of the predicted sialic acid binding motif in binding to neutrophils, site directed 
mutagenesis was carried out.  Single site directed mutants of each of the four predicted sialic 
acid binding residues were prepared, in addition to a combination mutant with all four 
residues replaced with alanine. Mutagenized proteins were expressed and purified under 
identical conditions and structural validation by circular dichroism and thermal shift was 
performed to ensure the mutations had not destabilised the proteins (Fig 4.4). The proteins 
were then examined for leukocyte binding capacity by flow cytometry analysis. The single 
site directed mutants SElX –E154A, K156A, Q169A and the combination mutant SElX-
EKQD-A exhibited almost complete loss of binding to neutrophils and monocytes compared 
to the WT rSElX suggesting an important role for these residues in neutrophil binding of 
SElX. The mutant SElX-D161A bound to neutrophils and monocytes at an equivocal level to 
WT rSElX, suggesting this residue is not essential for neutrophil binding. Taken together 
these data show that the predicted sialic acid binding motif (SAB) encoded in SElX is 
required for binding to neutrophils and monocytes.  
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Figure 4.4 Mutations in the predicted sialic acid binding site of SElX have limited 
impact on protein structure and stability.  Circular dichroism analysis was performed on 
SElX SAB mutants to ensure the secondary structure was not affected by the mutations (i). 
Thermal shift assays were performed to check the stability by thermal shift (ii). The Tm of 





Figure 4.5 SElX interaction with Neutrophils is mediated via the sialic acid binding 
motif. (a) Flow cytometry analysis of SElX binding to human neutrophils treated with 0.2 
U/ml neuraminidase versus untreated cells. 6 x His-tagged SElX binding was detected using 
Mouse anti-His FITC IgG. (b) Protein model of SElX showing the location of sialic acid 
binding residues (coloured green) in the protein structure these residues are magnified in the 
black box showing their atomic structure in the binding pocket. (c) Flow cytometry 
assessment of site directed mutants of the sialic acid binding pocket in SElX. Each of the 
residues in part (b) has been exchanged for an alanine. Binding to human cells was 
determined using flow cytometry and binding was detected using Mouse anti-His FITC IgG.   
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4.3.4 SElX interacts with different neutrophil glycoprotein receptors. 
This section of the study was performed by Dr David James and supervised by Prof. Victor J 
Torres based at New York University Medical Centre. Affinity precipitation analysis with 
human PMN lysates suggests that SElX can interact with multiple neutrophil proteins. The 
quantitative mass spectrometry analysis demonstrated that at least 12 proteins were enriched 
by SElX-coated Ni-NTA beads more than 5 fold higher than uncoated Ni-NTA beads (Table 
4.2). The enriched proteins represent a broad range of functional pathways in the neutrophil 
but the majority of enriched proteins were identified as surface glycoproteins. Of note, the 
most enriched proteins are four glycoproteins that display integrin or cell activation 
functions (CD45, CD13, CD31 and CD148). Another protein that was found to be highly 
enriched was maltase-glucoamylase (MGAM) which is an enzyme found in the gelatinase 
and ficolin granules of neutrophils (Rorvig et al., 2013). Other cytosol or granule proteins 
enriched by SElX include p22-PHOX and α-antitrypsin suggesting that the SElX interaction 
is not limited to neutrophil surface proteins. MGAM, p22-PHOX and α-antitrypsin all are all 
involved in the microbicide functions of neutrophils. If SElX is internalised then these 
cytosolic proteins could provide targets for SElX which could disrupt the neutrophil and 
immune function.  
   The affinity precipitation experiment was repeated with the SAB mutants of SElX 
and the reduction in protein enrichment that was observed (Fig 4.6) reflected the decrease 
observed in the leukocyte binding assay (Fig 4.5). This suggests that many of the proteins 
enriched during the precipitation assay are dependent on the predicted sialic acid binding 
motif. The mass spectrometry analysis was repeated (across 2 donors) and the peptide 
enrichment of CD45, CD31, CD13, CD148 and MGAM by each SAB mutant was 
determined. MS analysis was only possible on precipitation experiments from 2 donors, 
therefore no statistical analysis could be carried out. Mutants E154A and K156A and D161A 
exhibited limited reduction in enrichment for the 5 proteins analysed. However E154A did 
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bind differentially to CD31 and CD13 suggesting that this residue can contribute to specific 
binding of these receptors. The mutant Q159A exhibited a diminished enrichment for all 5 
proteins analysed suggesting an important role in the interaction between SElX and the sugar 
molecules on its glycosylated targets. Overall, enrichment by SElX EQKD-A demonstrated 
the lowest level of enrichment of all the SAB mutants tested. For SElX EKQD-A peptide 
enrichment was attenuated for all five neutrophil proteins analysed, especially CD31. Taken 
together these data indicate the interactions between SElX and neutrophil proteins observed 
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130.8 P08575-2 Protein tyrosine-protein phosphatase, critical in T-cell activation. Dephosphorylates LYN (Src 
family of kinases) and modulates LYN. 






109.5 P16284-3 Expressed on platelets and leukocytes and is primarily concentrated at the borders between 
endothelial cells. CD31 has been shown to interact with the Src family of kinases (Cicmil et al., 
2000). 





80.2 P15144 Alanine aminopeptidase involved in cell differentiation development and metabolism. Is up 







145.9 Q12913 CD148 is a receptor-like protein tyrosine phosphatase up-regulated on T cells after T cell 
receptor stimulation. It has also been shown to interact with the SRC family of kinases. 
>10 fold 
3/5 donors 
8 fold  
2/5 donors 




311 E7ER45 Enzyme with polysaccharide substrates shown to be a component of neutrophil  Gelatinase and 
Ficolin Granules (Rorvig et al., 2013) 







84.7 P05107 Integrin β2 involved in cell signalling and activation. Associated with CD11a, CD11b and 








119.1 P20701-3 Isoform 3 of Integrin alpha-L involved in cell signalling and activation. Associated with CD18 
forming critical leukocyte signalling complexes. 
4-10 fold  
2/5 donors 
 
CD11b 127.1 P11215 Integrin alpha-M involved in cell signalling and activation. Associated with CD18, forming 
critical leukocyte signalling complexes. 
2-4 fold  









Fold Enrichment vs 
no protein control 
     
Desmoplakin 331.6 P15924 Protein critical in the formation of desmosomes. >10 fold 
1/5 donors 
p22-PHOX 65.3 P04839 Cytochrome b-345 heavy chain, cytochrome b has been implicated as the primary component 









45.2 P00738 Haptoglobin captures, and combines with free plasma hemoglobin to allow hepatic recycling of 
heme iron and to prevent kidney damage. 
>10 fold 
1/5 donors 















37.3 B6EAT9 Hyaluronate receptor that can mediate lymphocyte activation, cell migration and variable 
glycosylation of this protein can mediate direct binding to fibrin and immobilised fibrinogen. 
 




66.1 B7Z747 Along with elastase, appears to be a regulatory factor in neutrophil migration across the 
basement membrane 
 





26.9 O00299 Cell metabolism, internal pH regulation and cell stabilisation 2-4 fold 
2/5 donors 
 
CD66c 37.2 P40199 Involved in neutrophil adhesion to fibronectin (Nair and Zingde, 2001) 5-9 fold  
3/5 donors 
a


















Figure 4.6 SElX binding mutants exhibit differences in protein enrichment for 
neutrophil lysates. (i) SDS-PAGE analysis of affinity precipitation experiments of SElX 
and SAB mutants with neutrophil lysates. Gels were stained with sypro ruby. Gel fragments 
in the blue boxes were excised and submitted for quantitative mass spectrometry analysis 
and compared to the non-specific binding sample. (ii) Proteins showing the highest level of 
enrichment from the SElX affinity precipitation with neutrophil lysates were analysed for 
peptide enrichment following incubation with SAB mutants. Data shown indicates the mean 
number of peptides detected from each enriched protein (± SEM from two donors). All data 












4.3.5 SElX interacts with CD50 in a sialic acid dependent manner. 
To determine if SElX was interacting directly with any of the protein targets indicated by the 
affinity precipitation analysis, ELISAs were performed with recombinant glycoprotein 
receptors. PSGL-1 (CD162) was selected as this had already been shown to interact with 
SElX (Fevre et al., 2014). Intercellular adhesion molecule 3 (ICAM-3) (CD50) was chosen 
from the affinity precipitation analysis as this is an important signalling molecule involved in 
a number of important functions including induction of apoptosis and cell to cell signalling 
(Costantini et al., 2011, Kessel et al., 2006). ICAM-3 was also one of the few receptors from 
the precipitation analysis that was available as a recombinant protein and had been prepared 
in a mammalian expression system. A mammalian expression system is important given the 
likely role of glycosylation in the binding of SElX to its target. The three proteins examined 
in this section were obtained from sources that had expressed these proteins in mammalian 
cells (Life technologies, UK).  The FcγR CD16b was selected as a negative control. The 
proteins were added to plates coated with SElX, SElX EKQD-A, SSl5 and SSl7. SSl5 
showed a high affinity for all three proteins tested suggesting that SSl5 can bind to a range of 
glycoproteins (Fig 4.7). As expected, SSl7did not interact with any of the glycoproteins 
tested. SElX demonstrated a strong interaction with PSGL-1 as previously shown (Fevre et 
al., 2014). Of note, SElX EKQD-A bound to PSGL-1 at a similar level as the WT suggesting 
this interaction is independent of the predicted sialic acid binding site. In contrast the SAB 
mutant exhibited a significant reduction in binding to ICAM-3 suggesting an interaction that 
involves a sialyted receptor.  
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Figure 4.7 SElX interacts with CD50 in a sialic acid-dependent manner. ELISAs were performed comparing the interaction between staphylococcal 
proteins and recombinant PSGL-1 (i), CD16b (ii) and ICAM-3 (iii). ICAM-3 binding to SElX and SElX EKQD-A was tested by T-test, * denotes a p-
vale <0.05.  
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4.4 DISCUSSION  
Nucleotide and derived amino acid sequence analysis in Chapter 3 demonstrated that SElX 
contains a conserved sialic acid binding motif. This is a common feature of the SSl-proteins 
binding to the surface of neutrophils and was confirmed to mediate the interaction seen 
between SElX and human neutrophils and monocytes. When the predicted sialic acid binding 
motif was attenuated the ability of SElX to bind to neutrophils was diminished, and in the 
case of the multiple residue mutant completely abolished. The structural analysis of these 
proteins demonstrated that the mutations had no impact on the folding of the proteins. This 
demonstrates that the predicted sialic acid binding motif is critical for the interaction 
between neutrophils and SElX. SElX demonstrates a high affinity for human neutrophils and 
monocytes, similar to the level seen for that of SSl5. The interaction with neutrophils is 
replicated in other mammalian species and is suggestive of an important role for SElX in S. 
aureus pathogenesis in mammalian hosts.  
 SElX exhibited strong binding to human neutrophils and monocytes as previously 
shown (Fevre et al., 2014). In this work we have also demonstrated that there was some 




 T-cells and there was 
no binding to B-lymphocytes. This is a characteristic of the SSl-proteins that bind to human 
leukocytes and may reflect the low activity of glycol-transfereases in peripheral lymphocytes 
prior to activation (Kumar et al., 1998). This would suggest that if lymphocytes become 
activated during infection then SElX or SSl-proteins may be able to target them in addition 
to neutrophils and monocytes. In lymphocytes, glycol-transfereases are activated by the 
presence of IL-2 which is an interleukin that can be induced by SAg-mediated activation of 
the lymphocyte (Kumar et al., 1998). It is possible that SElX can induce glycoprotein 
activation on the surface of lymphocytes then act as a glycoprotein antagonist modulating 
lymphocyte function.    
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SElX demonstrates the ability to interact with neutrophils from a range of 
mammalian species. The interaction with murine cells is noteworthy as it allows SElX to be 
potentially studied in a model where there is no interference from the superantigenicity of 
the protein. Classically, SAgs have not been studied in mouse models due to the differences 
in MHC class II alleles which prevent SAgs from activating murine lymphocytes. Although, 
this has not been demonstrated yet for SElX, lack of mitogenicity in mice is likely given its 
relationship to SAgs like TSST-1 (Tilahun et al., 2011).  SElX demonstrated the highest 
level of affinity for murine neutrophils, which may reflect the source of the cells. Unlike the 
other mammalian species tested murine neutrophils were isolated from bone marrow and not 
peripheral blood. It is possible that these cells display a different amount of glycoprotein 
receptors to peripheral cells. Rabbits are also another important model for S. aureus 
infections and the ability of SElX to bind to neutrophils from this species suggests that the 
role of neutrophil binding of SElX in S. aureus pathogenesis can be examined in this model. 
The mammalian species, rabbits and cattle, represent important veterinary hosts of S. aureus 
(Fitzgerald, 2012). The ability of SElX to bind to neutrophils from these species suggests 
this function is retained in different host species, suggesting a broad role for SElX across 
different host species. Importantly, the SAB identified in Chapter 3 was demonstrated to be 
highly conserved among alleles of SElX from human and animal strains (Fig 3.7).    
The other SAgs analysed in this study did not have the same level of binding affinity 
for neutrophils and monocytes as SElX with both TSST-1 and SElZ not exhibiting any 
binding to leukocytes. However SElY had a relatively low affinity interaction with 
neutrophils and to slightly greater extent monocytes in spite of the lack of a SAB. These data 
suggest that SAgs in addition to SElX have the capacity to bind to leukocytes via multiple 
mechanisms.  
The affinity precipitation analysis demonstrated that SElX can interact with an array 
of glycoprotein receptors, the most enriched were CD45, CD13, CD31 and CD148 and have 
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been shown to be involved in integrin function and cell signalling (Liu et al., 2012, Hart et 
al., 2000, Hermiston et al., 2009). CD45 and CD148 are both involved in activation of Src 
family kinases and cell activation (Hermiston et al., 2009), whereas CD31 is present on 
leukocytes and platelets and has multiple functions including cellular adhesion and activation 
(Liu et al., 2012). CD31 has also been shown to be associated with the Src family of kinases 
which upon activation leads to CD31 phosphorylation increasing adhesion of the protein to 
endothelial surfaces (Cicmil et al., 2000, Liu et al., 2012). These data suggests that SElX 
may bind to receptors involved in neutrophil activation and transmigration. 
In addition, SElX was also shown to interact with a number of intracellular proteins 
including MGAM, p22-PHOX and α-1-antitrypsin. This suggests that SElX may be 
internalised or expressed intracellularly allowing the targeting of intracellular pathways of 
neutrophil function. This has precedent as other several SSl-proteins are rapidly internalised 
by neutrophils and have been demonstrated to inhibit function (Baker et al., 2007, Chung et 
al., 2007, Hermans et al., 2012).  
When the affinity precipitation experiments were repeated with the SAB SElX 
mutants the enrichment of proteins from neutrophil lysates was reduced. For the mutants 
K156A and D161A enrichment was unaffected for all five of the proteins analysed. This 
suggests that these residues are not essential in coordinating the interaction between SElX 
and these protein targets. The SAB mutant Q159A showed a reduced enrichment for all five 
neutrophil proteins suggesting the importance of this residue in the neutrophil interaction. 
The mutant E154A showed differential enrichment to the glycoprotein targets with 2 of 5 
proteins diminished, suggesting this residue may confer a level of specificity to the SAB. 
The EKQD-A mutant of SElX exhibited reduced enrichment to all five protein binding 
partners. Taken together these data demonstrate the predicted SAB is required for SElX to 
interact with the binding partners identified by affinity precipitation analysis and that all four 
amino acid residues examined contribute to the binding of target proteins.  
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PSGL-1 was shown to interact with SElX by ELISA and in the current study ICAM-
3 was also shown to interact with SElX. Unlike PSGL-1, there was a significant reduction in 
binding of ICAM-3 to SElX EKQD-A, consistent with a sialic acid binding activity that 
mirrors the binding interaction seen on the surface of neutrophils. Of note ICAM-3 is a 
ligand for important activator pathways such as MAC-1 and LFA-1 (de Fougerolles and 
Springer, 1992, Petruzzelli et al., 1995). Blocking ICAM-3 can interfere with the activation 
of NK-cells and lymphocytes when these cells co-localise (Costantini et al., 2011, Petruzzelli 
et al., 1995). It has also been shown that ICAM-3 ligation in neutrophils can induce 
apoptosis and it is feasible that SElX may be able to activate this pathway (Kessel et al., 
2006). It is unclear why both the wild type SElX and the SAB mutant bound to PSGL-1 at a 
similar level, but we speculate that SElX has an alternative binding site for PSGL-1.  
In the current study we have demonstrated that SElX can bind to neutrophils and 
monocytes through a predicted SAB which is found in other SSl-proteins. Affinity 
precipitation analysis has suggested SElX can interact with a range of proteins from 
neutrophils which are critical to immune function. The functional impact of SElX is yet to be 






















































S. aureus has been demonstrated to produce an array of factors that interact with PMNs 
modifying their function through multiple mechanisms including direct toxicity or inhibition. 
Of note, the SSl-proteins can interfere with PMN immune pathway functions through 
numerous ways. For example, SSl5 interferes with integrin function (Bestebroer et al., 2007), 
and in the case of SSl3 binding of the protein inhibits cell activation by blocking of TLR2 
(Bardoel et al., 2012). Other SSl-proteins have been shown to interact with parts of the 
humoral immune system. For example, SSl7 can bind to both C5 and IgA and interfere with 
the complement pathway assisting S. aureus immune evasion (Bestebroer et al., 2010, 
Langley et al., 2005, Lorenz et al., 2013). SSl10 is another example of a complement 
inhibitor which binds to the IgG Fc region, blocking the activation of the classical 
complement pathway (Itoh et al., 2010b, Patel et al., 2010).  SSl8 has been demonstrated to 
interact with tenascin C and to interfere with wound healing by retarding the motility of 
keratinocytes (Itoh et al., 2013).   
We have shown that SElX binds to PMNs through the predicted glycan binding motif 
found in some SSl-proteins (Hermans et al., 2012). For SElX the functional consequences of 
this interaction are unknown but it is reasonable to speculate that it influences neutrophil 
function. SElX has already been demonstrated to act as a superantigen, but to date no other 
SAg has been reported to bind to leukocytes independently of the T-cell activation pathway. 
As such the molecular mechanisms underpinning the distinct function of SElX remain to be 
elucidated. A number of S. aureus virulence factors have been demonstrated to exhibit two 
or more functions. For examples, the collagen binding adhesin (Cna) has been demonstrated 
to bind to C1q (in addition to collagen) and prevent activation of the alternative complement 
pathway (Kang et al., 2013). In addition, FLIPr binds the formylated peptide receptor and 
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can induce inflammation, block the Fcγ-receptors and inhibit IgG-mediated phagocytosis 
(Prat et al., 2006, Stemerding et al., 2013). 
The aim of this part of the study is to determine if SElX has any functional impact on 
neutrophils and if this activity is distinct from its T-cell mitogenicity. The objectives include: 
 To test if the identified SElX neutrophil binding activity is distinct from its 
superantigenic activity.  
 Determining if SElX can enhance bacterial survival when incubated with 
neutrophils.  















5.2 MATERIALS AND METHODS 
5.2.1 Preparation of human serum and antibodies 
Blood donations were obtained from 10 healthy volunteers (5 male and 5 female) according 
to the protocol outlined in section 2.1. Blood was sampled without anticoagulant and 
following sampling was transferred into 50 ml conical tubes (BD falcon). Blood was 
incubated overnight at 4°C and allowed to clot. Following the overnight incubation the 
samples were centrifuged at 2000 x g for 10 min and serum supernatant was harvested and 
pooled with sera from the other donors. Pooled serum was filtered through a 0.45 µm 
membrane (Merk Millipore, Germany) to remove precipitates before snap-freezing on dry 
ice, aliquoted and stored at -80°C. When required, aliquots were defrosted on ice and for 
heat-inactivated serum an incubation step of 56°C for 30 min was employed. Purification of 
whole human IgG was performed using a Hitrap Protein G HP column (GE healthcare) on an 
AKTA FPLC machine (GE healthcare, Buckinghamshire, UK).The column was installed and 
run according to the manufacturer’s specification. IgG was purified by diluting the serum 
1/10 in PBS before being bound to the column. Following binding IgG was washed with 
PBS and eluted with 100 mM glycine (pH 2.7) buffer. The eluted antibodies were 
immediately dialysed into pH 7.3 PBS using Float-a-lyser units (10,000 MWCO) (Spectrum 
Laboratories, CA, USA). Antibody purity was examined by SDS-PAGE analysis and 
quantified using a Nanodrop spectrophotometer (ND1000) (Thermo Scientific, USA) before 
storing at -20°C.   
 
5.2.2 Bacterial survival assays  
Bacteria were cultured to an OD600 of 4.0 in BHI broth and then washed by diluting in PBS 




cfu/ml in HBSS containing 10 % (v/v) complement-inactivated serum. Isolated human 
neutrophils were added at a ratio of 1 bacterium to 10 PMNs, and incubated for either 15 or 
30 min at 37°C with shaking. Recombinant SElX was added to neutrophils to a final 
concentration of 10 µg/ml and incubated at room temperature for 30 min before the addition 
of the bacteria. 100 μl volume of the neutrophil bacterial suspension was diluted into 900 µl 
of PBS containing 0.05 % (v/v) Triton X 100 and incubated for 5 min at room temperature to 
lyse the neutrophils. Viable bacteria in each reaction mixture were counted following a 10-
fold dilution series in PBS. 100 μl of each sample was spread onto TSA plates, followed by 
overnight incubation at 37°C, surviving bacteria were enumerated and compared to the initial 
bacterial inoculum to determine percentage bacterial survival. 
 
5.2.3 Phagocytosis assays 
Phagocytosis was measured with FITC-labelled S. aureus. Briefly, CA-MRSA USA300 
spa::Tn (Table 5.1) was grown overnight and diluted to an OD600 of 0.5 followed by washing 
in PBS and centrifugation at 4000 x g for 10 min. The bacteria were re-suspended in an 
equal volume of PBS with FITC in DMSO to a final concentration of 0.5 mg/ml, and 
incubated in the dark at 4°C for 30 min. The bacteria were washed with PBS (4000 x g for 
10 min) to remove the excess FITC before the cells were re-suspended in assay media to an 
OD600 of 0.5. In 2 ml 96-well v-bottomed plates (Corning, USA), FITC labelled S. aureus 
were mixed with human serum, complement-inactivated serum or purified IgG for 15 min at 
37°C to facilitate opsonisation. Subsequently, isolated human neutrophils, with or without 
inhibitor (pre-incubated for 30 min at room temperature), were added at a 10:1 
bacterium/cell ratio and incubated for 15 min at 37°C with shaking at 750 rpm. The reaction 
was stopped with 1 % (v/v) paraformaldehyde (Fisher Scientific, UK), and cell-associated 
fluorescent bacteria were analysed by flow cytometry. Phagocytosis was defined as the 
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percentage of cells with a positive fluorescent signal.  Reduction in phagocytosis was 


























Table 5.1 S. aureus strains used in this study. 
Strain Description Reference 
USA300 LAC Wild Type (Voyich et al., 2006) 
USA300 LACΔselx Chromosomal deletion of selx (Wilson et al., 2011) 
USA300 LACΔselx rep Chromosomal repair of selx (Wilson et al., 2011) 












5.2.4 Cell line binding experiments 
For binding of recombinant SElX to Fcγ receptors a transfected human B-cell lymphoma line 
(5 × 10
6
 cells/ml) was incubated with increasing concentrations of 6 x HIS-tagged 
recombinant protein in RPMI 1640 (Gibco, UK) supplemented with 0.05 % HSA (Sigma 
Aldrich, Dorset, UK)  for 30 min on ice. After washing binding was detected using a FITC-
labelled monoclonal mouse anti-HIS-tag monoclonal antibody (LS Bioscience, WA, USA). 
Following washing the cell line population was determined based on forward and sideway 
scatter on a flow cytometer (FACSCalibur; Becton Dickinson, Franklin Lanes, NJ, USA) and 
fluorescence measured.   
 
5.2.5 Cytotoxicity determined by lactate dehydrogenase (LDH) release 
Human PMNs were isolated and re-suspended in HBSS (Gibco, UK) at a concentration of 
1x10
5
 cells/ml, followed by the addition of recombinant S. aureus proteins and incubated for 
1 h at 37°C with 5 % CO2. Following intoxication, cells were pelleted by centrifugation at 
450 x g at 4°C for 5 min. Lactate dehydrogenase (LDH) release was assayed as a measure of 
PMN viability using the CytoTox-ONE homogeneous membrane integrity assay (Promega, 
WI, USA) according to the manufacturer’s specifications. Briefly, 50 μl of culture 
supernatant was removed and added to wells containing 50 μl of LDH reagent and incubated 
for an additional 10 min at room temperature. Fluorescence was measured using a 
PerkinElmer Envision 2103 multilabel reader (excitation, 555 nm; emission, 590 nm) 
(PerkinElmer, MA, USA), and data were normalized to 100 % lysis as determined by the 
addition of 0.2 % Trition X (v/v) to the PMNs. These experiments were performed by Dr 




5.2.6 Determination of apoptosis 
For binding of recombinant proteins to leukocytes, neutrophils (5 × 10
6
 cells/mL) and 
PBMCs (5 × 10
6 
cells/mL) were incubated with increasing concentrations of HIS-tagged 
recombinant proteins in RPMI 1640 (Gibco) supplemented with 0.05 % HSA (v/v) (Sigma-
Aldrich, Dorset, UK)  for 30 min at 37°C. After washing with RPMI-HSA, cells were 
centrifuged at 400 x g for 10 min and then binding of the proteins was detected using a 
FITC-labelled monoclonal mouse anti-HIS-tag monoclonal antibody (LS Bioscience, WA, 
USA). The cells were washed one final time and re-suspended in assay media containing the 
nuclear dye DRAQ 5 (Biostatus, UK). Leukocyte populations were determined based on 
forward and sideway scatter on a flow cytometer (FACSCalibur; Becton Dickinson, Franklin 
Lanes, NJ) and fluorescence measured. Binding of the protein was determined on the FL1-H 
channel of this cytometer. DRAQ-5 fluorescence was determined on the FL3-H channel and 














5.3 RESULTS  
5.3.1 The mechanism of neutrophil binding of SElX is distinct from its 
superantigenicity. 
To determine if the superantigenic property of SElX was distinct from its neutrophil binding 
function, SAB mutants of SElX were examined for their ability to induce T-cell proliferation 
by [
3
H] thymidine incorporation. It was found that, despite the manipulation of the sialic acid 
binding site, all five SAB mutants were capable of inducing T-cell proliferation at 
comparable levels (Fig 5.1a).  Further analysis of the WT recombinant SElX protein and 
SElX-EKQD demonstrated that overall the superantigenicity of these proteins was not 
affected (Fig 5.1b),  inferring that the residues predicted for sialic acid binding required for 
binding neutrophils are not required to induce T-cell proliferation. 
 
5.3.2 SElX contributes to enhanced survival of S. aureus in the presence of 
neutrophils. 
To investigate the hypothesis that SElX contributes to the resistance of S. aureus to 
neutrophil killing, S. aureus strain USA300 LAC and its derivative selx deletion mutant 
(Table 2.1) were incubated with isolated human neutrophils with 10 % (v/v) heat inactivated 
serum (used as an opsonin to prevent complement mediated killing) (Fig 5.2).  After 15 min 
USA300 LACΔselx demonstrated a trend towards reduced survival but this was not 
significant (Fig 5.2). At the 30 min time point the survival of USA300 LACΔselx was 
reduced by over 50% compared to both the WT LAC strain and LACΔselx rep. Re-
introduction of selx or addition of recombinant SElX restored the survival of LACΔselx to 
WT levels. Taken together these data indicate that SElX enhances the capacity of S. aureus 
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Figure 5.1 Neutrophil binding-deficient mutants of SElX retain mitogenicity. (A) 
Isolated human PBMC were stimulated with recombinant WT SElX and SAB mutants and 
after 72 h exposure proliferation was determined, as indicated by the incorporation of [
3
H] 
thymidine. An experiment analysing the comparative potency of the WT SElX and mutant 
SElX-EKQD was also performed to determine the proliferation induced between 10 µg/ml 
and 100 pg/ml (B).  Results shown are the means of triplicate measurement from 3 human 
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Figure 5.2 SElX enhances S. aureus survival in the presence of human neutrophils. S. 
aureus survival assay with human neutrophils. S. aureus USA300 and selx deletion mutants 
were grown overnight and then diluted and incubated with isolated human neutrophils for 15 
or 30 minutes. rSElX was added to the neutrophils and pre-incubated at room temperature 
for 30 min. Following incubation neutrophils were lysed with Triton X 100 and surviving 
bacteria plated and enumerated. Percentage survival was calculated from initial inoculum 
and the normalised to the wild type. Results shown are the means of 3 independent 
experiments. Results were tested by T-test, * indicates p value < 0.05 and ** indicates a p 
value < 0.01.   
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5.3.3 SElX inhibits IgG-mediated phagocytosis. 
To determine if SElX or SElY had any impact on phagocytosis by PMNs, neutrophils where 
pre-incubated with SElX or SElY before opsonisation and the addition of bacteria. SElX 
reduced the ability of PMNs to take up bacteria when IgG was used alone as an opsonin (Fig 
5.3) and when 1 % heat-inactivated human serum was employed. These data demonstrate 
that IgG-mediated phagocytosis is inhibited by SElX. In contrast no reduction was seen for 
full human pooled serum (HPS) suggesting this effect is independent of complement-
mediated phagocytosis (Fig 5.3). SElY had no impact on phagocytosis in this assay (Fig 5.3).  
Further analysis of SElX-mediated inhibition demonstrated that the activity is highly 
potent inhibiting IgG mediated phagocytosis at a concentration of 0.4 nM (Fig 5.3). 
Inhibition of phagocytosis varies from 20 % to 30 % for SElX in comparison to the Fcγ 
antagonist FLIPr which can reduce the phagocytosis by up 75 %. Of note, no reduction in 
phagocytosis was observed when the SAB mutant, SElX EKQD-A, was used consistent with 
a requirement for neutrophil binding dependent on the sialic acid binding site (Fig 5.3).  
In order to test the hypothesis that SElX exerts its activity via binding to the Fcγ 
receptors, the interaction of SElX with the Fcγ receptors was tested. Interaction between 
SElX and the recombinant Fcγ receptors CD16b was examined in chapter 4 by ELISA and 
binding was not observed (Fig 4.6). Further, binding was not observed when Fcγ receptors 
were expressed in a human B-cell lymphoma line (Fig 5.4). These data suggest that the 
mechanism of inhibition of phagocytosis by SElX is independent of Fcγ receptor antagonism 
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Figure 5.3 SElX inhibits IgG-mediated neutrophil phagocytosis. (i) Phagocytosis of 
fluorescent S. aureus opsonized with 3 % (v/v) full human pooled serum (HPS), 3 % (v/v) 
Heat inactivated human pooled serum (ΔHPS) and purified IgG. Phagocytosis was 
performed with or without either 40 µg/ml of SElX or SElY. Assay was repeated with 1 % 
(v/v) full human serum (ii) 1 % (v/v) complement-inactivated serum (iii), or 150 µg/ml of 
purified IgG (iv) in the presence of SElX at various concentration. Inhibition by SElX was 
compared to the IgG-mediated phagocytosis inhibitor FLIPr and the SAB deficient mutant 
SElX EKQD-A (v). Phagocytosis was calculated as the percentage of cells with fluorescent 
bacteria and expressed relative to buffer-treated cells with 75 µg/ml human IgG. Results 
shown are the means of three different human donors (error bars SE of mean). Results 














Figure 5.4 SElX inhibition of IgG mediated phagocytosis is independent of Fcγ 
receptors. B-lymphoma cells were transfected with Fcγ receptor constructs and SElX 
binding was assessed at different concentration. Binding to cells was detected using Mouse 
anti-His FITC IgG binding to the HIS-tag on the recombinant protein. Data shown is 
representative of two experiments.  
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5.3.4 SElX inhibition of phagocytosis is not associated with leukocyte cell 
death.  
We speculated that the mechanism of neutrophil inhibition may be due to cell death induced 
by SElX. Accordingly, cell death induced via the necrotic and apoptotic pathway was 
examined. The capacity of SElX to induce LDH release from human PMNs was compared to 
the leucocidin LukAB (Fig 5.5). As expected LukAB was able to induce necrosis of PMNs 
down to a concentration below 40 ng/ml. In contrast LDH was not released in response to the 
high concentrations of SElX tested, suggesting SElX does not induce neutrophil necrosis. 
These experiments were performed by Dr David James and supervised by Prof Victor Torres 
at the NYU Medical Centre. 
To assess if SElX was capable of inducing apoptosis, the SElX leukocyte-binding 
assay was repeated and apoptosis was examined by nuclear fragmentation as detected by the 
nuclear stain DRAQ5. The addition of SElX to human leukocytes had no impact on the level 
of nuclear fragmentation observed in neutrophils, monocytes or lymphocytes (Fig 5.6). A 
degree of nuclear fragmentation was observed for neutrophils but this did not increase when 
SElX was added. For monocytes and lymphocytes nuclear fragmentation was not observed 
in the presence of or absence of SElX. Taken together these data suggest that SElX does not 
induce cell death when incubated with human leukocytes and inhibition of phagocytosis is 
































































































Figure 5.5 SElX does not induce necrosis of human PMNs. Isolated human neutrophils 
were intoxicated by various concentration of SElX and LukAB. After 1 h incubation the 
culture supernatants were assayed for the presence of LDH as a proxy for cell lysis. 
Percentage lysis was determined relative to complete lysis of the neutrophils which was 
determined by the addition of 0.2 % (v/v) Trition X to the cells. Results shown are the means 
of three different human donors, ± SD of the mean. These experiments were performed by 




Figure 5.6 SElX does not induce leukocyte apoptosis. Two colour flow cytometry was for 
leukocyte binding assays of SElX and human leukocytes. At the end of the assay the nuclear 
stain DRAQ5 was added to determine the level of nuclear fragmentation indicating 
apoptosis.  Quadrat plots show the binding of SElX along the X-axis and the Y-axis shows 
nuclear fragmentation indicated by higher DRAQ5 fluorescence. These data are 
representative of three experiments. 






 5.4 DISCUSSION 
Here we have investigated the interaction between SElX and human neutrophils 
using an array of functional assays. We have demonstrated that SElX has a clear functional 
impact on the human neutrophil that may enhance immune evasion during S. aureus 
infection. This is the first time a distinct function in innate immune evasion has been 
demonstrated for a bacterial SAg. 
Deletion of the selx gene resulted in reduced survival in the presence of neutrophils. 
Washing of S. aureus cells prior to neutrophil incubation should eliminate SElX secreted 
during culture, implying either that SElX is produced rapidly in response to neutrophil 
signals before being phagocytosed or alternatively the SElX is produced in the phagosome 
and enhances bacterial survival after phagocytosis. Of note, the addition of recombinant 
SElX enhanced the survival of LACΔselx, suggesting a role prior to uptake. Further work 
needs to be performed to establish if selx is being expressed upon uptake of the bacterial cell 
by the neutrophil and if SElX is acting within the neutrophil to contribute to S. aureus 
survival.   
SElX was demonstrated to reduce IgG-mediated phagocytosis by neutrophils 
independent of the Fcγ receptors. This inhibition was at a lower level compared to the 
characterised Fcγ receptor antagonist FLIPr, but inhibition by SElX was observed at a 
concentration as low as 0.4 nM consistent with a relatively high potency that could be 
physiologically relevant during S. aureus pathogenesis. The inability of the SAB mutant of 
SElX to inhibit phagocytosis demonstrates that binding to the neutrophil surface is essential 
for functionality which is dependent on the predicted sialic acid binding pocket of the 
protein. In the section 4.3.4 we demonstrated that SElX could potentially interact with a 
number of important signalling molecules such as CD50 and components of the MAC-1 
signalling complex. It is possible that SElX may bind via these glycoproteins and antagonise 
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signalling function leading to improper cell activation. Alternatively, internalisation of 
secreted SElX by the neutrophil may lead to an intracellular effect on neutrophil function. 
This property has been observed in a number of SSl proteins including SSl4, 5 and 11, 
although the functional impact of this internalisation is yet to be characterised (Baker et al., 
2007, Chung et al., 2007, Hermans et al., 2012). Furthermore some SAgs such as TSST-1 
have been shown to be able to mediate their own uptake into cells using the outside-in 
signalling motif described in chapter 3 (Brosnahan and Schlievert, 2011, Spaulding et al., 
2013, Stach et al., 2014).  
SElX does not appear to induce cell death as there was no evidence of apoptotic or 
necrotic processes induced by the co-incubation of SElX and leukocytes. Accordingly we 
suggest it is more likely that a targeted mechanism is acting on the neutrophil. Given the 
broad number of potential glycoprotein receptors that SElX may interact with it is feasible 
that SElX has multiple effects on the function of the neutrophil and other phagocytes such as 
macrophages. SElX has already been shown to interact with PSGL-1 albeit at high 
concentrations (Fevre et al., 2014) and the affinity precipitation analysis in section 4.3.4 
suggests additional integrins may be targeted. In this manner it is possible that SElX could 
contribute to blocking of neutrophil rolling and transcytosis to the site of infection similar to 
the function exhibited by SSl5 (Bestebroer et al., 2007).  
SElY was demonstrated in chapter 4 to bind to neutrophils and monocytes. However 
SElY did not have any effect on neutrophil phagocytosis of S. aureus even at very high 
concentrations (Fig 5.3) and additional assays are required to investigate the capacity of 
SElY to interfere with neutrophil function. 
S. aureus has been shown to encode at least 25 SAgs (Ono et al., 2015, Spaulding et 
al., 2013), but to date limited additional functions outside of inducing T-cell proliferation 
have been reported (Spaulding et al., 2013). Given the array of SAgs encoded by the great 
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majority of clinical isolates it seems likely that induction of T-cell proliferation is critical to 
persistence of S. aureus in its host, mediated via the activation of a broad range of T-cell Vβ 
subtypes and subversion of a critical arm of the adaptive immune system (Spaulding et al., 
2013). However, the partial redundancy in function of SAgs made by the same strain 
suggests the possibility of alternative functions.  Bi-functional SAgs have been observed in 
that some of these proteins can induce emesis which may aid the transmission between naïve 
host (Hu and Nakane, 2014). Other work has shown that SAgs can impact on the innate 
immune system by manipulating the cytokine expression resulting in TH17 immune 
dysregulation (Xu et al., 2014). This mechanism is dependent on inducing T-cell 
proliferation in different sites in the host, subverting cytokine release and causing immune 
dysregulation. The retained mitogenicity of the neutrophil binding deficient mutants of SElX 
demonstrates that SElX can induce T-cell proliferation irrespective of its ability to bind to 
neutrophils and monocytes. This is an important observation as it demonstrates that the 
protein mediates its function through, at least, 2 distinct structural sites within the protein. 
These data identify SElX as the first example of a SAg exhibiting 2 distinct immune evasion 
functions.  
The discovery of a bi-functional SAg correlates with a new appreciation in the field 
of staphylococcal diseases that many virulence proteins have multiple functions. For 
example, cellular toxins such as Hla, LukAB and PVL  (at sub-lytic concentrations) can 
subvert cellular functions and contribute to S. aureus persistence by inducing inflammation 
and mediating tissue damage (Davis et al., 2011, Holzinger et al., 2012, Melehani et al., 
2015, Kebaier et al., 2012, Munoz-Planillo et al., 2009). The major difference between these 
examples and SElX is that for the lytic toxins the secondary function is still mediated by the 
same binding interaction that leads to pore formation and as a result the functional impacts 
occur in the same cell subset that can be intoxicated. Having distinct binding-tropisms 
potentially allows SElX to interact with a wider number of cells and impact on a broader 
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range of immune functions either through direct functional inhibition or interference with 





















































































6.1 Sequence diversity amongst staphylococcal SAg. 
SAgs have been shown to play a direct role in severe systemic diseases such as toxic shock 
syndrome and food poisoning (Spaulding et al., 2013). However SAg genes are harboured by 
all clinical isolates of S. aureus suggesting they play an important role in general 
pathogenesis of S. aureus infection and potentially in colonisation (Omoe et al., 2005, 
Spaulding et al., 2013, Wilson et al., 2011). Given that these proteins interact with the TCR 
signalling pathway it is likely that non-specific activation of T-cells can contribute to 
immunomodulation by S. aureus. It has been shown that anergy of memory T-cells can be 
induced by exposure to SAgs leading to the clonal deletion of memory T-cells (Watson et al., 
2012). This may result in a significant deficiency in the ability of the adaptive immune 
response to respond effectively to infection. A similar process has been observed by the 
clonal deletion of B-lymphocytes following non-specific stimulation by SpA (Pauli et al., 
2014). The wide diversity in the sequence of SAgs is likely to have been generated in 
response to the diversity of Vβ sub-types of TCR allowing a small complement of SAgs 
expressed by one isolate to activate a wide array of T-lymphocytes sub-populations. Despite 
the critical role these genes play in pathogenesis it is possible there is some redundancy of 
function. This possibility allied to the emerging theme of the multi-functionality of S. aureus 
virulence determinants led us to the hypothesis these proteins may play more than one role in 
S. aureus infections and may exhibit functions distinct from the induction of T-cell 
proliferation.  
In the current study we investigated the structural, physical and functional properties 
of three staphylococcal SAgs with particular emphasis on the previously characterised SAg 
SElX. The SAgs SElY and SElZ have recently been identified and to date limited 
characterisation of their function and role in S. aureus pathogenesis has been performed. 
SElX was selected as it is found in more than 95% of clinical isolates of S. aureus and the 
phylogenetic analysis of the selx  gene demonstrated that the sequence of this protein is more 
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similar to the SSl-proteins than the majority of other SAgs (Wilson et al., 2011). SElY was 
also shown to share a sequence more closely related to the SSl-proteins than the majority of 
other staphylococcal SAgs. The relation to SSl-proteins is noteworthy as it suggests that 
SElX and SElY may contain motifs that are also found in the SSl-proteins which may confer 
immune evasion functions distinct from superantigenicity. Prior to the current project, SElZ 
had been shown to be mitogenic for bovine T-cell lymphocytes and this has yet to be 
demonstrated for human T-lymphocytes (Wilson, 2010). Therefore this study set out to 
determine the functional complement of three staphylococcal SAgs by determining emetic 
potential, further characterising the mitogenic function of these SAgs and studying any role 
in the modulation of the innate immune system.  
 
6.2 Staphylococcal virulence determinants can exhibit a broad functional 
complement. 
Examples of multifunctional determinants as described earlier include EAP which can play a 
role in host cell invasion and inhibit the activity of neutrophil elastase, PVL which has been 
demonstrated to induce inflammation independent of cell lysis and Cna which, in addition to 
its role as an MSCRAMM, can bind C1q and block the complement cascade (Kang et al., 
2013, Stapels et al., 2014, Holzinger et al., 2012). This is a limited list of examples but all 
demonstrate a new understanding in the field that many virulence factors exhibit multiple 
distinct functions.  
The apparent functional redundancy exhibited by S. aureus with regard to 
pathogenesis, re-enforced by the multifunctionality of many virulence proteins may allow S. 
aureus to retain infectivity in the face of immune neutralisation of specific virulence 
determinants. This is an important consideration for the development of vaccines and anti-
virulence therapy as creating immunity or blocking the activity to one or two virulence 
199 
 
determinants may prove ineffective if the bacteria can express an alternative protein which 
performs a similar function to the inactivated factor. Therefore developing an understanding 
of the full functional complement of critical S. aureus virulence determinants will give us the 
best chance of developing targeted therapies that will by-pass the redundancy intrinsic in 
these factors and help develop highly effective therapy against S. aureus disease. 
 
6.3 Mitogenic activity of SElX, SElY and SElZ. 
The superantigenic mechanism of SElX has been previously well described demonstrating 
potent T-lymphocytes mitogenicity, a Vβ specific T-cell activation profile and enhancement 
of LPS sensitivity (Wilson et al., 2011). One question that was not addressed completely in 
this study was how the protein interacted with MHC class II given the truncated OB domain 
that was predicted. In the current study this question was partly addressed by looking at the 
ability of SElX to bind zinc cations. It was found that this protein does not interact with zinc 
and therefore it is unlikely to encode a variant of the high affinity MHC class II binding site. 
The CD analysis also suggested that SElX contains more α-helical secondary structure than 
the model suggests. Given the OB domain of the SElX model is predicted to be made up 
entirely of turns and loops there is a strong indication this model is inaccurate. There are 
residues in the relative position that could form the low affinity site but given the structural 
data obtained so far it does suggest a novel MHC class II interaction may be involved in the 
SAg function of this protein.  
SElY has been shown to induce T-cell proliferation in humans previously (Ono et 
al., 2015) and the mitogenicity analysis performed in this study suggests it has a similar 
potency to other well characterised SAgs such as SEA and TSST-1. The zinc-binding 
experiments demonstrated that this SElY does not interact with zinc and therefore is likely to 
interact with the MHC class II site through the low affinity binding site only. The most 
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closely related SAg to SElY that has been characterised to date is SET and as suggested by 
Ono et al. (2015) SElY may share the property of T-cell activation independent of the of Vβ 
chain of the TCR (Ono et al., 2008a). Screening of the Vβ activation profile of SElY needs 
to be performed before this characteristic can be confirmed.  
SElZ was shown to be mitogenic for human T-cells and the potency of this SAg was 
found to be at a similar level to that exhibited by TSST-1 and SEA (Fig 3.6). The predicted 
structure of SElZ suggests this protein encodes two zinc binding sites along with the low 
affinity binding site for MHC class II. The zinc binding experiments performed in the current 
study suggests SElZ can bind to zinc although this did not appear to be dose-dependent. This 
is analogous to SEC which also expresses two zinc binding sites in its structure and 
contributes to dimerization of the protein and clustering of MHC class II complexes on the 
surface of an APC (Chi et al., 2002). If SElZ is binding to zinc then it may be used as a 
cofactor for MHC class II dimerization and it is proposed that the dimerization of MHC class 
II reduces the clearance of SAg-MHC class II complexes on the surface of the cell and 
activates the expression of IL-1β and TNF-α from the APC which increases the recruitment 
of T-lymphocytes to the APC, allowing the SAg to induce T-cell proliferation (Sundström et 
al., 1996, Mehindate et al., 1995).  In the host this mechanism could enhance the stimulation 
of T-lymphocytes by recruiting them to the activated APC increasing the potency of the SAg 
during infection. 
 
6.4 Emetic functions of SElX, SElY and SElZ. 
Staphylococcal food poisoning is highly prevalent worldwide and given the critical role that 
enterotoxins play in this disease it is important to identify all emetic proteins secreted by S. 
aureus as this will help to identify strains with food poisoning potential to assist in 
surveillance and control efforts (Hennekinne et al., 2012, Hu and Nakane, 2014). The current 
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study has demonstrated that SElX, SElY and SElZ are all highly stable, a property shared 
with other SAgs including TSST-1 and SEs (Cavallin et al., 2000b, Li et al., 2011). It is 
proposed that the highly stable structure of SEs allow the proteins to progress through the GI 
tract and induce emesis (Hu and Nakane, 2014). As SElX, SElY and SElZ all exhibit a high 
level of stability determination of emetic activity was critical as these three proteins may be 
novel enterotoxins. 
In the house musk shrew model it was found that SElZ and SElX were non-emetic. 
SElY was found to induce emesis in a study independent of this work (Ono et al., 2015). 
Given the novel predicted structure for SElX it is unsurprising that this protein does not 
exhibit emetic activity as it is quite distantly related to other enterotoxins and does not 
encode a predicted cysteine loop. Of the three proteins tested it was predicted that SElZ 
would induce emesis given its relatedness to other well characterised SEs and the predicted 
presence of a cysteine loop. However no emetic activity was seen in the house musk shrew 
model. This model was chosen as it has many practical benefits that make it more attractive 
than non-human primate models (Hu et al., 2003). It is possible that SElZ is emetic but that 
the model is not sensitive enough and it cannot be ruled out that it would be emetic in the 
primate model. SElY was found to be emetic in the house musk shrew model independently 
of this study (Ono et al., 2015). Ono et al (2015) reported a lower level of heat resistance 
compared to SET or SEA which is contrary to our data which suggests SElY exhibits 
structure with a similar heat resistance to that exhibited by TSST-1. One reason for this 
discrepancy may be the methods used to assess heat resistance as Ono et al. (2015) used SDS 
PAGE analysis to determine the degradation of SElY after boiling, reporting complete 
degradation after 2 h. Despite a lower resistance to heat degradation compared to other SEs, 
the stability data for SElY obtained in the current study suggests it can retain its structure at 
higher levels of heat than some SEs such as SEA. Accordingly, SElY could persist in food 
after improper cooking and pose a food poisoning risk to humans. 
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6.5 SElX exhibits two distinct immunomodulatory roles. 
In the current study for the first time we have identified a SAg, in SElX, that exhibits two 
distinct immunomodulatory functions. The study demonstrated that this protein shares a 
glycan-binding motif common in SSl-proteins, and in other bacterial and viral proteins which 
allow the protein to bind to the surface of neutrophils (Baker et al., 2007). The proteins are 
still mitogenic even when neutrophil binding is abolished demonstrating the superantigenic 
function of the protein is distinct from the neutrophil binding function.  
SElY was also found to interact with neutrophils and monocytes but unlike SElX 
this interaction appears to be limited to human cells. Also unlike SElX, SElY binding to 
neutrophils does not appear to be mediated by the glycan binding domain as this motif is not 
present in the SElY sequence. Given the SElY-neutrophil/monocyte interaction is unlikely to 
be glycan-mediated and lower affinity, compared to SElX, it suggests that SElY may be 
binding to a specific surface protein receptor(s) on the neutrophil and monocyte surface. 
SElY was tested in a number of functional assays including the phagocytosis assays and no 
functional impact on neutrophils was observed. SElY displays a slightly higher binding 
affinity for monocytes than neutrophils so any future work should include the functional 
impacts of SElY on monocytes and macrophages as well as neutrophils. Despite the lack of a 
characterised function to date, the leukocyte-binding activity of SElY suggests that the bi-
functionality of SAgs may not be limited to SElX and work should be extended to identify 
which other SAgs exhibit more than one immune evasion function. 
The identification of two distinct functions mediated by SElX poses the question of 
the relative role of these distinct functions in S. aureus pathogenesis. The transcriptional 
analysis of SElX demonstrated that this toxin is regulated by the saeRS locus and repressed 
by the agr locus. The saeRS regulon is made up of a number of important immune 
modulators including CHIPS, SCIN and many of the SSl-proteins (Rooijakkers et al., 2006, 
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Nygaard et al., 2010). Given this co-regulation it suggests that the primary role of SElX 
could be as an innate immune modulator. To test this hypothesis the mutations that abolish 
neutrophil binding in rSElX should be introduced into the chromosome of S. aureus and 
tested in an in vivo model. If the precise residues involved in superantigenicity can be 
defined in SElX then site-directed mutagenesis of these residues could be carried out, and the 
role of SElX superantigenicity examined in the same infection model.  
  
6.6 Potential mechanisms of SElX inhibition of neutrophil inhibition. 
The affinity precipitation analysis demonstrated that SElX can potentially interact with a 
large number of neutrophil proteins and that the binding of SElX may contribute to the 
inhibition of a number of important cellular processes. The binding partners of SElX 
determined by the affinity precipitation analysis (Fig 6.1) may be involved in the functional 
inhibition of neutrophils in the survival and phagocytosis assays. The binding of SElX to the 
surface of neutrophils allows the protein to play a role in early immune evasion against 
neutrophils. SElX was demonstrated to inhibit IgG-mediated phagocytosis independent of 
Fcγ receptor signalling which suggests the mechanism of neutrophil inhibition meditated by 
SElX is not due to the antagonism of these immune signalling receptors. Therefore an 
alternative mechanism of inhibition is reducing phagocytosis and this is likely due to 
activation or repression of other pathways in neutrophils which contribute to the regulation 
of immune processes in the neutrophil. The binding partners of SElX that were identified 
during this study include CD45, CD13, CD31, CD148 and CD50. These molecules are all 
important signalling molecules involved in both neutrophil and T-cell activation. It is 
possible the blocking of one or all of these receptors can impair mechanisms that require 
activation during the IgG mediated phagocytosis (Fig 6.1).  
204 
 
The role of CD45 and CD148 have been better characterised in lymphocytes but 
they have been shown in myeloid cells to play a role in cell adhesion (Hermiston et al., 
2009). Bone marrow derived macrophages deficient in CD45 were unable to maintain the 
adhesion to surfaces (Roach et al., 1997). The activation of myeloid cells is also affected by 
the deletion of CD45 as mast cells deficient in CD45 do not degranulate properly after IgE 
cross linking and immune activation by immunoreceptors (e.g. FcγR) is defective in 
macrophages  when CD45 is deleted (Berger et al., 1994, Zhu et al., 2008). The 
glycoreceptor CD148 activates the same kinase pathways as CD45 and contributes to the 
regulation of immune cell activation (Hermiston et al., 2009, Zhu et al., 2008). These studies 
suggests the blocking of with CD45 or CD148 with SElX on the surface of neutrophils could 
subvert the migration of neutrophils to the site of infection or prevent proper activation of the 
neutrophil even after stimulation of antigen receptors, such as the Fcγ receptors. Limited data 
is available on the role of CD45 in neutrophils but work does suggest this receptor is 
important in the repression of the oxidative burst and is down regulated once a neutrophil is 
activated (Fialkow et al., 1997). CD45 has been demonstrated to have a role in the regulation 
of IgG-mediated phagocytosis and can also reduce IgG opsonised particle uptake by 
dephosphorylating factors that lead to actin polymerisation (Yamauchi et al., 2012). Binding 
of CD45 to SElX could activate CD45 resulting in the repression of the oxidative burst and 
IgG mediated phagocytosis.  
Another possible mechanism of neutrophil inhibition is that SElX is internalised 
utilising a similar mechanism exploited by some SSl-proteins like SSl5 and SSl11 (Baker et 
al., 2007, Chung et al., 2007). Once inside the neutrophil SElX can interfere with internal 
pathways and promote S. aureus survival (Fig 6.1). We have demonstrated that SElX may 
interact with intracellular proteins as the affinity precipitation analysis revealed a potential 
interaction with MGAM, a glucamase found in neutrophil granules (Rorvig et al., 2013) and 
p22-PHOX, a key component in the cytochrome B complex (Dinauer et al., 1990). This idea 
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is given further weight by the reduced survival of the S. aureus selx deletion mutant after co-
incubation with human neutrophils. The most likely explanation for the effect of SElX in this 
assay is intraphagosomal expression of SElX leading to disruption of degradative enzymes 
like MGAM and interference with factors such as cytochrome B, involved in the oxidative 
burst (Fig 6.1). The structural analysis of SElX demonstrated that this protein exhibits a high 
level of structural stability at varied pH therefore it is possible the protein is capable of 
retaining activity within the low pH environment of the phagosome. However, the 
expression of SElX within the phagosome in addition to the possible internalisation of 
extracellular SElX needs to be investigated in future.  
In a previous study, SElX was shown to interact at high concentration with the 
neutrophil integrin PSGL-1, a target shared with SSl5 (Fevre et al., 2014). In the current 
study we have demonstrated another potential target these proteins share, matrix 
metallopeptidase 9 (MM9) (Itoh et al., 2010a). Inhibition of this protein could reduce 
neutrophil migration to the site of infection as MM9 contributes to basement membrane 
degradation allowing the neutrophil to transcytose through the endothelium of the blood 
vessel (Itoh et al., 2010a). CD50 (ICAM-3) and CD66c can both interact with CD11/CD18 
which form either the MAC-1 or LFA-1 complexes and are integrins which are critical in the 
activation of migration of leukocytes to the site of infection (Futosi et al., 2013, Skubitz et 
al., 1996, Campanero et al., 1993). If SElX is interacting with these proteins it is likely the 
protein is antagonising the activation of these complexes which would impact on the global 
activation of the cell and prevent immune processes such as phagocytosis and chemotaxis. 
CD31 is a molecule that can contribute to the rolling of neutrophils along the endothelium, 
the initial stage of neutrophil transcytosis (Liu et al., 2012). Affinity precipitation analysis 
suggests that SElX interacts with CD31 as well and may antagonise neutrophil rolling by 
blocking the binding of CD31 and as previously shown PSGL-1 (Fevre et al., 2014).  The 
inhibition of integrin function and interference with neutrophil migration has been shown to 
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be a critical function of SSl5 (Armstrong et al., 2012, Bestebroer et al., 2007, Bestebroer et 
al., 2009) and given SElX has been shown to interact directly with an array of molecules 
which contribute to neutrophil migration, it is likely SElX contributes to immune evasion 
through this mechanism in addition to direct inhibition of neutrophil function. Further 
functional assays need to be performed to determine the effect that SElX has on neutrophil 
migration given the broad number of targets identified in this study.  
The binding candidates of SElX identified in the affinity purification analysis 
suggest a potential role for SElX in the inhibition of neutrophils efferocytosis by 
macrophages. When apoptotic processes are activated the neutrophil undergoes changes in 
the expression of surface glycoproteins.  ICAM-3 is cleaved from the surface of an apoptotic 
neutrophil and acts as a chemoattractant for macrophages and ICAM-3 can also act as an ‘eat 
me’ signal to macrophages on the surface of neutrophils (Torr et al., 2012, Kristof et al., 
2013). The expression of CD13 is upregulated on the surface of apoptotic neutrophils and is 
proposed to enhance the degradation of proinflammatory cytokines and reduce inflammation 
(Hart et al., 2000). ICAM-3 and CD13 have both be shown to be potential binding partners 
of SElX in the current study. SElX may be able to bind to surface expressed or soluble 
ICAM-3 preventing this protein from being used as a signal for macrophages. The blocking 
of CD13 may prevent the degradation of pro-inflammatory signals which result in the 
continuation of inflammation and the blocking of efferocytosis. S. aureus has been shown to 
be able survive and persist within a neutrophil and to maintain this niche as the bacteria 
exploits mechanisms to prevent macrophages from removing infected neutrophils (Greenlee-









Figure 6.1: Proposed model of SElX function during S. aureus infection. (i) SElX has 
been shown to interact with a number of glycoproteins from neutrophils and these 
interactions could have wide ranging impacts on neutrophil function. (ii) SElX can interact 
and manipulate both adaptive and innate arms of the immune system. Figure prepared using 
images from Servier Medical Art.  
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6.7 Role of SElX in S. aureus pathogenesis. 
SElX exhibits distinct functions that can subvert different immune pathways. This insight 
allows us to develop a model for the role of SElX in S. aureus pathogenesis (Fig 6.1). In the 
current study we have demonstrated that SElX expression is under the regulatory control of 
the sae locus which is activated by signals associated with the phagocytes (Geiger et al., 
2008, Voyich et al., 2009). The activation of sae results in the expression of SElX which 
then binds with neutrophils reducing IgG mediated phagocytosis and in turn reduces the 
clearance of S. aureus. The interaction of SElX with neutrophils may affect the neutrophils 
in other ways as discussed in section 6.6 resulting in reduced recruitment of neutrophils to 
the sight of infection and enhancing S. aureus survival when the bacteria interact with 
neutrophils. SElX was shown to bind to monocytes and this interaction was shown to be 
mediated by the sialic acid binding motif which suggests that these monocytes could be 
inhibited in the same way as neutrophils. Further work needs to be done to understand how 
SElX interacts with other phagocytes and what impact this can have on S. aureus clearance 
by the immune system.  
 The stability of SElX may allow the protein to persist at the site of infection and 
subsequently act as a SAg as the adaptive immune response is recruited, inducing T-cell 
proliferation and resulting in immune dysregulation (Fig 6.1). As lymphocytes become 
activated the glycotransferase pathway is upregulated, glycosylating a number of receptors 
which may provide targets for SElX to bind to and inhibit. Further work should look at 
repeating the binding assays with activated lymphocytes to determine if SElX can bind to 
activated T-lymphocytes with high affinity, what the targets of SElX are on the surface of 






The sequence diversity found among staphylococcal SAgs facilitates interaction with one of 
the most complex parts of the immune system. However given the chance there is for 
overlap and redundancy it would be surprising if many SAgs did not exhibit more than one 
function. In the current study we have demonstrated that SAgs can exhibit functions not 
related to non-specific T-cell proliferation. SElX has been shown to be the first example of a 
bi-functional SAg with two distinct immunomodulatory roles in that it can both inhibit 
neutrophils and subvert T-lymphocyte activation. Given the sequence diversity of SAgs it is 
likely this bi-functionality is not limited to SElX, and more work needs to be done to further 
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Amino acid alignment of 20 allelic variants of SElY identified in the SHAC dataset. 20 different amino acid sequences were identified and aligned.  
Dots signify conservation with the corresponding location in SElY1, dashes signify a gap in the sequence alignment. Signal peptide was determined 











1.2 Amino acid alignment of SElZ allelic variants 
 
 
Amino acid alignment of 20 allelic variants of SElZ identified in the SHAC dataset. 11 different amino acid sequences were identified and aligned.  
Dots signify conservation with the corresponding location in SElZ1, dashes signify a gap in the sequence alignment. Signal peptide was determined 






1.3 Amino acid alignment of SElX and TSST-1 showing predicted positions of residues involved in superantigenicity  
 
 
Amino acid alignment of TSST-1 and SElX showing predicted residues involved MHC class II and TCR binding. TSST-1 and SElX were aligned 
using the BLOSUM protein weight matrix. MHC class II (purple) binding residues in TSST-1 had previously been identified by crystallography 
studies. The residues predicted to be involved in binding for SElX to MHC class II have been identified based on the residues involved in MHC class II 
binding in other SAgs including TSST-1. These potential residues were combined with the information regarding the position of MHC class binding 
amino acids within the TSST-1 protein then using the alignment the most likely MHC class II binding residues within the SElX protein were 









Amino acid alignment of TSST-1 and SElY showing predicted residues involved MHC class II and TCR binding. TSST-1 and SElY were aligned 
using the BLOSUM protein weight matrix. MHC class II (purple) binding residues in TSST-1 had previously been identified by crystallography 
studies. The residues predicted to be involved in binding for SElY to MHC class II have been identified based on the residues involved in MHC class II 
binding in other SAgs including TSST-1. These potential residues were combined with the information regarding the position of MHC class binding 
amino acids within the TSST-1 protein then using the alignment the most likely MHC class II binding residues within the SElY protein were 





1.5 Amino acid alignment of SElZ and SEC2 showing predicted positions of residues involved in superantigenicity and the 
emetic loop motif 
 
Amino acid alignment of SEC2 and SElZ showing predicted residues involved MHC class II and TCR binding. SEC2 and SElZ were aligned 
using the BLOSUM protein weight matrix. In SElZ a number of residues were predicted by the I-TASSER program to be involved in binding zinc 
(coloured grey) and play a role in binding MHC class II through the high affinity site. These residues match the relative location is SEC2. TCR binding 
residues have been identified in previous crystallography studies for SEC2 these were found to be shared by SElZ (yellow). The cysteine (emetic) loop 
motif was also identified in SElZ and is in a similar location compared to SEC2 (orange).  
 
 
